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2017 IPU AGM AND  
IPU SERVICES LTD AGM 
Friday 5 and  
Saturday 6 May 2017
(confined to paid-up members of the IPU)
FRIDAY 5 MAY
6.00pm 1. Welcome
2. One minute’s silence in memory of pharmacists who died since the 2016 AGM
3. Minutes of IPU 2016 AGM
4. Minutes of IPU Services Ltd 2016 AGM
5. Financial Report and Consolidated Accounts 2016
a. Adoption of Audited Statement of Accounts of IPU
b. Appointment of Auditors of IPU and IPU Services Ltd
c. Adoption of Directors’ Report and Audited Statement of Accounts of IPU Services Ltd
6. Overview from the Secretary General
7. Group Reports / Open Forum: Introduction and Update
a. Pharmacy Contractors’ Committee Report
b. Community Pharmacy Committee Report
c. Employee Pharmacists’ Committee Report
d. Communications Report
e. International Pharmacy Matters
8. Open Forum
7.15pm End of First Session
SATURDAY 6 MAY
4.30pm 9. Report on Motions from 2016 AGM
10. 2017 AGM Motions
11. Open Forum
6.00pm Closing of AGM Procedures by IPU President Daragh Connolly
AGENDA
Chairperson: Mr Daragh Connolly, President
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MESSAGE FROM  
THE PRESIDENT  
Daragh Connolly
Dear Colleagues and Friends,
The first cohort of pharmacists have submitted 
their CPD portfolios for review and we are 
delighted at the feedback they have given 
the IPU for the relevance and ease of use of 
the sessions provided at the conference and 
through IPU Academy during the year. The 
value of CPD is how we use it to create better 
outcomes for our patients and the teams we 
lead. CPD’s application is its purpose.
We have seen the launch of the Future 
Pharmacy Practice report by the PSI, which 
highlighted that patients want us to provide 
more services to our communities and to take 
a lead in the streamlining of obsolete practices, 
which generate so much duplication of effort 
and increase risk of error. A previous Public 
Survey - Attitudes to Pharmacy in Ireland found 
that 96% of the Irish public have never had 
cause to fault the professional service we 
provide. We have tirelessly engaged with the 
previous and current Government regarding 
achieving better outcomes and value for 
patients through modernising services such as 
EHC, Minor Ailment Scheme, Vaccination, 
Medicines Use Reviews, Healthmail, New 
It has been a great honour to represent my profession and 
colleagues as President of the Irish Pharmacy Union over 
the past year. It has been a very busy year for everyone 
in our profession since the last IPU National Pharmacy 
Conference and it seems hardly that long ago that I 
congratulated Kathy on a superb tenure as President.
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Medicines Service, Health Screening, 
Electronic Prescribing, High Tech, Naloxone 
and ORT. Progress has been swifter in some 
areas than others. This leads to an inevitable 
frustration both within the IPU Executive 
but also in the profession as a whole. A firm 
sign that our advocacy to help make a more 
efficient health service in Ireland is working are 
the changes to legislation already enacted to 
allow us to make a start with EHC. 
We have seen nationally and internationally 
a shift in legislation that recognises problem 
drug use, illicit or not, must be treated first and 
foremost as a healthcare issue. This year will see 
the first safe injection centre open in Dublin to 
help reduce the number of overdose deaths. As 
the most accessible and qualified experts in our 
communities, pharmacists should and will be at 
the vanguard of this change. 
Since our last conference, it has unfortunately 
become obvious of our need for a better way 
of working with the State. Our contractual 
relationship has been fraught on an ongoing 
basis and has, at times, bordered on being 
contemptuous. We will continue to work 
through our current contract whilst seeking 
a better way of delivering value for individual 
patients and the State alike. It is a pity that 
there seems to be a contractual priority list 
for varieties of healthcare professionals when 
what is needed is a patient contract outlining 
where and how each citizen will be treated 
for their healthcare needs. As we have borne 
the overwhelming burden of cutbacks in the 
budgets in primary care, our spend levels are 
now proportionately far below better run 
health systems. It is a fair question to ask on 
behalf of our patients if any efficiencies have 
been created in secondary care to produce 
better outcomes for patients. Unfortunately, 
we already know the answer.
The trust and esteem our profession enjoys 
has not come about by accident. Ours is a very 
hardworking profession that has an obvious 
fault of not making a fuss about the good we 
do, seen and unseen. It is the role of the IPU to 
advocate on behalf of your role as a healthcare 
expert in your community. It is an honour 
to do so. The IPU represents and advocates 
for its members as it can only be as strong as 
its membership. I thank you personally and 
on behalf of the entire profession for your 
dedication to your profession and ultimately 
to your patients and communities. We have 
earned the right to be proud of our profession. 
I wish to thank the very hardworking team in 
Butterfield House for making our conference 
an event we can be proud of as it shows 
our profession at its best. Pharmacists are 
renowned for being excellent multitaskers and 
those skills will be put to good use at this year’s 
conference. We will take the opportunities 
offered to advance our education, business, 
advocacy, leadership and management skills, 
while testing new ideas, catching up with 
old friends and making new ones. Please 
also take the opportunity to relax and enjoy 
the social aspect of our conference. I hope 
you will return to your practice invigorated, 
enthused and undaunted by the challenges and 
opportunities another year will bring.
The IPU’s 2017-2021 Statement of Strategy will 
be launched at the conference. This strategy 
document is not the work of any one individual; 
it was very much a team effort. It sets out 
a clear course for the next four years and is 
challenging, far-reaching and ambitious. 
Finally, on your behalf, I would like to take this 
opportunity to thank our Secretary General, 
Darragh O’Loughlin, for his enthusiasm, 
hard work and dedication to the IPU and its 
members. His counsel to me in my role as 
President and countless other members has 
been of huge value, seen and unseen.
Daragh Connolly MPSI
President, IPU
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MINUTES OF THE 43RD 
ANNUAL GENERAL 
MEETING OF THE IRISH 
PHARMACY UNION AND 
IPU SERVICES LTD
Crowne Plaza Hotel, 
Northwood, Dublin
22 & 24 April 2016
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1. The President welcomed the attendance to 
the 43rd Annual General Meeting of the 
Irish Pharmacy Union.
2. On the proposal of the President, all 
present stood in silence in memory of 
deceased members, family members and 
Enda Ryan, former Secretary General, who 
had died since the 2015 AGM. 
3. Minutes of 2015 AGM
 The report of the 42nd Annual General 
Meeting was taken as read. The report is 
available on the members’ section of www.
ipu.ie. The report was proposed by Carmel 
Collins, seconded by Stephen Nolan, 
unanimously approved and signed by the 
President.
4. Financial Reports and Accounts 2015
 Bernard Duggan (Honorary Treasurer) 
presented the IPU’s Financial Report and 
took queries from the floor. 
 He said that the total income for the 
year was €4,756,852 compared to 
€4,945,466 in 2014 which represented 
a 4% decrease in overall income for the 
year. This was largely due to the decrease in 
revenue received from the sale of the IPU 
Product File to external customers. 
 Revenue through membership 
subscriptions and levy income: 
membership had increased due to a small 
increase in membership numbers from 
2,140 in 2014 to 2,146 in 2015, while 
Friday 22 April – AGM Reports
Present: IPU President Kathy Maher and 43 members.
In Attendance: Darragh O’Loughlin, Jim Curran, Ciara Enright, Darren Kelly,  
Wendy McGlashan, Róisín Molloy and Patrice O’Connor.
Apologies: Apologies were received from five members. 
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levy income had continued to rise due to 
the continued increase in the number of 
medical cards being issued by the HSE 
in 2015. This trend had begun to level off 
towards the end of 2015.
 Other areas of note in income included 
advertising in the IPU Review, courses and 
the conference sponsorship:
n	Advertising in the IPU Review 
continued to grow in 2015;
n	Courses represented all the 
courses being provided by the IPU 
for members and non-members. 
The Technician and MCA courses 
continued to perform well. Some 
430 members joined IPU Academy 
in 2015 in addition to the 2146 IPU 
members who could also avail of the 
service. There were also a number of 
business-focused courses running, 
for which there had been a good 
uptake; and
n	Conference Sponsorship  
The IPU ran two conferences in 
2015: the IPU National Pharmacy 
Conference and the PGEU 
Conference. There was an increase 
in sponsorship revenue from the IPU 
National Pharmacy Conference in 
excess of €40k due to the change 
in the sponsorship structure. While 
the PGEU Conference generated 
income totalling €43k, the 
corresponding charges in relation to 
the PGEU Conference are reflected 
in the expenditure resulting in a small 
profit for the IPU.
 Total expenditure for the year was 
€4,209,390 compared to €4,307,949 
in 2014, which represented an overall 2% 
decrease in expenditure. 
 The Treasurer highlighted a number of areas 
where increased expenditure occurred and 
outlined the reasons:
n	 Legal Expenses & Consultancy;
n	 IT;
n	Repairs and Renewals;
n	Course Expenses;
n	 IPU Product File; and
n	 hmR.
 The IPU continued to introduce initiatives 
in 2015 to expand the value of membership 
of the IPU. In 2013, a free Irish Medicines 
Formulary was provided to each member 
who renewed their subscription. In 2014, 
fully paid-up members received both a free 
BNF for Children and a BNF. In 2015, 
members were able to avail of the Member 
Assistance Programme from the VHI which 
provides telephone assistance for any IPU 
Member or their staff should they require it.
 By year-end, the Mullally and Haire legal 
cases had moved towards resolution and, as 
such, the provision of €950,000, which 
was in the previous year’s accounts to cover 
possible further costs in these cases, had 
been written back into the accounts.
 Following the presentation, the following 
motion approving the accounts was 
proposed by Marie McConn, seconded by 
John Carey and carried unanimously: “That 
the Executive Committee Report and 
Audited Statement of Accounts for the 
Irish Pharmacy Union for the year ended 
31 December 2015 as submitted to this 
meeting be and are hereby adopted.”
 The following motion was proposed by 
Marie McConn, seconded by Peter 
McElwee and carried unanimously: “That 
this meeting agrees to the election of Baker 
Tilly Ryan Glennon for a further year as 
auditors for the IPU and IPU Services Ltd.”
5. IPU Services Ltd AGM
 The accounts were presented by the 
Treasurer and on the proposal of Stephen 
Nolan seconded by John MacNamara it 
was resolved: “That the Directors’ Report 
and Audited Statement of Accounts for 
the year ended 31 December 2015 as 
submitted to this meeting, be and are 
hereby adopted.”
 This motion was carried.
 The minutes of the 2015 AGM of IPU 
Services Ltd were taken as read.
 In conclusion, the Hon Treasurer thanked 
Ciara Enright, Secretary to the Finance 
Committee and his colleagues on the 
Committee for all their work over the 
past two years and wished the incoming 
Treasurer, Stephen Nolan, all the best for 
his time in office.
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6. IPU Secretariat Report
 The IPU Secretariat Report was circulated 
to members by post in advance of the 
meeting and a more detailed report was 
published on the members’ section of  
www.ipu.ie. 
7. Group Reports
a. Pharmacy Contractors’ Committee 
(PCC) Report 
This report was presented by Eoghan 
Hanly, Chairman of the Pharmacy 
Contractors’ Committee. The report 
was circulated to members in advance of 
the meeting and a more detailed report 
was published on the members’ section 
of www.ipu.ie. 
b. Community Pharmacy Committee 
(CPC) Report  
The CPC Chairman was not present. 
An overview of the CPC report was 
included in the President’s report. The 
report was circulated to members in 
advance of the meeting and a more 
detailed report was published on the 
members’ section of www.ipu.ie.  
c. Employee Pharmacists’ Committee 
(EPC) Report  
This report was delivered by Sheila 
O’Loughlin, Chairperson of the 
Employee Pharmacists’ Committee. 
The report was circulated to members 
in advance of the meeting and a more 
detailed report was published on the 
members’ section of www.ipu.ie.  
d. Communications Report  
This report was available on the 
members’ section of www.ipu.ie and was 
taken as read. 
e. International Pharmacy Matters 
This report was available on the 
members’ section of www.ipu.ie and was 
taken as read. 
9. President’s Address 
 The President gave a brief overview of 
the work of the IPU over the previous 12 
months, which is attached (see page 18).
10. Open Forum 
 Items discussed included:
a. The need to get more pharmacies 
to reply to the annual review of the 
sector as it was felt that, in the main, 
it was the larger pharmacies that were 
participating. It was noted that hmR data 
would be of assistance in future surveys;
b. The number of pharmacies in hmR, 
which, at the time of the meeting, was 
50% of IPU member pharmacies;
c. The process for unwinding of FEMPI;
d. The necessity to get the PCRS paper 
workload down/simplified. The Secretary 
General said that more electronic 
exchange was being implemented, which 
would streamline the process. The PCC 
strategy is to get a new, streamlined 
contract;
e. The Secretary General replied to 
Barra Nevin who asked what there 
was to prohibit the Government from 
reducing reference pricing to the 
absolute minimum. He said that if the 
reimbursement price went too low 
companies might not market their drugs 
but it was up to the PCRS to ensure 
that drugs were available for patients; 
and
f. Marie McConn said that the PCRS 
were back to underpaying claims.
The President then adjourned the AGM until 
Sunday 24 April at 12.30pm.
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10.Report on Motions from 2015 AGM
 The report on motions from the 42nd 
Annual General Meeting was taken as read. 
11. 2016 AGM Motions 
 The following motions were proposed 
in accordance with Article 30 of the 
Constitution. All motions were debated and 
considered by the meeting and then passed.
a. “That this AGM calls on the 
Government to recognise pharmacy as 
a crucial element of primary care and 
to allocate the necessary resources to 
developing pharmacy services in order 
to alleviate pressures caused by the 
persistent GP manpower crisis and 
ensure easy access for patients and the 
public to safe, convenient and cost-
effective healthcare.”
 Proposed: Kathy Maher
 Seconded: Carmel Collins
In proposing this motion, Kathy Maher 
stated that “with increasing demand for 
health services and shrinking resources, 
the healthcare system is under 
unprecedented pressure. The service 
is near breaking point, with hospitals 
overstretched and GPs struggling with 
their existing workload. 
In a recent survey published in the Irish 
Medical Times, GPs were found to have 
been overrun by “a tsunami” of visits 
from children under six being brought 
to their surgeries because the service 
is now free for children, which has had 
a knock-on effect on their ability to 
provide prompt appointments for other 
patients who are genuinely unwell. 
The demands on the health system and 
on GPs in particular are set to increase 
further. Free GP care for the under 
6s and the over 70s, and the planned 
extension of free GP care to the whole 
population, combined with an ageing 
population, will have a major impact on 
the future. 
A workforce planning exercise carried 
out late last year by the HSE’s National 
Doctors Training and Planning Unit 
concluded that there is a significant 
undersupply of GPs in Ireland at present 
and that, by 2025, the predicted 
shortage of GPs will be anything from 
493 to 1,380 – depending on increased 
levels of access to free GP care.
But it’s not just about alleviating the 
workload of GPs. Patients benefit too.
There is clear evidence to show that 
pharmacy-based services in other 
jurisdictions have led to considerable 
improvements in patients’ health 
outcomes and considerable savings 
to healthcare budgets. In England, 
Scotland and Canada, for example, 
where demand for GP services 
exceeded the available capacity, 
the unique skills and expertise of 
pharmacists have been used to enhance 
access to healthcare.
In response to the shortage of GPs in 
Canada, pharmacists’ scope of practice 
has been extended to include Chronic 
Disease Management: monitoring 
patients with chronic illnesses, renewing 
and adjusting their prescriptions 
to ensure tighter control of their 
symptoms. This is done in collaboration 
with the patient’s doctor, not in 
competition, and has been found to 
deliver better treatment outcomes, with 
reduced morbidity and mortality.
Data from Scotland shows that in-depth 
Medicine Use Reviews conducted by 
pharmacists, with patients suffering 
from chronic illnesses, reduced hospital 
readmission rates by a third.
Sunday 24 April – AGM Motions
Present: IPU President Kathy Maher and 41 members.
In Attendance: Darragh O’Loughlin, Jim Curran, Darren Kelly, Wendy McGlashan,  
Róisín Molloy and Patrice O’Connor.
Apologies: Apologies were received from five members. 
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Extending pharmacist services in this 
way has resulted in better access to 
primary health care and a substantial 
reduction in morbidity and mortality 
rates from illnesses such as heart disease 
and diabetes. 
Pharmacists in Ireland have the requisite 
expertise, skill-set and accessibility 
to introduce services like Health 
Screening, a Minor Ailment Scheme, 
New Medicine Service or Chronic 
Disease Management, all of which would 
assist in delivering on the Government’s 
programme of improving the health and 
wellbeing of people living here.
The ability of pharmacists in Ireland to 
deliver additional key services is beyond 
doubt. The introduction of the flu 
vaccination service, reclassification of 
Emergency Hormonal Contraception 
and a smoking cessation service has 
shown that pharmacy can deliver, in a 
cost-efficient manner, services that 
patients want and avail of. 
The public are hugely supportive of 
an extended role for pharmacists. 
Our independent market research 
confirms that 92% of the public are 
in favour of pharmacies providing a 
minor ailment scheme, with 94% in 
favour of pharmacies providing services 
to improve patient adherence to 
medicines.
Just last October, the Joint Oireachtas 
Committee on Health and Children 
published a report which recommended 
an expanded role for pharmacists, 
something which all the main political 
parties committed to in their recent 
election manifestos. 
Pharmacists rank second only to nurses 
as the healthcare professionals most 
trusted by the public but, unfortunately, 
Ireland lags well behind other countries 
when it comes to allowing pharmacies to 
deliver additional services.
There is a lot of talk about creating a 
patient-focused health service delivered 
at the lowest level of complexity. 
Pharmacists already play a vital role in 
ensuring patient safety and wellbeing. 
If allowed and if given appropriate 
resources to do so, pharmacists are 
willing, ready and able to help alleviate 
pressure on GP surgeries and on 
hospitals by providing a broader range of 
healthcare services to their patients and 
the public, in line with what happens in 
other countries.
We propose that this AGM calls on the 
Government to recognise pharmacy as 
a crucial element of primary care and 
to allocate the necessary resources to 
developing pharmacy services in order 
to alleviate pressures caused by the 
persistent GP manpower crisis and 
ensure easy access for patients and the 
public to safe, convenient and cost-
effective healthcare.”
This motion was carried unanimously.
b. “That this AGM calls on the 
Department of Health to commence 
negotiations with the IPU on a new 
Pharmacy Contract that is fit for 
purpose and which reflects the needs of 
patients and the practice of pharmacy 
in the 21st Century.”
Proposed: Eoghan Hanly 
Seconded: Ray McSharry 
In proposing this motion, Eoghan 
Hanly stated that “in 1996, the 
then Pharmaceutical Contractors’ 
Committee of the IPU, negotiated 
the terms of the current Community 
Pharmacy Contract with the 
Department of Health, in conjunction 
with regulations governing pharmacy 
establishment and location. At the 
time, it was regarded as a tremendous 
achievement and positioned pharmacy 
well for many years. However, time 
passes and circumstances change.
The associated regulations, which at the 
time and from our perspective, were a 
key part of the deal, were repealed in 
January 2002 by the then Minister for 
Health, Micheál Martin.
In 2008, the HSE, then embroiled 
in a bitter dispute with the IPU over 
pharmacists’ right to representation 
in negotiations with the State, set out 
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a framework process for negotiating 
a contract and setting pharmacists’ 
remuneration. However, no contract 
talks ever took place and the detested 
FEMPI Act – which we are all painfully 
familiar with – superseded any possibility 
of negotiation.
The Contract was revised in 2010, 
but this was simply for the purposes 
of updating some of the definitions 
contained within it and there was no 
substantive change to its provisions. 
We are grateful to the IPU 
representatives that negotiated the 
terms of the 1996 agreement. The 
negotiations took many months and a 
lot of hard work and dedication on their 
part. The benefits that accrued to all of 
the parties to the 1996 agreement and 
the contract that resulted from it cannot 
be underestimated. However, that 
Community Pharmacy Contract is 20 
years old this year and it is now apparent 
that it is in urgent need of review.
n	Since 1996, a number of 
Schemes and Services have been 
introduced in a piecemeal manner 
and many disparate and, at times, 
confusing changes or restrictions 
in the terms and conditions and 
rules applicable to the schemes 
have been made;
n	 There is no clear process for 
consultation between the 
Department of Health and the 
IPU on matters of importance;
n	 The provisions of the Contract do 
not accurately reflect the legal 
or regulatory framework within 
which pharmacies operate today;
n	 The Contract is inflexible and 
increasingly does not support 
pharmacists to meet the needs of 
patients in modern-day Ireland;
n	 The process in place for making 
small changes to pharmacy 
ownership structures is 
unnecessarily convoluted;
n	 There are no provisions in 
relation to funding or updating 
IT infrastructure to create 
efficiencies and cost savings 
within the system, despite the 
obvious need to do so; and
n	 There is no defined dispute 
resolution procedure for unpaid 
claims, nor is there a clear 
sanctions policy to bind PCRS 
behaviour. Transparency and 
fairness require both.
In 2013, the then Minister agreed 
with the IPU that it was time for a new 
Pharmacy Contract to be put in place, in 
addition to a new GP Contract. In 2015, 
the Department of Health, driven by a 
political imperative, opened negotiations 
with the IMO on a new Contract for 
GPs. A new Pharmacy Contract is 
equally necessary. 
The agreed framework for the GP 
negotiations should form the basis of 
any engagement between the IPU, the 
Department of Health and the HSE. 
There is recognition that pharmacists 
can deliver far more services than are 
currently delivered and it is obvious that 
the health service needs us delivering 
services. 
Equally, it is clear from our dealings 
with them, that the PCRS needs a clear 
and balanced set of rules to govern 
the administration and payment of 
our claims, with a defined process for 
agreeing changes to reimbursement 
rules and a clear framework for agreeing 
the scope, operation and remuneration 
of all future new services. 
We therefore call upon the Department 
of Health to commence negotiations 
with the IPU on a new Pharmacy 
Contract that is fit for purpose and 
which reflects the needs of the patients 
and the practice of pharmacy in the 21st 
Century.”
This motion was carried unanimously.
c. “That this AGM calls on the Minister 
for Health to review the Medical 
Card Prescription Levy; initially by 
exempting all vulnerable patients – 
including homeless patients, palliative 
care patients and others who require 
their medication changed on a daily 
or weekly basis, patients in residential 
care settings, patients with intellectual 
disabilities and patients receiving 
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treatment under the Methadone 
Treatment Scheme in respect of other 
medication that they may require – 
and ultimately by phasing it out over a 
three-year period.”
Proposed: Ciara McCabe 
Seconded: Michael Walsh
In proposing this motion, Ciara McCabe 
stated that “all of us in this room are well 
aware of the impact of the prescription 
levy, particularly on economically 
vulnerable patients. The levy at €2.50 
has increased fivefold since it was first 
introduced in June 2010 at €0.50 per 
item. Many patients, particularly those 
on fixed incomes, just cannot afford 
to pay the levy. Instead, they gamble 
with their health every day either by 
reducing their medication or by stopping 
it entirely. The ultimate outcome is 
sicker patients, with more complex 
medical needs, needing advanced care 
in an already extremely overburdened 
health system. The imposition of the 
levy is creating more future demand for 
a health service that is already struggling 
to cope.
The impact of the levy can be seen 
from the findings of a Behaviour & 
Attitudes Survey on behalf of the IPU, 
undertaken in March of this year. In the 
survey, 28% of medical card holders 
said that they ‘think twice’ about taking 
their prescribed medicines because of 
the cost of the levy and 1 in 7 confirmed 
that they have not filled a prescription 
because of the levy.  
There was a study published in March 
of this year which was funded by the 
Health Research Board, and co-
authored by researchers in University 
College Cork (UCC) and Trinity College 
Dublin. This study only looked at the 
impact of the increase in the levy from 
50cent to €1.50. However, it found 
that prescription charges on the medical 
card scheme led to reductions in the use 
of medicines by Irish patients, with some 
types of medicines being affected more 
than others. 
In October of last year, the Government 
signed regulations exempting asylum-
seekers living in direct provision from the 
levy in response to evidence that recent 
increases in the charge caused hardship 
among that group of people.  
Putting economic barriers in the 
way of patients taking their medicine 
doesn’t make sense. People living with 
heart disease, or at risk of the disease, 
should be focusing on getting better 
and keeping well, not worrying about 
how they’re going to pay for their next 
vital prescription. Poor adherence to 
treatments, especially in the case of 
chronic illness and long-term patients, 
will mean more hospital stays, more 
pressure on our already struggling and 
depleting health service and more cost 
to the Exchequer in the treatment of 
these patients in the long run. Patients 
need to be supported not penalised.  
In this motion, therefore, I am calling 
for a two-step approach. Firstly, I am 
calling on the Minister for Health to 
immediately exempt the following 
vulnerable patients from the  
prescription levy:
n	Patients in residential  
care settings; 
n	Patients with intellectual 
disabilities; 
n	Patients receiving treatment 
under the Methadone Treatment 
Scheme in respect of other 
medication that they may require; 
n	Homeless patients including those 
in homeless shelters; and 
n	Palliative care patients and other 
patients who have their medicines 
changed on a daily/weekly basis. 
 
Secondly, I am calling on the Minister 
for Health to review the Medical Card 
Prescription levy with a view to phasing 
it out entirely by steadily reducing the 
amount over a multi-year period.”
This motion was carried unanimously.
d. “That this AGM calls on the Minister 
for Health to engage promptly with 
the IPU on the recommendations of 
the Joint Committee on Health and 
Children on expanding the role of  
the pharmacist, namely:
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n	Establishing a New  
Medicines Service;
n	 Introduction of Medicine  
Use Reviews;
n	Consideration of what other 
steps could be taken to enhance 
the role of the pharmacist in 
the provision of primary care to 
patients;
n	Assessment of a financial 
incentive mechanism for 
pharmacists to supply biosimilars;
n	A detailed analysis of the 
potential of community 
pharmacists to expand their 
role by delegating prescription 
authority to them; and
n	 The reclassification of a wider 
range of medicines from 
prescription-only to non-
prescription.”
Proposed: John O’Connell 
Seconded: Roma O’Loughlin
In proposing this motion, John 
O’Connell stated that “on 9 October 
2015, the Joint Committee on Health 
and Children published its Report 
on the Cost of Prescription Drugs in 
Ireland. The IPU made written and oral 
presentations to the Committee. The 
report made a number of important 
recommendations, intended to reduce 
the long-term cost of pharmaceutical 
drugs and increase the use of generic 
drugs in Ireland. In addition to 
recommendations to reduce the cost of 
medicines, the report also called for a 
number of new pharmacy services to be 
introduced.
NMS, MURs and Role of Pharmacist
In relation to the role of the pharmacist, 
the Oireachtas Committee considered 
the potential for community 
pharmacists to play a more proactive 
role in reviewing prescription use. In this 
regard, the IPU highlighted the UK’s 
New Medicine Service as an example 
of best practice. We also discussed 
Medicines Use Reviews, whereby 
community pharmacists meet with 
patients with long-term illnesses to carry 
out joint reviews of their prescriptions 
on an annual basis.
The findings from the evaluation of 
the New Medicine Service suggest 
that such reviews have the potential 
to enhance patients’ lives, reduce the 
number of hospital stays, and result in 
more effective use of prescription drugs.
Medicines Use Reviews were previously 
recommended by the Joint Committee 
in 2007. An MUR pilot project, 
prepared for the HSE’s Primary Care 
Group in 2012, recommended that 
MURs should be implemented as a 
practice-based service, supported by 
the HSE. In Scotland, MURs have 
reduced hospital re-admission rates 
by more than 30% for elderly patients 
suffering chronic illnesses and taking 
multiple medications.
Consequently, the Committee 
recommended the establishing of 
a New Medicine Service and the 
introduction of Medicines Use Reviews, 
where patients with long-term illness 
jointly review their prescriptions with 
pharmacists on a regular basis. The 
Committee also recommended that 
the Minister should consider what other 
steps could be taken to enhance the 
role of the pharmacist in the provision of 
primary care to patients.
Prescribing and Switching
In relation to prescribing and 
switching, the Oireachtas Committee 
acknowledged that, although 
pharmacists have no role in the 
setting of reimbursement prices for 
medicines, the role of the community 
pharmacist is recognised as integral to 
the provision of advice to patients on 
generic substitution. Under the Health 
(Pricing and Supply of Medical Goods) 
Act 2013, pharmacists must supply 
a substitute generic product (via the 
designated Interchangeable List) if a 
proprietary branded drug is not explicitly 
requested in handwriting on the 
prescription by the GP.
The Committee further acknowledged 
that the role of the pharmacist extends 
to improving patient awareness including 
supporting patients to make healthier 
lifestyle choices. Consequently, the 
Committee said that, considering 
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the wide knowledge possessed by 
community pharmacists and their 
proximity to patients, a detailed analysis 
of the potential to expand their role 
with respect to the delegation of 
prescribing competencies merits further 
consideration. The Committee also 
supported the reclassification by the 
Health Products Regulatory Authority 
(HPRA) of a broader level of medicines 
from prescription-only to over-the-
counter, in line with best practice in 
other EU countries.
Biosimilars
With regard to biosimilars, according to 
the HSE, the High Tech Drug scheme 
is the only PCRS scheme which has 
seen an increase in expenditure from 
€315m (in 2009) to €485m (in 2014), 
or 54%. In the future, the expectation 
is that new medicines will, in the main, 
be in the High Tech area. As such, the 
Committee felt that action in this area 
was viewed as necessary.
One option proposed is for the State 
to enact legislation to facilitate the 
listing of biosimilar medicines as 
“interchangeable”, something which 
is currently prohibited. It was stated 
that this could reduce the State’s 
pharmaceutical bill, treat more patients 
within existing budgets, and allow 
improved access for patients to newer, 
innovative medicines. 
The Committee, therefore, 
recommended that the potential 
application of a financial incentive 
mechanism for pharmacists to supply 
biosimilar versions of products on the 
High Tech Drug scheme should be 
assessed.
Conclusion
It is refreshing to see a Committee 
as influential as the Joint Committee 
on Health and Children make such 
innovative recommendations on 
expanding the role of the pharmacist 
and we now call on the Minister for 
Health to engage promptly with the IPU 
on these recommendations.”
This motion was carried unanimously.
e. “That this AGM calls upon the 
Department of Health and HSE 
to immediately roll out a national 
Pharmacy Minor Ailment Scheme 
following the completion of the three-
month pilot scheme.”
Proposed: Sheila O’Loughlin 
Seconded: Sarah Magner
In proposing this motion, Sheila 
O’Loughlin stated that “Community 
pharmacists deal routinely with minor 
ailments as part of their normal 
practice, giving advice to patients on 
how to treat self-limiting conditions 
and distinguishing between minor 
illness and major disease. By giving 
appropriate advice and recommending 
effective treatments, community 
pharmacists play a major role in keeping 
minor ailments out of the GP surgery. 
Furthermore, they act as a filter for 
referral where a GP consultation is 
needed.
The Minor Ailment Scheme is an 
internationally-recognised extended 
pharmacy service, which demonstrates 
how pharmacists can improve public 
health access, shape future services 
and broaden pharmacy roles to deliver 
quality patient care and improve health 
outcomes. 
The basis of the GMS Scheme is to 
provide full pharmaceutical services 
for persons who are unable, without 
undue financial hardship, to provide 
such services for themselves and their 
dependants. The primary aim of a Minor 
Ailment Scheme is to enable medical 
card patients to receive treatment 
for common illnesses free-of-charge 
directly from their local community 
pharmacy in a timely manner and 
without the need for a visit to the GP; 
such a scheme would be cost-neutral to 
the Exchequer. 
In the UK, the Royal College of General 
Practice and the College of Emergency 
Medicine have estimated that one in 
seven GP consultations and one in 12 
A & E attendances could have been 
dealt with by a visit to a pharmacy. 
Improving the accessibility of treatment 
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for minor ailments in a pharmacy setting 
through a Minor Ailment Scheme would 
facilitate more prompt treatment of 
ailments, thereby improving the quality 
of life for patients, and would alleviate 
pressures on GP surgeries and prevent 
unnecessary use of Accident and 
Emergency services. 
The IPU is currently working with the 
HSE on a three-month pilot Minor 
Ailment Scheme in four towns around 
the country. We now wish to ensure that 
the scheme becomes a national service 
once the pilot is complete.  
We therefore call on the Department 
of Health and HSE to immediately roll 
out a national Pharmacy Minor Ailment 
Scheme following the completion of the 
three-month pilot scheme.”
This motion was carried unanimously.
f. “That this AGM calls upon the 
HSE to roll out a pharmacy-based 
anticoagulation service in areas of the 
country where such a service is not 
easily accessible.”
 
Proposed: Jonathon Morrissey
Seconded: Ultan Molloy
In proposing this motion, Jonathon 
Morrissey stated that “treatment with 
warfarin requires regular monitoring 
of the International Normalised Ratio 
(INR) to ensure the patient’s level of 
anticoagulation is maintained within 
a safe range. The aim is to maintain 
patients within their therapeutic range 
for the maximal possible time (which 
is known as the percentage time in 
therapeutic range or TTR). 
In order to ascertain appropriate rates 
of INR control with warfarin, clinicians 
review past results and calculate the 
amount of time the INR results were 
within their defined range, with optimal 
therapy considered when the TTR is > 
70%. 
The non-vitamin K oral anticoagulants 
(NOACs) first became available in 
Ireland in 2008. Not all patients are 
suitable for warfarin therapy due to labile 
INRs or drug allergies so the availability 
of NOACs afford the opportunity to 
treat a larger cohort of atrial fibrillation 
patients than was previously possible.  
The number of people being treated 
with NOAC therapies under the 
Community Drug Schemes has risen 
steadily; in October 2013, 10,131 
patients were dispensed a NOAC, while 
33,585 were dispensed warfarin. One 
year later, in October 2014, 16,272 
patients were dispensed a NOAC 
and 30,620 patients were dispensed 
warfarin. The NOACs represent a 
considerable cost to the HSE; total 
drug expenditure on NOACs amounted 
to €1.5 million for the month of 
October 2014 alone, in comparison to 
a total drug expenditure on warfarin of 
€0.4 million during this time.
Non-compliance with warfarin therapy 
is not considered a suitable reason 
for choosing a NOAC above warfarin 
therapy, due to the short elimination 
half-life associated with the NOACs 
and the consequent risk of reduced 
anticoagulation if there is poor 
compliance. Warfarin therapy is also 
less expensive than newer treatments, 
even when taking account of the cost of 
monitoring through warfarin clinics or 
GP practices. 
For these reasons, the HSE’s Medicines 
Management Programme (MMP) 
considers that there is little difference, 
in terms of health outcomes, between 
warfarin therapy and NOACs, when 
warfarin is well tolerated and the INR 
remains within range. Consequently, 
the MMP has re-affirmed that warfarin 
is the preferred oral anticoagulant 
for stroke prevention in non-valvular 
atrial fibrillation. As with previous 
MMP Preferred Drugs initiatives, 
prescribers are encouraged to consider 
the preferred drug when initiating 
anticoagulant therapy.
The difficulties arising from insufficient 
anticoagulation services in primary care 
in Ireland have been well documented. 
Most patients attend a hospital warfarin 
clinic to have their INR tested, typically 
having to wait for several hours before 
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their results are confirmed. Indeed, 
in some parts of the country, there 
is no such clinic. Some GP practices 
also offer this service. Community 
pharmacists, as experts in medicine, 
have an ideal skillset to manage patients 
on warfarin successfully and are well 
placed to provide such a service.
 
Dermot Twomey, a community 
pharmacist from Cloyne, Co Cork, has 
been running an anticoagulation clinic in 
his pharmacy since 2010, in conjunction 
with the Consultant Haematologist at 
Cork University Hospital. His results 
have met with the international standard 
for the provision of anticoagulation 
services, with TTR readings consistently 
above 70%. 
In a meeting with the IPU in July 2015, 
both the Minister for Health and the 
Minister of State for Health indicated 
their support, in principle, for widening 
anticoagulation management services 
through community pharmacy and 
expressed a desire to see a proposal 
for such an initiative brought forward 
through the HSE.
There is international evidence of the 
value of such a pharmacy service. A 
report on New Zealand’s Community 
Pharmacist-led Anticoagulation Service 
(CPAMS) showed that pharmacy sites 
achieved a mean TTR in excess of 70%. 
Compliance with appointments was 
excellent at 83.1%. The great majority 
of patients found the CPAMS to be 
convenient and accessible, preferable 
to the previous system, and expressed 
confidence in the pharmacist to 
perform the service. The predicted 
budget impact is a net reduction in 
anticoagulation-associated costs of 
approximately NZ$177 million over five 
years (for 80% of patients managed 
under the CPAMS) or NZ$111 million 
over five years (for 50% of patients 
managed under the CPAMS).
We therefore call upon the HSE to roll 
out a pharmacy-based anticoagulation 
service in areas of the country where 
such a service is not easily accessible.”
This motion was carried unanimously.
g. “That this AGM calls on the 
Department of Health and the HSE 
to implement the recommendations 
of the Joint Committee on Health 
and Children on medicine shortages, 
namely:
n	Maintain strong surveillance on 
the impact of national medicine 
price policy on the medicine 
supply;
n	Prepare a contingency plan to 
consider certain export controls 
should medicine shortages arise;
n	Examine the feasibility of 
introducing concessionary pricing 
where medicine supply is an 
issue;
n	Commission a future-focused 
assessment of the challenges 
posed by pricing, supply and 
demand for pharmaceuticals  
in Ireland.”
 
Proposed: Daragh Connolly  
Seconded: Caitriona O’Riordan
In proposing this motion, Daragh 
Connolly stated that “medicine 
shortages are an ongoing problem 
that is putting patients’ health at risk. 
On a daily basis there is a shortage of 
one medicine or another and in many 
cases a nationwide shortage of critical 
prescription medicines. 
Results from a survey of members 
undertaken in August of last year 
highlighted the scale of the problem, 
with 99% of pharmacists indicating 
that they had experienced medicine 
shortages in the previous three months. 
Nearly a third (30%) had encountered 
shortages of 20 or more medicines, and 
nearly half (46%) of pharmacists believe 
that their patients’ health outcomes had 
been “adversely affected by medicine 
shortages.  
Patients can sometimes wait for weeks 
to get a new supply of a common drug. 
Not only is this putting their health 
at risk but it is causing undue stress, 
fear and anxiety for them. Instead of 
directing their efforts and professional 
expertise towards the needs of patients, 
pharmacists are spending anything from 
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five to 30 hours plus a week resolving 
medicine shortages and firefighting on 
behalf of our patients.
Adding to these concerns is the fact 
that pharmacists typically receive little 
or no warning that these medicines 
are going out of stock and there 
is often little information on when 
these stocks will be replenished. It is 
extremely inconvenient and poses a 
risk to the health of some patients to 
have to return to a doctor to have a 
new prescription written because the 
medicine that they should receive is out 
of stock; indeed, quite often, there is no 
alternative available on the Irish market.
Falling medicine prices are adding to 
the problem as more medicines are 
either being exported out of the country 
to other jurisdictions where medicine 
prices are higher, or are simply not being 
supplied.
We, as pharmacists, as healthcare 
professionals, have a responsibility 
to ensure, as best we can, that key 
medicines are available to our patients 
as and when they require them. It is 
not our responsibility alone, however. 
The Department of Health, the HSE, 
manufacturers, wholesalers and 
regulators need to coordinate a national 
plan to deal with medicine shortages, 
which would include putting steps in 
place to prevent medicine shortages 
and a comprehensive communications 
plan to gather and publish accurate, 
timely information on shortages before 
they occur.
This is an extremely serious situation 
that needs to be urgently tackled. 
To address this ongoing problem and 
to ensure there is a steady supply of 
medicines available in pharmacies, 
we are proposing that this AGM 
calls on the Department of Health 
and the HSE to implement the 
recommendations of the Joint 
Committee on Health and Children on 
medicine shortages, namely:
n	Maintain strong surveillance on 
the impact of national medicine 
price policy on the medicine 
supply;
n	Prepare a contingency plan to 
consider certain export controls 
should medicine shortages arise;
n	Examine the feasibility of 
introducing concessionary pricing 
where medicine supply is an issue;
n	Commission a future-focused 
assessment of the challenges 
posed by pricing, supply and 
demand for pharmaceuticals in 
Ireland.”
 This motion was passed with 1 vote against.
h. “We wish to propose that the IPU 
engages in a process of membership 
consultation prior to making 
submissions to the PSI, Department of 
Health or any other relevant bodies.”
Proposed: Nicola Cantwell
Seconded: Marie McConn
In proposing this motion, Nicola 
Cantwell stated that “Richard Collis and 
I, as [PSI] Council members, have found 
huge value in the feedback from the 
public consultations from pharmacists 
when trying to ensure that the voice of 
community pharmacists is heard when 
discussing the issue of patient safety 
and welfare. Looking at the positivity 
and engagement at the conference this 
weekend, it is obvious that the IPU is 
the only credible voice of community 
pharmacy in Ireland and we need to 
encourage more involvement from 
members to keep pharmacy at the 
heart of the community. Many people 
don’t want to engage with the PSI, (to 
raise their heads above the parapet) nor 
have they the time to get involved with 
IPU committees. I think that setting up 
membership consultations will encourage 
those who haven’t gotten involved 
previously to get involved. It could be as 
simple as a note in the memorandum 
alerting members that there is an open 
PSI consultation, a looming budget or 
other issue with an email address and a 
cut-off date for comments. There are 
2,246 IPU members, all of whom have 
ideas and comments, and it would be of 
huge value to the Union if we could get 
even more people involved. It is all about 
communication, and an initiative like this 
can only serve to strengthen the IPU.
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Following a detailed discussion, the 
following amendment to the motion was 
proposed by Ultan Molloy, seconded 
by Nicola Cantwell and agreed with one 
abstention and one vote against.
“We wish to propose that the 
IPU encourages further member 
engagement prior to making submissions 
to the PSI, Department of Health or any 
other relevant bodies.”
The amended motion was put to the 
meeting and passed with 4 abstentions 
and 4 votes against.
12. Open Forum
The President thanked the organisers of 
the conference for all the work in making 
the weekend such a success. She thanked 
the IPU Secretary General and staff, 
committee members and colleagues 
for their support during her two-year 
Presidency and wished the incoming 
Officers, President Daragh Connolly, 
Vice-President Carmel Collins and Hon 
Treasurer Stephen Nolan all the best for the 
next two years. She then passed the chain 
of office to the new President of the IPU.
Daragh Connolly paid tribute to the 
outgoing President and presented her 
with a bouquet of flowers. He briefly 
addressed the meeting and then closed the 
43rd Annual General Meeting of the Irish 
Pharmacy Union. 
President’s Address at AGM  
– 22 April 2016
Vice-President Daragh Connolly, Honorary 
Treasurer Bernard Duggan, Secretary General, 
Darragh O’Loughlin, fellow members of the 
Irish Pharmacy Union.
We are here this evening to discharge the 
requirements of the Annual General Meeting 
of the Irish Pharmacy Union. We are also here 
to attend our sixth IPU National Pharmacy 
Conference and I would like to welcome you 
all for what promises to be a fantastic event.
Even though the economy continues to 
improve, we know that our sector is still faced 
with a number of significant threats and 
challenges. The FEMPI cuts, reference pricing, 
falling medicine prices and new business 
models are contributing to what remains an 
extremely difficult environment. While in the 
last 12 months there have been some tentative 
signs of improvement in front of pharmacy, 
dispensary revenues continue to struggle.
The rush to drive down the price of medicines, 
regardless of the impact on supply, continues 
to challenge us. The IPU has consistently 
warned the Government of the impact on 
supply of medicines from setting the price too 
low.  The evidence confirms that our warnings 
are justified. This is a problem which continues 
to get worse and an issue that we will continue 
to keep on the Government’s radar.
The considerable regulatory burdens imposed 
by the PSI, through Fitness to Practise and the 
increased amount of legislative requirements, 
is becoming onerous and a serious impediment 
to pharmacy practice. The fact that we have to 
pay, by international standards, extortionate 
fees to fund the operation leaves a sour taste. 
As your representatives, we in the IPU are 
extremely conscious of these issues and we 
have made every effort to try and alleviate 
these difficulties by addressing them head-on 
with the relevant powers that be. At the same 
time, we continue to promote the sector as a 
key element of the healthcare system.
Outstanding Court actions have been settled 
and written commitments have been received 
from Government that the reversal of FEMPI 
would commence imminently. Although 
the amounts indicated for restoration to 
pharmacists are almost laughably low, the main 
thing is that the process has already begun. 
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We made written and oral submissions to the 
Department in February setting out clearly our 
view and we now await the outcome.
I will be telling the Minister tomorrow that 
what has been offered is unacceptable and it is 
our intention to continue to push for equitable 
and proportionate reversal of the cuts, in line 
with other similar groups.
We have had a number of meetings with the 
PSI to discuss, among other issues, Fitness 
to Practise and Corbally, wholesale deliveries 
to pharmacies and PSI fees and minor 
administrative changes to registration details.
We have worked with the PCRS in our efforts 
to get them to address serious failings from 
pharmacy’s perspective in the administration 
of State schemes and this has resulted in 
some improvements. However, we recognise 
that there is still a long way to go. Restrictions 
to reimbursement of medicines should not 
come at the expense of pharmacists whose 
only crime is trying to ensure their patients 
receive the medicines they need. We will 
continue to press for practical improvements 
in communication and information flow to 
pharmacists so that we can be assured of 
reimbursement before medicines are ever 
dispensed, rather than depending on hope and 
goodwill afterwards. 
As a result of our constant political lobbying 
efforts, two favourable Oireachtas Committee 
presentations (2014 and 2015) have resulted in 
positive recommendations from the Committee 
for further expansion in pharmacy services. 
In addition, the IPU is a valued participant in 
the development and implementation of the 
Government’s eHealth Ireland strategy. It is 
important that the IPU is regarded positively by 
policy makers as a proactive and constructive 
stakeholder in health and that pharmacists are 
positioned as the go-to profession for the roll 
out of any new service. 
As a result of these efforts, Ministerial approval 
has been gained for enhancement of the role 
of the pharmacist and changes have been 
implemented. Regulations are now in place to 
allow the expansion of pharmacy vaccination 
and we await PSI and IIOP action to allow 
those new vaccines to be administered. 
Moreover, a Minor Ailment Scheme pilot is 
about to get underway; and legislation to allow 
for non-prescription supply of emergency 
contraception on the GMS, which we formally 
proposed following last year’s conference, has 
been drafted and is awaiting passage through 
the Oireachtas. 
We are also working hard for the introduction 
of other additional services, including 
Medicines Use Reviews, New Medicine 
Service and a Health Check Service, and 
have made strides in getting more medicines 
reclassified, with Dovonex Psoriasis Ointment 
and Voltarol 2% Gel approved already this 
year; but we still have a way to go. 
Of course, we need to be adequately 
remunerated for delivering any new services. 
The introduction of additional services is not 
for everyone, but it is incumbent on us, as 
your representatives, to do everything we can 
to reinforce our position in the healthcare 
system, to protect our existing resources and 
to expand our role in areas that can enhance 
our offering to patients and consumers, and 
introduce additional income streams. 
We all know that there are other health 
professions who are opposed to any expansion 
of our role, who claim that pharmacists are a 
commercial entity only interested in driving 
footfall and we are not qualified to deal with 
patients and offer advice on minor ailments. 
Nonsense. As pharmacists, we are only 
interested in one thing and one thing only, and 
that is providing the safest and best healthcare 
possible to our patients, acting in partnership 
with other healthcare professionals, not against 
them. 
The narrow-minded opposition of others won’t 
put us off. What I will be telling the Minister 
is that we are ready, willing and available to 
provide additional healthcare services that the 
public wants and which the system needs. We 
have the expertise, we are accessible and we 
have the trust and respect of our patients. 
I will also be telling him that Government 
needs to support the contribution that 
pharmacy makes to patient care. They need 
to realise that instead of taking resources out 
of pharmacy, which depletes existing services, 
they should be investing in pharmacy, as a key 
component of a first-class healthcare system, 
especially in light of the pressures in other 
areas of healthcare, where A & E Departments 
are at breaking-point and getting an early 
appointment with a GP is becoming more 
difficult by the day. 
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Through hard work and determination, we have 
made a lot of progress over the last couple of 
years. Relationships with Government, the 
Department of Health, the HSE PCRS and 
the PSI have improved and now provide a 
basis for constructive discussions on the issues 
that matter to IPU members. But there is still 
some way to go and we will continue to work 
constructively, with whatever administration 
is in power, with a view to building on the 
progress we have made to date.
By any objective measure, the IPU is today 
in a far more positive place than it was a short 
number of years ago. 
Membership numbers have never been 
higher than they currently stand and the 
proportion of pharmacies that are members 
is also considerably higher. Engagement and 
communication with pharmacists has also 
been strengthened, all of which solidifies the 
IPU’s position as the only credible voice for 
community pharmacy in Ireland. 
Our lobbying campaign was successful in 
ensuring that all the main political parties in the 
recent election referenced pharmacy in their 
party manifestos, with all of them supporting an 
expanded role for pharmacists. I can assure you 
that when a new government is formed, we will 
be actively engaging with the key participants 
to ensure that our policies are considered in a 
new Programme for Government.
Our advertising campaign, based on the 
slogan “Ask Your Pharmacist First”, remains 
an extremely potent vehicle for getting our 
message across to the public, with latest 
market research confirming that our TV 
ads have doubled viewership since they first 
appeared in 2014. 
Our PR and media coverage continues to 
perform well. The media is fickle and prefers 
a good headline to a balanced or factual news 
story. There are some in the media and, it has 
to be said, within our own profession who try 
to undermine us at every opportunity for their 
own purposes. On this issue we are clearly 
aware that there have been a number of 
articles in the press recently in relation to the 
price of medicines. Our approach, in response, 
has to be, and is, strategically thought out. It 
is easy to respond in a knee-jerk fashion, but 
experience has taught us that this is not always 
the right response. I can assure you though 
that we will continue to defend the profession 
in the media at every opportunity, but only 
under the right and proper circumstances and 
not simply to have a row or to prolong any one 
individual’s time in the limelight.
IPU Academy has been providing CPD to 
community pharmacists for three years and 
has gone from strength to strength, delivering 
a wide variety of live learning and eLearning 
courses. As new CPD requirements come to 
the fore, IPU Academy will continue to deliver 
to your needs. With CPD now mandatory 
and all of us obliged to use the e-Portfolio, I 
encourage everyone to attend IPU Academy 
events or participate in the webinars. They’re 
informative, useful and designed to help us all 
comply with our CPD requirements.
In addition to this, the IPU, through the 
Business Department and the Business 
Steering Group, continues to explore ways 
of improving efficiency and maintaining and 
generating income streams to ensure a viable 
pharmacy model.
Training, both professional and business, 
continues to make massive strides with 
increasing numbers participating every year.
As I mentioned earlier, we are involved with 
the Government’s eHealth Ireland strategy 
and we are participating in eHealth Ireland’s 
ePharmacy Programme, which will bring 
together the whole range of health, wellbeing 
and social care stakeholders interested in 
developing a joint health agenda. We are also 
involved in a multi-stakeholder group that 
will plan and ultimately implement medicines 
authentication in Ireland as required under the 
Falsified Medicines Directive.
Our health campaigns continue to gain 
considerable traction and our recently 
launched Sexual Health Campaign received 
a significant amount of media coverage and 
support from other stakeholder organisations 
including the Irish Family Planning Association 
and the HSE Sexual Health and Crisis 
Pregnancy Programme. We plan to launch a 
further campaign on Men’s Health in June.
The huge success of our involvement 
with RTÉ’s Operation Transformation 
demonstrates the importance of pharmacy to 
our communities and the key contribution we 
can make to the nation’s health. We are now 
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seen as a central part of the campaign, which is 
a huge achievement.
hmR Ireland continues to grow and is 
producing extremely powerful data and 
information, which is becoming an invaluable 
source in our negotiation with Government 
and other agencies. Pharmacy Watch has 
been launched and is providing participating 
members with vital information allowing 
them to make decisions about their business 
from a more informed perspective. The 
team from hmR is here this weekend so 
ask them to show the system to you. If you 
have not already signed-up to hmR, I would 
encourage you to do so. 
I should also mention the fantastic achievement 
of the IPU Product File Department, with 
the support of the IT Programme Manager, 
in successfully achieving ISO Certification 
for 9001 (Quality) and 27001 (Information 
Security). The process highlights the value of 
the IPU Product File, which belongs to all of us, 
and we should be proud that it has cemented 
its position as the definitive pharmacy product 
catalogue in Ireland. 
Following suggestions from members, we 
have also recently hired a Membership Liaison 
Officer who will be out and about visiting 
members in their pharmacies to offer support, 
establish your concerns and see what the IPU 
can do for you.
This is only a flavour of what we have done 
this last year on your behalf. I assure you that 
we will continue to promote your agenda by 
engaging constructively with Government, 
other healthcare professionals and with the 
public to ensure that the potential of pharmacy 
is realised and to develop services to support 
practising pharmacists. We will seek out and 
seize every opportunity to secure the future 
of community pharmacy. This is done with the 
huge support of members who are actively 
involved in our decision making and the 
implementation of our policies on the ground. 
The sector has gone through many changes 
over the last number of years. We have had to 
endure difficult times, deal with uncertainties 
and at the same time deliver the same 
first-class level of professional service to 
our patients as we always have. But we are 
nothing if not resilient, and we have to be. We 
have faced many challenges in the past, and 
overcome them, and we will continue to do so 
into the future. With the amount of change 
happening today, it is difficult to establish 
what the future holds for our profession 
but I can assure you that the IPU, as your 
representative organisation, will continue to 
deal with whatever comes our way. But it is 
not only important that we are prepared for 
all eventualities, it is essential that we in the 
IPU are ahead of the curve and that we are 
the ones influencing future policy, setting 
the agenda and shaping the future of the 
pharmacy sector.
It is vital that we have a united and strong 
IPU that will carry the community pharmacy 
agenda forward.
Before I conclude, I would like thank all our 
committee members, who have given of their 
time over the past number of years.
I would also like to take this opportunity to 
thank Vice-President Daragh Connolly, 
Honorary Treasurer Bernard Duggan and all 
our hard working committee members who 
work tirelessly on your behalf. They are ably 
supported by the dedicated staff in Butterfield 
House, all of whom remain committed to 
supporting and assisting all of us. On your 
behalf, I thank all of them most sincerely for 
their commitment, dedication and enthusiasm. 
I would like to pay particular thanks to our 
Secretary General, Darragh O’Loughlin, for his 
considerable efforts in promoting the sector 
and protecting the interests of our members 
and for his support, advice and guidance to me 
in my role as President.
Finally, as I prepare to hand over the chain of 
President to my worthy successor, I would like 
to thank you all for your support and kindness 
throughout my presidency. I am proud to be 
a pharmacist and proud of my profession. It 
has been a huge honour and a real pleasure 
to have been given the opportunity to serve 
this profession for the last two years. I have 
no doubt that you will extend your full support 
to Daragh Connolly as he takes office as 
President of the IPU and to our new Vice-
President, Carmel Collins, and Honorary 
Treasurer, Stephen Nolan.
I would like to wish you all a very enjoyable 
evening and weekend.
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The following motions were proposed 
in accordance with Article 30 of the 
Constitution. All motions were debated and 
considered by the meeting and then passed.
1. “That this AGM calls on the Government to 
recognise pharmacy as a crucial element of 
primary care and to allocate the necessary 
resources to developing pharmacy services 
in order to alleviate pressures caused by 
the persistent GP manpower crisis and 
ensure easy access for patients and the 
public to safe, convenient and cost-effective 
healthcare.”
Proposed: Kathy Maher
Seconded: Carmel Collins
Action
The Minister for Health expanded the 
pharmacy vaccination service to include 
pneumococcal and shingles for the 
2016/17 season. We have made a proposal 
for further expansion of the service and for 
pharmacists to be permitted to vaccinate 
patients in nursing homes, rather than only 
in the pharmacy, as is currently the case. 
2. “That this AGM calls on the Department of 
Health to commence negotiations with the 
IPU on a new Pharmacy Contract that is 
fit for purpose and which reflects the needs 
of patients and the practice of pharmacy in 
the 21st Century.”
Proposed: Eoghan Hanly 
Seconded: Ray McSharry 
Action
A delegation from the IPU met with the 
Minister for Health in June 2016. At this 
meeting, the Minister was made aware 
that the current Community Pharmacy 
Contractors’ Agreement is now 20 years 
old and while it was modernising contract 
and positioned pharmacy services well for 
many years, it was now in urgent need of 
review. The Minister indicated that, in his 
view, contracts for health professionals, 
including pharmacists, needed to be 
reflective of the role each profession 
plays in the delivery of healthcare within 
a single coordinated approach to health, 
rather than silos for each profession, 
and acknowledged that the future role 
of pharmacists and any contractual 
arrangements would need to be addressed 
in that context.
Subsequently, the Pharmacy Contractors’ 
Committee (PCC) formed a sub-
committee, the purpose of which is 
to prepare a new draft Community 
Pharmacy Contractors’ Agreement for 
consideration by the PCC, which is fit 
for purpose and reflects the needs of 
patients and the practice of pharmacy 
in the 21st Century, and which will form 
the basis of the IPU’s engagement with 
the Department of Health (DoH) and 
the Health Service Executive (HSE) 
on the negotiation of a new pharmacy 
contract. The sub-committee will also 
make recommendations to the PCC in 
relation to its strategy for negotiations with 
the DoH and HSE. The sub-committee 
expects to complete its work by August 
2017.
3. “That this AGM calls on the Minister 
for Health to review the Medical Card 
Prescription Levy; initially by exempting all 
vulnerable patients – including homeless 
patients, palliative care patients and others 
who require their medication changed on a 
daily or weekly basis, patients in residential 
care settings, patients with intellectual 
disabilities and patients receiving treatment 
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under the Methadone Treatment Scheme in 
respect of other medication that they may 
require – and ultimately by phasing it out 
over a three-year period.”
Proposed: Ciara McCabe 
Seconded: Michael Walsh
Action
In our August 2016 pre-budget submission 
to the Department of Finance and the 
Department of Public Expenditure and 
Reform, the IPU again called for the 
phasing out of the prescription levy and 
at the very least that it not be applied to 
vulnerable patients. A number of press 
releases were issued throughout the year 
repeating this message, which generated 
media coverage including an appearance 
by IPU President Daragh Connolly on 
RTÉ Radio One’s Morning Ireland. The 
Government reduced the prescription levy 
for the over 70s and their dependants in 
the budget. The IPU wrote to the Minister 
after the announcement in the budget 
seeking that the Government apply the 
reduction to all medical card holders.
4. “That this AGM calls on the Minister 
for Health to engage promptly with the 
IPU on the recommendations of the Joint 
Committee on Health and Children on 
expanding the role of the pharmacist, 
namely:
n	Establishing a New Medicines 
Service;
n	 Introduction of Medicine  
Use Reviews;
n	Consideration of what other steps 
could be taken to enhance the role 
of the pharmacist in the provision of 
primary care to patients;
n	Assessment of a financial incentive 
mechanism for pharmacists to supply 
biosimilars;
n	A detailed analysis of the potential 
of community pharmacists to expand 
their role by delegating prescription 
authority to them;
n	 The reclassification of a wider range 
of medicines from prescription-only to 
non-prescription.”
Proposed: John O’Connell 
Seconded: Roma O’Loughlin
Action
In January 2017, with the support of 
an educational grant from Pfizer, we 
commenced a New Medicine Service 
(NMS) pilot. NMS aims to provide 
support for people who have been newly 
prescribed a medicine for certain long-
term conditions or therapies (asthma, 
COPD, Type 2 diabetes, hypertension, 
antiplatelet/anticoagulant therapy, statin 
therapy and chronic pain). It consists of 
a structured intervention at initiation of 
therapy with follow-up in the short term 
to improve medicines adherence and 
increase effective medicine taking. 96 
pharmacies across 23 counties applied to 
participate. The pilot was registered as a 
clinical trial with ISCRTN and we received 
ethics approval from NUIG. The pilot ran 
for three months and we are now in the 
process of evaluating the results. 
Following extensive engagement with 
all political parties in the run-up to the 
General Election campaign in 2016, 
the Department of Health Strategy 
2016-2019, published in December 
2016, committed to expand the role of 
community pharmacists in managing the 
health of their patients and medicine 
prescription. 
We met with the Department of Health in 
March 2017 to discuss a pharmacy service 
whereby GMS patients can access EHC 
without a prescription directly from their 
pharmacist; legislation to facilitate this was 
passed by the Oireachtas in March 2017 
following extensive lobbying by the IPU. 
Dovonex Psoriasis was switched in May 
2016 and Buscopan in April 2017. We are 
working with a number of other pharma 
companies on further switches. 
In February 2017, the Minister for Health 
announced that he was going to publish a 
national policy on biosimilars in the near 
future.   
5. “That this AGM calls upon the Department 
of Health and HSE to immediately roll 
out a national Pharmacy Minor Ailment 
Scheme following the completion of the 
three-month pilot scheme.”
Proposed: Sheila O’Loughlin 
Seconded: Sarah Magner
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Action
The IPU, in partnership with the HSE 
and the Department of Health, launched 
a pharmacy-based Minor Ailment 
Scheme (PMAS) pilot on 1 July 2016. 
The Pilot ran for three months in four 
towns across Ireland: Kells, Co. Meath; 
Roscommon Town; Edenderry, Co. 
Offaly; and Macroom, Co. Cork. The pilot 
allowed medical card patients to receive 
treatments for specific minor ailments 
under their GMS entitlements directly 
from their pharmacist without having 
to attend their GP surgery to obtain a 
prescription. The participating pharmacies 
were permitted to dispense specific OTC, 
GMS-reimbursable treatments for five 
conditions without prescription as per 
agreed protocols. Those conditions were: 
Dry Eye, Dry Skin, Scabies, Threadworms 
and Vaginal Thrush. The pilot is complete 
and the HSE is in the process of finalising 
the evaluation for publication. It is hoped 
that we can secure a nationwide rollout of 
a PMAS and that additional minor ailments 
will be added on in stages.
6. “That this AGM calls upon the HSE to roll 
out a pharmacy-based anticoagulation 
service in areas of the country where such a 
service is not easily accessible.”
Proposed: Jonathon Morrissey
Seconded: Ultan Molloy
Action
We proposed and discussed this with 
the previous Minister for Health and 
participated in a cross-stakeholder 
group of clinicians, pharmacy schools, 
HSE and PSI, which produced a report 
recommending that such a service be 
established. 
7. “That this AGM calls on the Department 
of Health and the HSE to implement the 
recommendations of the Joint Committee 
on Health and Children on medicine 
shortages, namely:
n	Maintain strong surveillance on the 
impact of national medicine price 
policy on the medicine supply;
n	Prepare a contingency plan to 
consider certain export controls 
should medicine shortages arise;
n	Examine the feasibility of introducing 
concessionary pricing where medicine 
supply is an issue;
n	Commission a future-focused 
assessment of the challenges posed 
by pricing, supply and demand for 
pharmaceuticals in Ireland.”
Proposed: Daragh Connolly  
Seconded: Caitriona O’Riordan
Action
The Department of Health (DoH) carried 
out a consultation on Medicine Shortages 
in 2012 to which the IPU made a 
submission. However, the Department has 
still not released their report on Medicines 
Shortages following that consultation. As 
the report is now 18 months old, it will need 
to be revisited before being published. It is 
up to the Medication Safety Forum, which 
is chaired by the DoH, to take the lead 
on this initiative. The IPU has raised the 
issue repeatedly with the relevant officials. 
At our meeting with the HPRA in March 
2017, they confirmed that it is a priority 
for the HPRA to set up a stakeholder 
workshop to discuss and agree how best to 
handle medicines shortages.
8. “We wish to propose that the IPU engages 
in a process of membership consultation 
prior to making submissions to the PSI, 
Department of Health or any other relevant 
bodies.”
Action
Since the last AGM, we have made 
submissions to two PSI public 
consultations on behalf of IPU members 
– Draft Regulations on Videolink and 
PSI Customer Charter. Before we 
made the submissions, we put a note in 
the eNewsletter and/or GM asking for 
members’ input into our submissions. 
No feedback was received for either 
submission.  
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OVERVIEW FROM THE 
SECRETARY GENERAL  
Darragh O’Loughlin
1. Introduction 
The Irish economy, once again, performed well 
in 2016, with positive economic growth and 
falling unemployment. Unfortunately, however, 
the economic improvement has not been 
reflected in consumer sentiment or pharmacy 
businesses. The continual implementation of 
reference pricing and the new Framework 
Agreement on the Supply of Medicines to the 
public Health Services between IPHA and 
the Government have exacerbated downward 
pressure on already weak pharmacy revenues, 
and Brexit-related concerns resulted in year-
end consumer sentiment at a two-year low. As 
a result, average pharmacy operating profits fell 
further during the year.
The general election in 2016 saw the 
introduction of “new politics” and a terminally 
weakened Government. Following the 
appointment of a new Minister, and despite 
clear commitments from his predecessor, 
the Government has taken no tangible steps 
towards unwinding the cuts to payments to 
pharmacists and other professions which 
were implemented under the punitive 
Financial Emergency Measures in the Public 
Interest (FEMPI) Act. The IPU relentlessly 
continues to pursue an equitable unwinding 
of pharmacists’ FEMPI cuts in line with any 
unwinding applied to other similar groups.
Close scrutiny of the HSE PCRS by the 
Comptroller and Auditor General has led to a 
tightening of audit and validation obligations 
for pharmacists and an increased emphasis on 
claims accuracy and probity. The increased 
administrative workload in pharmacies 
brings no benefit to pharmacists or their 
patients but is a feature of our increasingly 
regulated society. The IPU has sought, as far 
as is possible, to achieve a reasonable and 
proportionate approach by PCRS and to 
mitigate and minimise the imposition of the 
new requirements.
The IPU exists only to serve the interests 
of its members. There are comprehensive 
reports in this publication which illustrate the 
wide range of activities that the IPU engages 
in. The Executive Committee oversees 
the management of the IPU and the work 
of the three main IPU Committees – the 
Community Pharmacy Committee, Employee 
Pharmacists’ Committee and Pharmacy 
Contractors’ Committee – ensures the IPU’s 
continued importance to and focus on the 
needs of practising pharmacists. 
The members of the IPU’s committees 
have worked hard all year to support the 
community pharmacy profession. The term 
of office of the current committees will 
finish at the end of this year. We are lucky to 
have so many hardworking and experienced 
committee members working on the 
committees on behalf of all members, at all 
times bringing the perspective and concerns 
of everyday practising pharmacists, and we 
hope that they will remain willing to do so 
into the future. The pooling of members’ 
ideas, efforts and resources, matched with 
the enthusiasm of the pharmacists who 
give generously of their time, energy and 
experience, ensures that all pharmacists 
benefit from IPU services in their 
practices and their businesses and 
also ensures that we are here 
to support, advise 
and assist 
individual 
members 
whenever 
you need 
us. 
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2. Membership & Pharmacy Ownership (as at 16 March 2017)
a. Membership of the IPU
Community Proprietors 862
Industry & Wholesale 5
Community Employees 1,398*
Hospital 0
Army, Academic & Admin     2
Associate Members 7 2,272
b. Number of Community Pharmacies
Pharmacist Owned:
Single shops 674
Chains 745 1,419
Non-Pharmacist Owned:
Single shops 61
Chains 264 325 (1,743)
c. Total Number of Chains (2 and over)
Pharmacist  Non-Pharmacist
Two pharmacies 114 7 242
Three 45 1 138
Four 12 48
Five 10 50
Six 5 30
Seven 4 2 42
Eight 4 32
Nine 1 9
Ten 1 10 110
Eleven 2 22
Thirteen 1 13
Sixteen 1 16
Seventeen 1 17
Twenty 1 20
Twenty-Six 1 26
Thirty 1 30
Thirty–One 1 31
Sixty 1 60
Eighty-Three 1 83
Ninety 1 90
(745) (264)
*Notes on Employee Membership
728 are Supervising Pharmacists availing of the free membership for additional pharmacies.  
Three are Supervising Pharmacists in non-pharmacist owned pharmacies and are covered  
by the sub paid by the pharmacy. 57 are availing of the free first-year membership.  
16 are joint pharmacy owners who pay a CE subscription.
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3. Administration Unit
The Administration Unit has three staff 
members. Róisín Molloy is responsible for all 
aspects of membership and the management 
of the Secretary General’s office. Patrice 
O’Connor looks after membership support 
and assists in the day-to-day running of the 
office. Ciara Enright, who works part-time 
as the IPU’s accountant, is Secretary to the 
Finance Committee. She maintains books of 
account and advises members on a range of 
taxation and accountancy issues. 
4. IPU Product  
File Unit
The IPU Product File is 
managed by Fiona Hannigan 
and her team: Ger Gahan, 
Tara Kelly, Eilish Barrett and Alan Collins. As 
well as supplying price updates and product 
information for members, they provide the 
following services and advice: 
n	Product sourcing;
n	General queries on the  
IPU Product File;
n	GMS pricing issues;
n	Medicine Shortages; and
n	Discontinued Lists.
IPU Product File Update
n	 ISO Certification awarded  
to IPU Product File
• Stage 2 Audit, February 2016;
• ISO Certification for 9001 (Quality) 
and 27001 (Information Security), 
February 2016; and
• ISO Certification maintained, 
through quarterly audits.
n	 IPU Product File Distribution 
• Work has commenced on developing 
a new distribution method for the 
IPU Product File;
• Vendors were consulted with and 
provided with a status update at 
quarterly meetings; and
• Test environment for the new 
distribution method was made 
available to vendors.
n	Enhancements to the IPU Product File
• Route of Administration Field  
added in May 2016; and
• Snomed CT Affiliate Licence for 
mapping to IPU Product File was 
granted in December 2016.
5. Contractual Issues 
The Contract Unit consist 
of two staff members, Derek 
Reilly, Contract Manager and 
Secretary to the Pharmacy 
Contractors’ Committee (PCC), and Aoife 
Garrigan, Contract Administrator.   
As PCC Secretary, Derek plays a key role in 
developing and promoting PCC initiatives and 
the resolution of issues arising with the HSE, 
PCRS and the Department of Health. The 
Contract Unit spent much of the year liaising 
directly with the HSE PCRS in an effort to 
resolve the numerous contractual queries and 
payment issues that arose.
The PCC Secretary met with the HSE 
PCRS regularly throughout the year as 
part of a number of fora including the 
Joint Consultative Group, which facilitates 
consultation and negotiation between the 
HSE and the IPU; the Joint Operational 
Group, in which issues involving processing 
payment of claims and resolving queries raised 
by individual pharmacy contractors are dealt 
with; and the Pharmacy Interface Project, 
whereby the pharmacy interface between 
pharmacy contractors and the PCRS will be 
upgraded to the benefit of all parties.
In addition to assisting with the above, Aoife is 
responsible for compiling information on raids 
and robberies that have occurred and highlight 
any trends which have been identified. She 
is also responsible for notifying members of 
forged and stolen prescriptions in circulation 
via the IPU eNewsletter. 
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6. Communications  
and Public Affairs
Jim Curran, as Director 
of Communications & 
Strategy, oversees the 
IPU’s internal and external communications 
and is responsible for developing the IPU’s 
strategy. The Communications Team, which 
includes Aoibheann Ní Shúilleabháin and 
Ciara Browne, are responsible for promoting 
the interests of the IPU and the membership 
through effective communications with 
members, media, the public and other parties 
that influence the sector. Jim is responsible 
for overseeing business development and 
policy research, as well as the new strategy 
statement for the IPU, which will cover the 
period 2017-2021. Jim is also Secretary to the 
Executive Committee and represents the IPU 
on external committees.
Aoibheann coordinates the communication 
activities for the IPU across multiple channels. 
She is responsible for IPU publications, 
particularly the IPU Review and the Annual 
Report, as well as the annual IPU National 
Pharmacy Conference. She manages 
the IPU’s website, www.ipu.ie, as well as 
coordinating advertising and marketing 
campaigns. Aoibheann oversees the  
branding of the IPU.
Ciara assists with all IPU communications and 
is responsible for the production of IPU News 
(the weekly eNewsletter) and the monthly 
GM. She coordinates the IPU’s presence 
on social media channels and is an editorial 
associate of the IPU Review. She also assists 
with media coverage for the IPU.
Communications update since the last AGM
n	Communications with Members: 
Communications with members 
continue to improve, with the IPU 
website, IPU News (the weekly 
eNewsletter) and the IPU’s social  
media channels all seeing an increase 
in uptake from members. The monthly 
GM is sent to members by email and 
post. Regular communications are  
sent to keep members up-to-date  
with vital current information to run  
an efficient pharmacy.
n	Advertising Campaigns: The IPU 
continues to promote the ‘Ask Your 
Pharmacist First’ message with national 
radio and television ad campaigns. The 
2016 advertising campaign consisted of 
five segments: three radio ads and two 
television ads. The ads were broadcast 
at different stages throughout the year, 
according to the issue being highlighted, 
receiving extensive national airplay, and 
were also well-received on social media.
n	Publications: The IPU Review, IPU 
Yearbook & Diary and Annual Report 
are all produced in-house.
n	Annual Review: The Annual Review 
of the Sector is part of an ongoing 
annual series that authoritatively tracks 
changes in community pharmacy. It 
enables us, as a representative body, 
to promote members’ interests based 
on credible facts that are measured 
consistently over time. The 2015/6 
review was carried out by Fitzgerald 
Power.
n	Submissions: The IPU makes 
submissions on behalf of members on 
a range of issues. A number of these 
submissions are available on www.ipu.ie.
n	Market Research: The IPU undertook 
market research amongst the general 
public on their pharmacy usage and 
attitudes towards pharmacy. 
IPU National Pharmacy Conference
The annual IPU National Pharmacy 
Conference has been a great success since 
the inaugural event in 2011. Since then, 
the conference has grown and expanded 
to facilitate the needs of members. The 
conference is a great opportunity for 
members to come together in an educational 
and social environment and provides valuable 
networking opportunities for pharmacists. 
Over the weekend, pharmacists have the 
opportunity to build on their continuing 
professional development (CPD) and receive 
updates on the work of the IPU at the AGM. 
The President’s Dinner & Ball is also held over 
the weekend of the conference. 
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7. Pharmacy Services
The Director of Pharmacy 
Services, Pamela Logan, 
coordinates all Professional, 
IT and Training matters 
within the IPU. Pamela acts as Secretary to 
CPC and details of issues covered by this 
committee can be found in the CPC report. 
She works with relevant departments and 
agencies, both nationally and internationally, 
to promote the role of the pharmacist. Pamela 
also represents the IPU at PGEU and FIP. 
Liz Hoctor is the Professional Development 
and Learning Manager and has been 
instrumental in the setting up of IPU 
Academy. IPU Academy has gone from 
strength to strength in 2016, providing 
members with access to high-quality learning 
opportunities and offering them support 
and assistance in complying with obligations 
under the regime of mandatory continuing 
professional development. Liz also oversees 
IPU NET, our online web-based platform 
designed to support members in the delivery 
of new pharmacy services. Alma Barr, 
Education and Event Coordinator, assists Liz 
with IPU Academy and also organises the IPU 
National Pharmacy Conference.
Alan Reilly is our ICT Programme Manager, 
responsible for developing the IPU’s IT 
strategy.
8. Training & HR Department 
Susan McManus, Training & HR Manager, 
organises and coordinates a selection of 
training courses for pharmacy staff. Janice 
Burke assists Susan in this department. 130 
Pharmacy Technicians graduated in March 
2017. There are 207 students at present 
partaking in Year 1 and 196 students in Year 
2 of the course. In addition, 417 attended 
continuing professional development (CPD) 
for qualified pharmacy technicians in 2016. 
134 students completed the Medicines 
Counter Assistant (MCA) Course in 2016 
in seven venues around the country and 11 
students completed the Medicines Counter 
Assistant (MCA) Refresher Course. 103 
students completed the Interact course and 
24 completed the Interact Plus course. The 
fifth cohort in the Diploma in Leadership 
and Management commenced in September 
2016 with 12 enrolments, while 25 students 
completed the Supervisory Development 
Course in 2016. Six students completed 
the Award in Leadership and Management 
in 2016. Eight people enrolled onto the 
Pharmacy Retail Sales course in October 
2016 and 31 purchased the ‘Medicines in 
Care Homes’ training package in 2016. The 
Dublin and Dun Laoghaire Education and 
Training Board (DDLETB) Pharmacy Sales 
Traineeship course was administered in a 
number of educational institutes and senior 
colleges around the country.
Another addition to the Training Department’s  
portfolio is the Return to Community 
Pharmacy Practice course, launched in January 
2017, with seven candidates attending. The 
material has been developed for pharmacists 
returning from a career break, e.g. maternity 
leave or a sabbatical or for newly registered 
pharmacists from another jurisdiction. 
Susan also acts as Secretary to the Employee 
Pharmacists’ Committee (EPC), co-produces 
the IPU Yearbook and Diary and Wall-
Planner, and advises members on human 
resource issues. 
9. Business Services
The Business Development 
Manager, Darren Kelly, is 
responsible for business 
services and advice to 
members, along with Jim Curran. Darren and 
Jim represent IPU members on a number 
of strategic retail forums that have enabled 
us to provide a platform for a structured 
engagement between the retail sector and 
relevant Government departments and 
agencies on areas such as crime prevention, 
upward-only rent issues and town centre 
issues. As part of the IPU Business Strategy 
to assist members in engaging with digital 
marketing and social media to enhance their 
business offering, we ran a number of training 
programmes for pharmacies in 2016. The 
workshops were fully attended and feedback 
was extremely positive. We also ran a number 
of Essential Pharmacy Store Management 
training programmes around the country in 
September and October 2016. All sessions 
were full and feedback from attendees was 
very positive. 
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The IPU Business Department held its annual 
Business Briefings, entitled “Increase your 
Pharmacy’s Efficiency”, around the country 
in June 2016. Four expert speakers covered 
a range of topics: Customer Perceptions of 
Pharmacy; Maximising Retail Potential in your 
Pharmacy; Why you have Financial Planning 
and Employment Law – How to ensure 
compliance. Seven sessions were held and 
over 100 members attended.
Members are kept up-to-date with 
current legislation through notices in IPU 
communications. The business Tip of the 
Week was introduced to the eNewsletter this 
year and has proven to be very popular with 
members. A number of affinity schemes have 
been negotiated for members on a range of 
products and services and details can be  
found on www.ipu.ie. 
Darren operates the IPU Retail Review 
Consultancy Service, which is available to 
members at a discounted rate. Over 100 
pharmacies have availed of this service to 
date. Darren visits pharmacies for a full-
day retail review, develops a retail plan and 
implements the plan over the course of the 
day. The feedback from members who have 
availed of this service has been very positive. 
Details of this service can be found on  
www.ipu.ie. Members can contact the 
Business Department for advice and 
information on the Business Helpline  
01 406 1558.
Joyce Mulpeter joined the IPU in February 
2017 as the Member Relationship Manager. 
Joyce has over 25 years’ experience in 
business and will be calling to pharmacies 
throughout the year, ensuring they are up-
to-date on ongoing issues and are aware of 
additional services that we are providing.
Darren also oversees the general maintenance 
and upkeep of Butterfield House. 
10. External Consultants
MKC Communications (PR Consultants); 
Coolamber (IT Consultants); John Behan 
(Industrial Relations Advisor) and Sean 
McHugh (Industrial Relations Advisor) provide 
advice and support to the IPU as requested 
on an ongoing basis. Leaf Environmental has 
been retained as consultants to the IPU on 
matters regarding environmental and waste 
management issues. Legal advice is provided 
by DAC Beachcroft on an ongoing basis 
and by Beauchamps solicitors in relation to 
specific matters.
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11. Main Committee Meetings
The number of committee meetings was:
’16 ‘15 ‘14 ‘13 ‘12
Executive Committee 5 7 7 5 7
Community Pharmacy Committee 4 5 4 4 4
Pharmacy Contractors’ Committee 4 6 2 3 6
Employee Pharmacists’ Committee 3 3 5 4 4
Finance Sub Committee 6 5 6 5 6
All Committee Meetings 0 0 0 0 1
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12. Conclusion
The business environment for pharmacy is 
constantly changing and getting increasingly 
difficult. Pharmacies need better and faster 
information to run their businesses effectively 
and profitably. In order to ensure that our 
members have access to the best business 
intelligence available, the IPU launched 
Health Market Research (hmR) in 2014 in 
partnership with ANF, based in Portugal, to 
collate anonymised data from pharmacists’ 
systems, aggregate the information and 
deliver best-in-class benchmarking and 
trend reports to participating members. The 
Pharmacy Watch service has been adopted by 
more than 1,100 pharmacies and is delivering 
accurate and up-to-date information to 
participating pharmacies. It also provides 
the IPU with essential information and 
analysis on the evolving state of the overall 
pharmaceutical market and the impact of 
ongoing reimbursement changes, which 
allows for more effective engagement with 
Government, the HSE and the media. I would 
encourage all of you to participate, as the 
benefits to all of us increase with the number 
of participants and the purpose of the project 
is solely to benefit IPU members. 
I am lucky to work with a great team in 
Butterfield House, who are fully united in 
their determination to represent and serve the 
community pharmacy profession to the best 
of their ability. We will continue to innovate 
in order to effectively assist our members in 
ever-changing circumstances, while working 
ceaselessly to represent, advocate for and 
defend the community pharmacy sector, and 
promote the valuable work that pharmacists 
do every day in every town, village and 
community in the country. We are grateful 
for the incredible support we get from 
our members, without which we could not 
function, and we are always keen to receive 
your feedback, either directly or via your 
committee members.
Darragh J O’Loughlin
Secretary General
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The Pharmacy Contractors’ Committee 
(PCC) is chaired by Eoghan Hanly, with 
Grainne O’ Leary as Vice-Chairperson. The 
committee held four meetings in 2016 and 
two meetings so far in 2017. Three further 
meetings are scheduled for this year. The 
PCC’s mission statement is:
Advocating and negotiating on behalf of 
community pharmacy contractors with 
government and its agencies to secure fair 
remuneration and equitable contractual 
terms for the delivery of services to patients.
Over the past 12 months, the PCC has dealt 
with a variety of issues and has progressed a 
number of different items on behalf of the 
contractor members of the IPU. The following 
is a summary of the key issues dealt with since 
the last AGM.
HSE Contract Matters
n	Participating in regular meetings as  
part of the Joint Consultative Group  
to resolve issues and minimise the 
impact on members; 
n	Working with the HSE PCRS at the 
Joint Operational Group to resolve 
individual member issues;
n	Advocating for the streamlining of the 
Long Term Illness Scheme;
n	Agreeing a flyer with the HSE PCRS to 
inform patients of the need for NOAC/
Fampyra approval, thereby supporting 
them to receive reimbursement;
n	Requested HSE PCRS to issue an 
updated list of Exempt (unlicensed) 
Medicinal Products from 2010 to ensure 
clarity and correct reimbursement;
n	 Issued a poster advising patients who are 
aged 70 and over to make themselves 
known, thereby supporting members 
in securing the correct payment of the 
prescription levy from patients; and
n	Worked with the HSE PCRS to  
provide a Hardship FAQs to provide 
clarity for members.
Joint Consultative Group
The purpose of the Joint Consultative Group 
(JCG) is to allow direct liaison, discussions, 
consultation and negotiations between 
senior representatives of the IPU and PCRS, 
with the objective of seeking agreement on 
matters pertaining to the administration 
of the Community Drug Schemes and 
associated remuneration and reimbursement 
of pharmacists. The JCG has met on six 
occasions in the past 12 months. The PCC, in 
what was a difficult year, with increased audit 
and probity from the HSE PCRS, continues 
to advocate strongly through the auspices of 
the JCG on behalf of members. The following 
are just some of the main issues tackled  
during the past year.
n	Phased dispensing was on the agenda 
for much of the year, given that 
this element of pharmacy fees now 
accounts for almost €100m per year, 
it was under very close scrutiny by 
the Comptroller and Auditor General 
and the HSE. The IPU sought to 
mitigate and advocate on behalf of 
all members and there was regular 
correspondence between IPU and the 
HSE on this matter. Since May of last 
year, the phased dispensing fee rules 
are that there is a requirement for 
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multiple supply occasions. The IPU has 
consistently argued that this rule should 
not be applied retrospectively. We have 
supported members with individual 
advice, as well as through the weekly 
eNewsletter and FAQs.
n	 In May of last year, the HSE issued a 
circular advising pharmacists that they 
could make a disclosure in cases where 
owings claims were made without a 
‘genuine expectation’ that the patient 
would return and that no legal or 
disciplinary process would be invoked if 
such disclosures were made. The PCC 
has kept this process under constant 
review and has raised concerns on 
behalf of members on both a collective 
and individual basis. Attempts by the 
HSE and Department of Health (DoH) 
to introduce a reduced fee for owings 
where no ingredient is dispensed were 
successfully resisted by the PCC.
n	 The introduction of third party 
verification for GMS prescriptions 
was intended to commence not long 
after the 1996 contract but was never 
implemented until this year. The 
PCC raised a number of concerns on 
behalf of members, resulting in some 
common sense measures being applied 
whereby once a pharmacy makes 
‘reasonable efforts’ to obtain signatures 
they will be reimbursed, and in nursing 
home settings, that the signature of 
the person in charge signing for all 
medicines received is acceptable for 
probity purposes, rather than requiring 
that every prescription be signed.
Joint Operational Group
The work of the Joint Operational Group 
(JOG) involves arrangements for processing 
payment of claims and resolving claim-related 
queries/issues raised by individual community 
pharmacy contractors and other operational /
administrative arrangements. The JOG met 
six times in the past year. This forum has 
proved beneficial in resolving the majority of 
issues raised on behalf of members.
PCRS Pharmacy Interface Project
The purpose of this project is to enhance 
the electronic interface between pharmacy 
contractors and the PCRS. This project was 
delayed for a period of time while the HSE 
sought to introduce a reduced fee for owings. 
The issue was resolved with the owings fee 
remaining as is. The first deliverables of this 
project – electronic submission of Dental, 
EU claims, managing owings and enhanced 
XML listing – are due to be rolled out later 
this year.
Pharmacy Contract  
Sub Committee
The PCC formed a sub-committee, the 
purpose of which is to prepare a new 
draft Community Pharmacy Contractor’s 
Agreement for consideration by the PCC, 
which is fit for purpose and reflects the needs 
of patients and the practice of pharmacy 
in the 21st Century and which will form the 
basis of the IPU’s engagement with the DoH 
and the HSE on the negotiation of a new 
pharmacy contract. The sub-committee may 
also make recommendations to the PCC in 
relation to its strategy for negotiations with 
the DoH and HSE. The committee has met 
twice this year and expects to complete its 
work by August 2017.
Policy Matters
IPHA Agreement
The agreement between the State (DoH 
and HSE) and the pharmaceutical industry 
(IPHA) was announced on 20 July 2016. The 
announcement at the time gave pharmacists 
just over one week’s notice to prepare for 
price reductions. The IPU made multiple 
representations to the PCRS, HSE, DoH and 
Minister for Health, insisting that we must, at 
a minimum, receive four weeks’ notice of any 
price changes.
While the agreement states that it does not 
fetter or limit the exercise of the HSE’s 
powers under the Health (Pricing and Supply 
of Medical Goods) Act 2013, the legislation 
which gives them power to set reimbursement 
prices unilaterally and which does not oblige 
them to give notice to pharmacists (except for 
reference prices) does not prevent the HSE 
from giving reasonable notice, nor does it 
prevent them from applying price reductions 
to reimbursement prices one month after 
they apply to ex-factory or wholesale prices. 
Of note in correspondence received from the 
DoH in July 2016 was that ‘…with regard to 
the implementation of the price reductions, this 
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is an operational matter for the HSE.’ The IPU 
continues to make representations on behalf 
of our members for minimum notice periods 
of all price changes from the DoH and HSE.
Financial Emergency Measures in the Public 
Interest (FEMPI) Act
The IPU met with the Minister for Health, 
Simon Harris, in June 2016, seeking that 
the DoH begin the long-overdue and 
previously committed unwinding of the 
reductions in payments to community 
pharmacy contractors under the FEMPI 
Act. The Minister undertook to re-examine 
the issue and then revert. However, despite 
repeated correspondence, the Minister has 
failed to follow up. The PCC regards this 
as unacceptable in circumstances where 
the previous Minister, Leo Varadkar, had 
committed to commencing the unwinding 
of the reductions in payments which were 
introduced under the Act and where the 
IPU participated fully and constructively in 
the statutory consultation process including 
making a detailed submission of how the 
FEMPI cuts for community pharmacy 
contractors should be reversed. The PCC 
continues to press, at every opportunity, the 
DoH and elected representatives to begin the 
process of unwinding FEMPI. 
Government Policy
A submission was made to the Oireachtas 
Committee on the Future of Healthcare. 
The IPU submitted that the policy options 
available to the Government include 
expanding the role of the community 
pharmacist and introducing properly 
resourced pharmacy-based services, which 
have been shown to operate very effectively 
in other countries. The submission set out 
a menu of additional services that can be 
provided by pharmacists to the public to 
support and assist in the provision of universal 
healthcare for all of the population.
A further submission was made to the DoH as 
part of their public consultation process prior 
to developing their strategy for the period 
2016-2019. The submission outlined how the 
development of pharmacy services is essential 
for the optimisation of healthcare in Ireland. 
This submission also set out priorities the DoH 
must adopt in planning their strategy with 
regards to community pharmacists.
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The Community Pharmacy Committee (CPC) 
is chaired by John O’Connell, with Mark Sajda 
as Vice-Chair. CPC’s mission statement is:
CPC – working to serve and support 
community pharmacists in their practices 
and to promote and expand their role as 
pharmacists by continually developing 
professional, ethical, business and 
technological ideals and standards.
CPC is split into three sub-groups:
n	Professional Steering Group:  
Louise Begley, Anna Kelly, Elizabeth 
Lang, Jonathon Morrissey, Sheila 
O’Loughlin and Mark Sajda.
n	Business Steering Group:  
Mary Barry, Roy Hogan,  
David Gormley and Aidan Walsh.
n	 IT Steering Group:  
Jack Shanahan, Noel Stenson. Ann 
Marie Horan (Exec) and Michael Walsh 
(PCC) have been co-opted onto ITSG, 
along with David Reen, Joseph Haire 
and Ciaran Mulligan.
CPC has met three times since the April 2016 
AGM (July and October 2016 and February 
2017), dealing with a wide variety of issues. 
The following is a summary of the key issues 
dealt with over the last 12 months under the 
headings outlined in the CPC Strategy 2016-
18, which was developed by CPC in April 
2016. 
Professional Issues
Promote the role of the pharmacist in 
Government and HSE Strategy 
We met with the European Commission 
Representation in Ireland in April 2016 
to discuss a range of issues in relation to 
Ireland’s health policy. We met with the 
Department of Health’s Director of Patient 
Safety & Clinical Effectiveness in May 2016 
to discuss a Patient Safety Initiative proposal. 
We met with the Minister for Health in June 
2016 to discuss a range of issues including 
Government healthcare strategy and health 
service reform. The Department of Health 
Strategy 2016-2019 has committed to 
expanding the role of community pharmacists 
in managing the health of their patients and 
medicine prescription. We met with the 
Department of Health in March 2017 to 
discuss a pharmacy service allowing GMS 
patients to access emergency hormonal 
contraception without a prescription directly 
from their pharmacist; legislation to facilitate 
this was passed by the Oireachtas in March 
2017. We made a submission to the National 
Drug Strategy in October 2016 and met 
with the Minister of State for the National 
Drug Strategy in March 2017 to discuss our 
submission. 
      
Work with relevant stakeholders to further 
improve accessibility of medicines through 
switches from POM to Pharmacist/
Pharmacy Only
We worked with Leo on a POM to P switch 
for Dovonex Psoriasis. For its launch in May 
2016, we provided members with a template 
sales protocol. We made a presentation to 
IPHA Consumer Division on switching in 
March 2016. In April 2017, Sanofi switched 
Buscopan and we developed a sales protocol 
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for members. We have been liaising with 
other pharma companies in recent months on 
proposed switches.   
Pursue defined strategies to improve patient 
adherence and optimise medicines use
In Q3 2016, Pfizer gave us a grant to develop 
a pilot New Medicines Service. The pilot was 
scoped out in Q4 2016 and launched in Q1 
2017; 96 pharmacies across 23 counties 
applied to participate. The pilot was registered 
as a clinical trial with ISCRTN in November 
2016 and we received ethics approval from 
NUIG in January 2017. We engaged with 
Pharmapod to develop a platform for data 
collection. We are now in the process of 
evaluating the pilot.  
Continue to extend the pharmacy 
vaccination service to include other vaccines, 
other injectables and other patient cohorts
We produced an FAQ on emergency 
medicines and extended vaccinations in 
June 2016. We wrote to the Minister for 
Health in July 2016, asking that pharmacy 
reimbursement for pneumococcal vaccination 
be included in the estimates for 2017. We 
produced SOPs, protocols and promotional 
materials for flu, pneumococcal and shingles 
vaccinations in August 2016. We made 
a proposal to the Minister for Health on 
expanding the pharmacy vaccination service 
in December 2016. We wrote to the Minister 
for Health in January 2017, advocating that 
pharmacists be allowed to vaccinate patients 
in residential care facilities.   
Develop an anticoagulation service  
through community pharmacy
We proposed and discussed this service 
with the previous Minister for Health and 
participated in a cross-stakeholder group of 
clinicians, pharmacy schools, IIOP, HSE and 
PSI, which produced a report recommending 
that such a service be established. 
Assist members in dealing with  
PSI/HSE/HPRA/DAFM inspections  
and Fitness to Practise issues
We assisted a number of members on FTP 
and other PSI issues. We made a submission 
to the PSI in March 2016 on the Pharmacy 
Assessment System. We developed a 
Pharmacy Assessment System Support Tool 
in November 2016.  
Lobby for amendments to the  
Pharmacy Act 2007
We met with the Minister for Health in June 
2016 and raised the issue of bankruptcy 
and PSI fees. We wrote to the PSI in June 
2016 asking for clarification on the status 
of Irish students studying pharmacy in the 
UK following the Brexit vote and wrote to 
the Department of Health regarding Brexit 
in December 2016. We met with the PSI in 
October 2016. We wrote to the Minister for 
Jobs, Enterprise and Innovation in December 
2016 in relation to PSI fees.
Maintain and strengthen relationships with 
Pharma, Schools of Pharmacy, IIOP and 
patient groups to assist in the provision of 
CPD and other relevant learning
IPU Academy was awarded an educational 
grant by GSK to support the development 
and delivery of the Update on the Management 
of Allergies module for the IPU Academy 
Autumn Programme 2016. The development 
and delivery of the Infant Nutrition module for 
the IPU Academy Autumn Programme 2016 
was supported by an educational grant from 
Nestle. A number of meetings were held with 
pharma companies (Pfizer, Kabi Fresenius, 
AbbVie, Novartis and Boehringer Ingelheim) 
to explore potential opportunities to partner 
together in developing educational initiatives 
for the Autumn Programme 2016 and 
Spring Programme 2017. The IPU Adrenaline 
Administration Training Pack was supported by 
Lincoln Medical, Bausch & Lomb, Mead and 
Alk-Abelló, and distributed to pharmacies in 
Q2 2016. 
In August 2016, IPU Academy and the 
School of Pharmacy & Pharmaceutical 
Sciences, Trinity College Dublin, signed 
an agreement to review and accredit IPU 
Academy Programmes. IPU Academy 
broadcast the following live national webinars: 
in association with Fresenius Kabi on the topic 
of Malnutrition – A Patient Focus in November 
2016; in association with Pfizer on the topic 
of Epilepsy – The Clinicians Perspective in 
November 2016; in association with Pfizer on 
the topic of Health Living/Ageing in January 
2017; and in association with Novartis on the 
topic of Heart Failure Management in February 
2017.  IPU Academy has partnered with 
Abbvie to host five eLearning symposia on 
Biologic and Biosimilar Medicines on the IPU 
Academy Learning Management System. 
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Continue to develop IPU Academy to 
support members’ engagement with CPD
A Coaching and Training course (QQI level 
6 awarded by the Institute of Leadership & 
Management) was delivered to IPU Academy 
tutors in 2016. In order to support recording 
CPD activity in the ePortfolio, we created 
short eLearning presentations (five minutes’ 
duration) for each topic in the IPU Academy 
Programmes, describing “Integrating your 
attendance at an IPU Academy course into your 
ePortfolio”. CPD articles were commissioned 
and published in the IPU Review each month. 
Develop Services Frameworks for  
innovative pharmacy services
In conjunction with the HSE, we launched 
a Minor Ailment Scheme pilot in July 2016 
in 19 pharmacies in four towns. We provided 
participating pharmacies with protocols, 
surveys and promotional materials. We 
worked with Hibernian Healthcare to develop 
Pharmacycare, a platform for paid services 
in community pharmacy. Members are 
encouraged to sign up to Pharmacycare as 
the more pharmacies are signed up, the more 
services we can attract. 
IT
Maintain the IPU Product File as the 
definitive file on the Irish market for 
medicines and medical devices
VMP Classification is now complete and is 
available via Web Service Distribution. The 
IPU Product File continues to adhere to ISO 
standards and requirements, with ongoing 
internal and external audits. We successfully 
secured an Affiliate Licence for Snomed CT 
in Q4 2016 to enhance clinical coding and 
interoperability of the IPU Product File and 
work has commenced on mapping Snomed 
CT to the IPU Product File.
Promote the adoption of the IPU Product 
File as the HSE/eHealth Ireland National 
Medicinal Product Catalogue
We submitted a proposal to eHealth Ireland in 
Q2 2016, offering the IPU Product File as the 
main source for the National Medicinal Product 
Catalogue (NMPC). We met with the HSE 
Project Manager for ePharmacy and the HSE 
Project Manager for Primary Care in Q2 2016 
to discuss the proposal. In Q1 2017, we met 
with the HSE Project Manager for ePrescribing 
to discuss the usefulness of the IPU Product 
File as the main data source for the NMPC.
Continue to work with HIQA’s eHealth 
Standards Advisory Group (eSAG) on the 
development of pharmacy-related standards 
We participate in HIQA’s eHealth Standards 
Advisory Group. We participated in other 
HIQA working groups to develop the Draft 
eDispensing Dataset and Clinical Data 
Architecture (CDA); the National Standard 
for a Dispensing Note and CDA was 
published in January 2017.  In Q3 2016, we 
consulted on the Draft National Standard for 
a Procedure Dataset and Clinical Document 
Architecture Template.
Continue to work with the HSE and eHealth 
Ireland on the implementation of the 
eHealth Strategy for Ireland
We met with the Department of Health’s 
Assistant Secretary R&D and Health 
Analytics and the Head of ICT in Q2 2016 
to discuss our IT agenda and our work with 
eHealth Ireland. We frequently meet with 
project managers from eHealth Ireland to 
assist with progressing their ePharmacy 
Programme. The IPU is represented on the 
National ePrescribing Steering Group. In Q1 
2017, we provided eHealth Ireland with three 
personas as part of their Electronic Health 
Record (EHR) project. In January 2017, 
the IPU hosted a meeting with Julie James, 
a Specialist Informatics Consultant with a 
long-standing relationship with the IPU, on 
the concept of a Medication Profile within a 
Summary Care Record. Representatives from 
HIQA, ICGP, the HSE and eHealth Ireland 
attended. In March 2017, the IPU joined 
the eHealth Ireland Access to Information 
Steering Committee; this committee will have 
direct input into enabling digital solutions to 
be made available effectively in the healthcare 
environment in Ireland, e.g. the National EHR 
and Summary Care Record. 
Work with the PSI and pharmacy system 
vendors on the standardisation of dispensary 
systems with the aim of getting certification 
to comply with pharmacy regulations
In March 2017, we wrote to the DoH 
regarding their intention to engage with a 
number of stakeholders about pharmacy 
computer software being independently 
validated and certified. We made them aware 
that the IPU IT Steering Group had done a 
significant amount of work, in association 
with the three system vendors, to produce 
a dispensary system specification that 
accurately reflects the current dispensary 
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systems and how they comply with all 
medicines and pharmacy legislation.
Continue to foster good relationships with 
vendors with a view to developing a roadmap 
for dispensary system developments
In 2016, the IPU facilitated meetings with the 
vendors and the PCRS to help resolve various 
reimbursement system issues. In Q1 2017, 
the IPU met with vendors to discuss ICT 
developments for pharmacy.
Continue to work with the HSE PCRS on the 
implementation of the Pharmacy Interface 
Project, ensuring that the elements of 
benefit to pharmacy are delivered 
The HSE PCRS Pharmacy Interface Project 
Group now includes the pharmacy system 
vendors (Clanwilliam, McLernons and 
Touchstore). The group meets on a monthly 
basis as part of the implementation phase of 
the project. The first phase deliverable has 
been agreed (Dental Claims, EU Claims, 
Owings and Enhanced XML Listings), with 
timelines to be finalised. 
Participate in the Irish Medicines  
Verification Organisation (IMVO)  
to plan and ultimately implement  
medicines authentication in Ireland
We are actively participating in the IMVO 
to prepare pharmacies for medicines 
authentication in 2019. 
Secure access to Healthmail and its 
connected agencies
Following an evaluation in Q4 2016, the IPU 
worked with Healthlink on a project to roll out 
Healthmail to community pharmacy. In April 
2017, the IPU and eHealth Ireland launched 
Healthmail, agreeing design of the service and 
providing registration assistance, supporting 
material on the IPU website and an article in 
the IPU Review.
Develop a social network to connect 
members to professional learning materials 
through communication, trending activities, 
sharing of ideas and existing online resources
We met with Synergy (the company that 
provides the IPU Academy Learning 
Management System) to learn more 
about their product offerings with regards 
developing a social network and online space 
for IPU members to connect and share 
learning materials through communication, 
trending activities etc. We have asked Synergy 
to deliver a social network module as part of 
the upgrade to the IPU Academy LMS. 
Develop strategies, policies and guidance  
to ensure members’ compliance with  
all data protection legislation 
In 2016, we reviewed the data protection 
arrangements of pharmacies in the context 
of data harvesting and data extraction, i.e. 
companies that extract and/or process 
pharmacy data. This is a project we worked 
on collaboratively with all the system vendors 
and other companies with access to, and 
extracting information from, pharmacies, 
to ensure that everyone is protected and 
meeting data protection requirements. A 
letter was issued in September 2016 with 
advice for members.
Business
Business Policy – Continue to provide 
input into national policies affecting small 
businesses through the Retail Consultation 
Forum, Consumer & Competition 
Commission, National Retail Security 
Forum, Government Departments and other 
relevant organisations on areas such as rates, 
rent reviews, retail planning, budgets and 
to identify business trends and introduce 
policies accordingly
As part of our involvement in the Retail 
Consultation Forum, we are part of the Retail 
and Digital Economy Group, which is looking 
at how to create a self-help guide for business 
owners, identifying the key steps that need 
to be considered with regard to using digital 
and social media in the sector. We attended 
a meeting of the Retail Digital Economy 
Working Group in September 2016 to discuss 
the specific sectoral issues of concern around 
digital skills in the retail sector. This Group 
has now been renamed the Retail and Digital 
Skills Forum. The aim of the group is to 
provide retailers with the best-in-class retail 
and digital training for their employees. Our 
review of recent planning experience of retail 
pharmacy businesses in Ireland, prepared by 
our planning consultants BMA Planning, was 
completed and forwarded to the Minister for 
Housing, Planning, Community and Local 
Government.
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Business Support – Build on relationships 
with independent pharmacies, symbol 
groups and chains to identify opportunities 
to support members through Retail Reviews, 
Membership Liaison, HR, Business Audit 
Tool, Business Advice, Business Mentoring 
Service and Affinity Schemes
In May 2016, we took a stand at the UD 
Pharmacy Show. Members of the IPU team 
were available to over 500 members who 
attended the three-day event. 14 Retail 
Reviews were carried out in Q3 & Q4 2016. 
2017 has started positively with four Retail 
Reviews carried out in Q1. The results have 
been very positive to date.  
Business Training – Continue with the 
delivery of the Diploma in Leadership & 
Management and develop new business 
training programmes
We developed a beginner’s programme 
in Digital Marketing & Social Media for 
members with no experience of using 
digital marketing or social media and a more 
advanced programme for members whose 
pharmacies would have some knowledge of 
using social media. Workshops were organised 
in May and September 2016 in four locations. 
All the workshops were fully attended and 
feedback was extremely positive. We also 
ran a number of Essential Pharmacy Store 
Management training programmes around 
the country in September and October 2016. 
All sessions were full and feedback from 
attendees was very positive. In September 
2016, the fifth cohort of students began 
the Diploma in Leadership & Management. 
The IPU Online Retail Selling Skills Training 
course was held in October 2016. The Spring 
Business Programme began in February 2017 
with a range of courses: Customer Service, 
Retail Merchandising, Pharmacy Store 
Management and Digital Marketing. 
Business Briefings – Identify and deliver 
relevant business topics for half-day  
briefing sessions
The IPU Business Department held its 
annual Business Briefings, entitled “Increase 
your Pharmacy’s Efficiency”, around the 
country in June 2016. We had four expert 
speakers covering: Customer Perceptions 
of Pharmacy; Maximising Retail Potential in 
your Pharmacy; and Why you have Financial 
Planning and Employment Law – How to 
ensure compliance. Seven Briefings were held 
and over 100 members attended.
Business Intelligence – Assist members in 
utilising hmR reports, report to members 
on global business trends, and continue to 
produce an Annual Review of the Sector, 
B&A survey and business trends surveys 
Behaviour & Attitudes public opinion 
survey results were sent to all members in 
May 2016. The results of the survey were 
one of the topics covered at the Business 
Briefings. The Annual Review of the Sector 
was published in July 2016. Business Trends 
Surveys were sent to members in July and 
October 2016, with articles on the results 
published in the IPU Review.
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The Employee Pharmacists’ Committee 
(EPC) represents the interests of community 
pharmacy employee members of the IPU. The 
EPC is chaired by Sheila O’Loughlin, who took 
over from Elizabeth Lang in February 2016, 
with Gillian McGrath as Vice-Chair, succeeding 
Sheila O’Loughlin. Currently there are 1,411 
community employee members of the IPU, 
which comprises 62% of the full membership. 
The mission statement of the EPC is: 
To promote the professional and economic 
interests of employee pharmacists and 
constructively engage with other Committees 
of the IPU and other stakeholders through 
the Employee Pharmacists’ Committee.
The EPC met three times since the 2016 
AGM (June 2016, November 2016 and 
March 2017). The EPC continues to 
have active representation on other IPU 
committees, with an allocation of three 
employee representatives on the Executive 
Committee and four representatives on 
the Community Pharmacy Committee. 
This representation guarantees that the 
views of employee pharmacists are voiced 
and heard on the other committees of the 
IPU, therefore empowering employee input 
into decisions and in the development and 
implementation of IPU policies. 
Communications
The redesign of the IPU website in 2015 has 
facilitated the development of the Employee 
Pharmacists section of the site, providing 
easier access to the information required by 
employee pharmacists.
The EPC’s article published in this year’s 
March issue of the IPU Review provided  
a guide for employee pharmacists on 
pensions, outlining the employer  
obligations and staff options.
Events
In 2016, Sinead Ryan, on behalf of EPC, 
made a presentation at the Pharmaconex – 
Pharmacist and New Graduate Seminar  
on 16 November; 23 attendees signed-up  
to IPU membership. 
Increase and retain  
IPU Membership 
Throughout the year, the EPC endeavoured 
to encourage non-members to sign up to IPU 
membership. In order to assist in retaining 
current members, the EPC will be available at 
this year’s IPU National Pharmacy Conference 
in Croke Park, Dublin, to meet and talk with 
employee members face-to-face. 
Representation and services
The EPC will continue to pursue its objectives 
with intent and to actively represent the 
interests of employee members. It will also 
ensure that the IPU continues to provide 
services and support to employee members 
within the community pharmacy sector. 
Conclusion
The EPC urges employee members to 
use their membership to the full and keep 
themselves well-versed by reading the IPU 
weekly eNewsletter, General Memoranda, 
IPU Review, IPU Yearbook and Diary and 
other information provided by the IPU. In 
June 2010, all IPU members were assigned 
an @ipumail.ie email account and the EPC 
continually reminds employee members 
who have not activated their account to 
do so without delay. The EPC would also 
recommend that employee members check 
the ‘Employee Pharmacists’ section of  
www.ipu.ie on a regular basis. 
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The Communications Team includes Jim 
Curran, Aoibheann Ní Shúilleabháin and Ciara 
Browne and external advisors, and has an 
important role in communicating key messages 
to the media, the public, stakeholders and 
members. A wide range of communication 
tools, including newsletters, emails, text alerts, 
social media, the IPU Review and the IPU 
website, are used to keep members up-to-date 
on ongoing and urgent issues. Press releases 
are issued regularly, promoting the role of 
the pharmacist and highlighting pharmacists’ 
concerns to the media. The Communications 
Team invest a great deal of time, effort and 
resources in working with the media to brief 
journalists on issues affecting community 
pharmacy. Communications with the public 
is strengthened with advertising campaigns 
throughout the year. 
Media relations
There has been a substantial amount of media 
coverage since the last AGM. Regular press 
releases are issued by the IPU, promoting the 
role of pharmacists, raising concerns affecting 
community pharmacists and advocating 
on behalf of patients. We receive regular 
coverage in the national media, including 
on RTÉ, TV3, Today FM and Newstalk. The 
national newspapers, including The Irish Times, 
Irish Independent, Irish Examiner and Herald, 
also carry regular articles and interviews 
with IPU representatives. We also receive 
significant coverage in online media, medical 
journals and provincial media, with IPU 
spokespersons appearing frequently on local 
radio and quoted in local media.
There were many press releases issued over 
the past year with pharmacists offering advice 
on a range of issues. Pharmacists were in the 
media advising on head lice, children’s minor 
ailments, driving while taking prescription 
medicines, advice on colds and flu, the 
dangers of mixing alcohol and medicines, and 
much more. Some of the key issues that arose 
during the last year were:
n	Call for tougher crime sentences;
n	 The price of medicines;
n	Antibiotic awareness; and
n	Warning on counterfeit medicines.
We thank IPU spokespersons, who do great 
work throughout the year, for taking time out 
from their pharmacies to be interviewed and 
brief journalists. 
A list of all the press releases issued since the 
last AGM is in Appendix III.
Advertising Campaign  
– ‘Ask Your Pharmacist First’
The IPU continues to promote the ‘Ask 
Your Pharmacist First’ message with national 
advertising campaigns on television and radio.
The 2016 advertising campaign consisted 
of five segments: three radio ads and two 
television ads. The ads were broadcast 
at different stages throughout the year, 
according to the issue being highlighted, and 
received extensive national airplay. The first ad 
campaign of the year was the Hay Fever radio 
ad which ran in the second week of May and 
encouraged people to ‘Ask Your Pharmacist 
First’ about their hay fever symptoms and the 
best treatment options available. Posters were 
sent to pharmacies to support the message. 
The next segment of the campaign was the 
‘Toe to Go’ TV ad, which ran for three weeks 
in June. The ad highlights the importance 
of seeking healthcare advice from a trusted 
healthcare professional. The ad was shown on 
RTÉ, TV3, UTV and on various channels in 
the Sky Media package, as well as on YouTube. 
The ad also ran on Farm TV in 21 livestock 
marts around the country. The ad would have 
been seen by two million adults and they 
would have had the opportunity to see it 3.4 
times.
The next burst of radio ads ran in September 
to coincide with the flu season. The ad 
performed exceptionally well, airing on Today 
FM, 2FM, UTV and regional radio. 75% of 
adults 55+ would have heard the ad at least 
once and had the opportunity to hear it four 
times. 
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The second of our TV ads returned to the 
screens at the beginning of October and 
ran for three weeks. The ad focuses on 
getting the wrong information by turning 
to the internet for advice. The ad appeared 
during programmes such as RTÉ One’s Six-
One News, Coronation Street, Emmerdale, 
Eastenders, TV News at 5.30 and an Irish 
soccer World Cup Qualifier. 65% of all adults 
would have seen the TV ad at least once. In 
addition to the television packages used for 
the previous TV ad, the ad appeared on video 
on demand. The ad would have been seen by 
408,000 people through this medium. 
The final radio ad of 2016 ran from 5 
December for one week. The ad aired on 
national and regional radio stations and 
focused on the retail aspect of pharmacies. 
Operation Transformation
The IPU supported Operation 
Transformation’s Live Longer, Live Better 
campaign for 2017. This is the third year that 
pharmacies have partnered with Operation 
Transformation to offer the public support in 
achieving a healthy lifestyle and weight. 
This year, we were involved in the Stroke and 
Heart Attack aspect of the campaign, which 
involved pharmacies carrying out free blood 
pressure measurements for one week from 
26 January to 2 February. There was a huge 
response from pharmacies that wanted to 
take part in the campaign with almost 750 
pharmacies signed-up to participate. Posters 
and patient record cards were also sent to 
participating pharmacies.
Community pharmacies’ involvement in the 
campaign was highlighted on the television 
programme, as well as in regional media 
around the country. 
Communications to Members
Communications to members continue to 
develop and uptake continues to increase. 
The IPU Review and monthly General 
Memorandum are vital resources of 
information for members. The open rate 
of IPU News, the weekly eNewsletter, is 
increasing with more members accessing their 
IPUMail regularly. Social media is another tool 
for communicating with both members and 
the public, and the number of followers on our 
Facebook, Twitter and LinkedIn accounts are 
growing each week. We also use SMS to get 
information to members quickly on important 
updates and deadlines. 
Political Engagement
A delegation met with the Minister for 
Health in June 2016 to discuss Government 
healthcare strategy, medicine prices, 
unwinding of FEMPI, legislation and 
regulatory issues, and health service reform.
A meeting was held in March 2017 with the 
Minister for State for Communities and 
the National Drug Strategy to discuss the 
contribution that community pharmacists can 
make to the Strategy.
A number of meetings were held throughout 
the year with TDs to discuss issues of interest 
to the membership.
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The Pharmaceutical Group of the European 
Union (PGEU) is the European association 
representing community pharmacists in 32 
European countries including EU Member 
States, EEA countries and EU applicant 
countries. Overall, PGEU represents over 
400,000 community pharmacists in 
Europe through their professional bodies and 
pharmacists’ associations. PGEU’s objective 
is to promote the role of pharmacists as key 
players in healthcare systems throughout 
Europe and to ensure that the views of the 
pharmacy profession are taken into account in 
the EU decision-making process. 
The IPU is represented at PGEU by Darragh 
O’Loughlin, Head of Delegation, Kathy Maher 
and Pamela Logan. We have been very active 
within PGEU over the past year, ensuring that 
community pharmacy is considered in a wide 
variety of EU Directives. 70% of legislation in 
Ireland comes from EU Directives so it is vital 
that lobbying is done at this level rather than 
waiting for transposition into Irish legislation. 
Over the past year, PGEU has been involved 
in a large number of directives and regulations 
and the following is a short summary of the 
main dossiers. 
Medicines Authentication
All Member States must implement 
medicines authentication by 9 February 
2019. The European Medicines Verification 
Organisation (EMVO) has produced tools 
to assist National Medicines Verification 
Organisations (NMVOs) in setting up a 
National Medicines Verification System 
(NMVS). Agreement has been reached by 
all EMVO stakeholders on the issue of data 
ownership. Data contained within the end 
user system will belong to the end user and 
EMVS/NMVS data and its further use must 
be agreed by all data owners. EMVO has 
developed an NMVO end user template 
contract which covers the obligations, rights 
and liabilities of pharmacies, wholesalers and 
NMVOs. End users, e.g. pharmacies, can 
‘sign’ the final contract by ticking a box and 
agreeing to the T&Cs. Any future changes will 
be subject to prior consent. 
Medical Devices Regulation
The Medical Devices Regulation was adopted 
by the European Council in March 2017. The 
regulation has a direct impact for pharmacies 
in both medical devices and in-vitro Medical 
Devices Regulations. The regulation 
establishes that pharmacists should record 
the medical devices they have been supplied 
with. In the case of implantable devices (class 
III) and a group of devices to be decided by 
implementing acts, pharmacists shall store 
and keep, preferably by electronic means, 
information about the devices which they 
have supplied or they have been supplied 
with. Instructions for use of self-testing 
devices must contain a statement directing 
the user to consult the appropriate healthcare 
professional before taking any decision of 
medical relevance.
Pharmacists must:
n	Check that the manufacturer 
has assigned the Unique Device 
Identification (UDI) to the medical 
device;
n	Check that the information supplied by 
manufacturer complies with labelling 
requirements;
n	Keep a register of complaints about 
suspected incidents, non-conforming 
products and products recalls and 
reporting manufacturers and importers;
n	Cooperate with other operators and 
competent authorities to eliminate risks 
of potential non-conforming devices 
(corrective action); and
n	Comply with such obligations within the 
scope of their role and responsibilities.
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The regulation ensures the compatibility 
of the new traceability system with the 
requirements set by the Falsified Medicines 
Directive; therefore, pharmacies will not need 
to invest in new technology to comply with 
two legal frameworks. The new regulation 
on medical devices was adopted on 7 March 
2017 and will start applying three years after 
publication in the Official Journal, expected to 
be April 2017.
Veterinary Medicines Regulation
The main areas of concern in this regulation 
relate to internet supply; special licence 
to supply; recognition of cross-border 
prescriptions; and pharmacy records. The 
European Parliament (EP) adopted most 
of PGEU proposals initially; however, in 
February 2016, the EP published compromise 
proposals, which overturned some of PGEU’s 
original proposals:
n	 In relation to the internet, the 
prohibition on supply of prescription-
only veterinary medicinal products 
will only be limited to antimicrobials, 
psychotropics and biologicals/
immunologicals and national competent 
authorities will need to justify any 
further prohibitions;
n	 The new proposals advocate prohibiting 
prophylactic prescribing, i.e. if one 
animal on the farm gets sick, the 
vet can’t treat the rest of the herd 
prophylactically; and
n	 The new proposals want the European 
Commission (EC) to make decisions 
about the disposal of veterinary 
medicinal products.
Most Member States are against the EP 
proposal and are expected to modify it in the 
Council position (to support Member States’ 
right to prohibit the sale at a distance of 
prescription veterinary medicinal products).
Health claims for food
Health claims for food are regulated under 
EU law. Claims are subject to scientific 
assessment by the European Food Safety 
Agency (EFSA). EFSA’s scientific evaluation 
helps to ensure that health claims made 
on food labelling and advertising enable 
consumers in making healthy diet choices. In 
May 2012, the EC published a list of accepted 
claims (80% of claims were rejected). No 
health claims for botanical ingredients have 
been accepted so far. 
Therapeutic properties of herbal medicines 
(not food) are based on the concept of 
‘traditional use’, which is considered not 
sufficient to support health claims for food 
under EU law. As a result, the authorisation 
of almost 2,000 health claims for botanicals 
are currently on hold at EFSA. Currently 
there is no clear distinction between use of 
botanicals in food supplements and traditional 
herbal medicines (the same botanical can be 
used in food and medicinal products). There 
are important differences between herbal 
medicines and food (manufacturing and 
quality standards, labelling regimes, different 
intent of medicines and food).
In June 2016, the EC launched an evaluation 
on current rules concerning health claims 
of plants and their use in foods in order to 
assess the current legislative framework in 
28 Member States and its adequacy and 
the impact of possible changes (or absence 
of changes) in the regulatory framework 
applicable to health claims. Two main 
scenarios are being considered:
n	A: not to accept traditional use as 
substantial evidence and forbid health 
claims for botanicals used in food; or
n	B: consider traditional use sufficient for 
health claims in food.
PGEU made a submission to the consultation, 
pointing out that if health claims for food 
containing botanicals are allowed without a 
robust scientific assessment, this will have 
negative consequences for the traditional 
herbal medicines sector and will lower the 
quality of products containing botanicals, to 
the detriment of patients. 
Proportionality Test Directive
The EC has proposed a directive on a 
proportionality test for the adoption of new 
or amended regulations for professionals 
covered by the Recognition of Professional 
Qualifications Directive, including engineers, 
accountants, real estate professionals, lawyers 
and healthcare professionals. The Commission 
is concerned that current regulations are 
not based on objective analysis and lack 
transparency, and therefore negatively 
impact on professional mobility and provide 
unjustified barriers to access professions. 
The proposal introduces a set of criteria for 
Member States’ competent authorities, e.g. 
PSI, to use to conduct a mandatory evidence-
led analysis of the need for and likely 
impact of a regulation before introducing or 
amending any professional regulations. 
PGEU and the European bodies for dentists 
(CED) and doctors (CPME) have grave 
concerns that this directive, if applied 
to healthcare professionals, may have 
unintended consequences for patient safety 
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and have published a joint statement calling 
for the exclusion of said professions from the 
scope of the directive. 
The EC’s proposal introduces binding 
criteria which Member States must use 
when introducing any legal or administrative 
provision which may restrict access to or the 
exercise of regulated professions on public 
health grounds. It also calls for periodic review 
and modernisation of existing regulation. In 
practice, this means that before a Member 
State can adopt new or modify existing 
legislative, regulatory or administrative 
provisions restricting access to or pursuit of 
the pharmacy profession, the competent 
authority, e.g. PSI, will have the following 
obligations:
n	Provide a detailed statement showing 
compliance with the principle of 
proportionality;
n	State the reasons for considering 
that a provision is justified, necessary 
and proportionate which must be 
substantiated by objective evidence 
(qualitative and quantitative);
n	Monitor the proportionality of 
regulation on a regular basis and having 
due regard to any developments;
n	 Involve independent scrutiny 
bodies to ensure the assessment of 
proportionality is carried out in an 
objective and independent manner;
n	 Take into account the economic impact 
of the measure, including a cost-benefit 
analysis with particular regard to the 
degree of competition in the market 
and the quality of service provided; and
n	Carry out a comparison between the 
national measure at issue and the 
alternative and less restrictive solutions 
that would allow the same objective to 
be attained.    
The obligations which the new directive 
imposes will place significant administrative and 
time-consuming burdens on Member States’ 
competent authorities which it is feared will 
make it very difficult, if not impossible, to justify 
any new regulation of the pharmacy profession. 
Consequently, there will be no incentive to 
de-regulate or regulate the professions falling 
under the scope of the proposal.
Medicines Shortages
The European associations representing 
manufacturers (EFPIA), self-medication 
industry (AESGP), generics (MfE), parallel 
distributors (EAEPC), wholesalers (GIRP), 
hospital pharmacists (EAHP) and community 
pharmacists (PGEU) issued a Stakeholder 
Statement on Information and Medicinal 
Products Shortages in November 2016. The 
statement agreed on principles for improving 
collection, communication and transparency 
of information on shortages of medicines. 
eHealth Statement
In November 2016, PGEU published a 
Statement on eHealth which included the 
following recommendations:
n	Policy makers, ICT developers and other 
healthcare professionals should engage 
with pharmacists to develop eHealth 
policies and services at local, regional or 
national levels as appropriate;
n	 eHealth should be integrated into 
health systems complementing and 
supporting existing practice, with 
pharmacy potentially as a link between 
several services, organisations and 
infrastructures;
n	Electronic health records should be 
linked with ePrescribing systems, 
allowing HCPs to access necessary 
patient information from the EHR (with 
possibility for read-write function);
n	Communication and collaboration 
between patients, healthcare 
professionals and ICT developers is 
crucial to obtain the full potential of 
eHealth technologies and to build 
confidence and trust;
n	When developing guidelines for 
eHealth, policy makers are called upon 
to meaningfully involve their end users; 
and
n	 The community pharmacy profession 
should be recognised, supported 
and adequately reimbursed for their 
continuous investment in eHealth,  
ICT infrastructure, eSkills of the 
workforce and contribution to  
improved health outcomes and  
reduced healthcare costs.
Waste Directive Reform
This directive, which is due to be adopted in 
2017, will regulate waste disposal. In particular, 
the directive imposes strict conditions for the 
disposal of hazardous waste. Some medicines 
and medical devices fall under the hazardous 
waste definitions, e.g. sharps and narcotics. It 
is proposed that the recording of hazardous 
waste disposal must be in an electronic format 
and in electronic registries facilitated by 
Member States. Pharmacies offering waste 
disposal of medicines/sharps might need 
to adopt their recording practices to the 
proposed criteria.
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Report on FIP Congress,  
Buenos Aires, 2016
Reducing the global burden of disease – 
Rising to the challenge
The 76th Annual World Congress of 
Pharmacy and Pharmaceutical Sciences 
was held in Buenos Aires, Argentina, from 
28 August to 1 September 2016. The 
congress was hosted by the International 
Pharmaceutical Federation (FIP) in 
collaboration with the Confederacion 
Farmaceutica Argentina (COFA). FIP is the 
global federation of national associations of 
pharmacists and pharmaceutical scientists, 
and is a non-governmental organisation 
in official relations with the World 
Health Organisation. With 132 member 
organisations, FIP represents more than 
three million experts in medicines, supporting 
the responsible use of medicines around the 
world.
FIP President’s opening address
In her opening address, President of FIP, 
Dr Carmen Peña, said that community 
pharmacy’s important social role must not 
be forgotten. “Healthcare can no longer be 
separated from social issues. Pharmacists and 
other healthcare professionals need to be 
more concerned with continuity, integration 
of processes and socio-health coordination, 
which is an important but often forgotten role 
of community pharmacies.” 
Dr Peña used her opening address to 
focus on people — patients and healthcare 
professionals. “Today’s patients have new 
demands; new needs. They are increasing 
in number and age. Many of our health 
systems were created in the 20th century 
for a society of patients with acute illnesses, 
but nowadays we live in a society of patients 
with chronic illnesses, many of whom require 
polymedication,” she said.
“This new profile demands new areas of action 
from pharmacists in terms of home care 
as well as healthcare. Self-care and non-
prescription medicines also deserve greater 
attention in this new era of healthcare,” she 
added.
Dr Peña called for policies that enable 
cooperation and care coordination between 
healthcare professionals, with respect for 
their various functions, for the benefit of 
patients. However, she also said that fostering 
trust, improving communication and sharing 
information should include non-health 
professionals, such as hospital managers, 
lawyers and economists, all of whom are 
essential to building a new concept of 
healthcare. 
Dr Peña gave particular mention to clinical 
records. Patients should be the ones to decide 
the extent to which information is shared 
among health professionals, empowering 
them to look after their own health. 
“We need to rethink healthcare. We need 
to break down barriers and prevent patients 
from getting lost in labyrinths of specialties 
and bureaucracy. The system should follow 
patients, rather than patients following the 
system,” she said.
Community pharmacies have the potential 
to vaccinate at least one in eight people right 
now
At least 940 million people live in countries 
where over 193,000 community pharmacies 
can potentially offer access to vaccination 
services, according to new research 
commissioned by FIP. Based on a global 
population of 7.4 billion, this represents at 
least one in eight people.
A survey of 45 countries, conducted by 
the FIP Collaborating Centre at University 
College London, found that nearly half 
(44%) have community pharmacy premises 
offering vaccinations, demonstrating the 
expansion and growing acceptance of 
pharmacy immunisation services around the 
world. An increasing number of countries are 
introducing immunisation rights specifically 
for pharmacists. In 13 of the 45 countries, 
pharmacists themselves have the authority 
to administer vaccines and, therefore, the 
potential to reach 655 million people, the 
researchers estimate.
The findings of this study were published in a 
global report “An overview of current pharmacy 
impact on immunisation”.
“The World Health Organisation (WHO) 
estimates that vaccination saves between 
two and three million lives each year. It is 
one of the safest, more efficient and cost-
effective measures for preventing, controlling 
and eradicating life-threatening infectious 
diseases. The accessibility and distribution 
of community pharmacies make them a 
first point of contact for patients, providing 
an excellent opportunity to address low 
immunisation coverage,” said Dr Helena 
Rosado, research scientist at UCL School of 
Pharmacy and co-author of the report.
“With the recognition of the role of 
pharmacists as immunisers in the latest FIP-
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WHO guidelines on good pharmacy practice, 
we considered it a good time to see how 
far this has been implemented. This report 
offers, for the first time, an international 
overview of pharmacists’ activities to support 
immunisation. We look forward to a day when 
pharmacists all over the world are recognised 
for their full potential and can add to the 
immunisations offered by other healthcare 
professionals, especially in hard-to-reach and 
high-risk populations,” Dr Peña said.
The report includes in-depth case studies 
from Argentina, Australia, Belgium, France, 
Ireland, Philippines, Portugal, South Africa, 
Switzerland, UK and USA, with advancement 
examples that can potentially be adopted by 
other countries to advocate for a national 
immunisation strategy that actively involves 
pharmacists as part of the public health 
agenda. The findings also highlight that, in 
some countries, vaccine administration is part 
of the pharmacy undergraduate curriculum 
and that the perceived competition threat 
to other healthcare professionals providing 
immunisation services is diminishing.
Reducing the effect of medicines  
on the environment
Pharmacists and pharmaceutical scientists 
must take responsibility for mitigating the 
environmental consequences of medicines, 
according to an official policy statement 
adopted by the FIP Council in Buenos Aires. 
The policy specifies that this responsibility 
encompasses the entire course of medicines 
use, from manufacture and distribution to 
prescribing and dispensing, and to disposal and 
reduction of the discharge of metabolites of 
medicines into the environment.
The policy statement sets out a number 
of recommended actions for FIP member 
organisations (national professional 
associations of pharmacy and pharmaceutical 
sciences), schools of pharmacy, individual 
pharmacists and governments. For example, 
it recommends that pharmacists work to 
encourage rational prescribing practices, 
such as the use of starter doses and starter 
quantities and limiting the general number 
of doses prescribed (and dispensed) to 
reasonable amounts, and that they make 
counselling on the environmental impact 
of medicines part of their practice. The 
statement also highlights the contribution 
non-adherence makes to medicines waste.
The new FIP policy, “Environmentally 
sustainable pharmacy practice: Green 
pharmacy”, also says that “green” principles 
should be taught by pharmacy schools and it 
calls on governments to include appropriate 
environmental risk assessments as part of 
medicines approval processes.
“This statement of policy recognises the 
global challenge of the detrimental effect of 
pharmaceuticals on the environment. FIP 
believes that pharmacists and pharmaceutical 
scientists are well placed to give meaningful 
leadership in conquering this challenge 
and urges them, national organisations and 
governments to do so, ensuring at the same 
time that any solutions do not compromise 
access to medicines,” said FIP Vice-President 
Ms Eeva Teräsalmi.
The 77th FIP Congress will be held in Seoul, 
South Korea from 10 to 14 September 2017. 
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2017 AGM MOTIONS
1. “That this AGM calls upon the 
Department of Health and Health Service 
Executive to implement a national roll-out 
of both a Minor Ailment Scheme and a 
New Medicine Service.” 
 Proposed: John O’Connell 
Seconded: Sheila O’Loughlin
2. “That this AGM calls upon the Department 
of Health and Health Service Executive to 
extend phased dispensing service eligibility 
from GMS patients only to those on all of 
the Community Drug Schemes.” 
 Proposed: Eoghan Hanly 
Seconded: Barry Brennan
 
3. “That this AGM calls upon the Department 
of Health and the Health Service Executive 
to roll out the Pharmacy Needle Exchange 
Service nationally and to implement 
further recommendations of the Liverpool 
John Moore’s University review.” 
 Proposed: Mike Walsh 
Seconded: Janet Hanly
4. “That this AGM calls upon the Department 
of Justice and Equality to treat possession 
of small amounts of illegal drugs for 
personal use as a health issue rather than a 
criminal issue.” 
 Proposed: Daragh Connolly 
Seconded: Kathy Maher
 
5. “That this AGM calls upon the Department 
of Health and Health Service Executive 
to deliver a National Primary Care 
ePrescribing System via a State-hosted 
public platform and an open specification 
in line with published standards.” 
 Proposed: Jack Shanahan 
Seconded: Noel Stenson
6. “That this AGM calls upon the IPU to 
ballot members to take action against any 
future proposed PSI fee increases.” 
 Proposed: David Jordan 
Seconded: John Barry
The following motions, proposed in accordance 
with Article 30 of the Constitution, are 
brought before the meeting for consideration:
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FINANCIAL STATEMENTS
FOR YEAR ENDED  
31 DECEMBER 2016
1. Irish Pharmacy Union
A summary of the accounts has been 
circulated to members as part of the 
Executive Summary of the 2017 Annual 
Report of the IPU Executive Committee.
Financial Reports and Accounts for  
Year Ended 31 December 2016
In accordance with the Constitution of the 
IPU, the Executive Committee submits 
the audited accounts for consideration by 
members. The full details of the accounts are 
available on the members’ area of www.ipu.ie.  
 
If the accounts are approved by the meeting, 
after their presentation, members will be 
asked to formally adopt the Accounts for the 
year ended 31 December 2016. In accordance 
with Article 26.b of the IPU Constitution, the 
Trustees have appointed JPA Brenson Lawlor 
as Auditors for the IPU and IPU Services Ltd. 
Members will be asked to agree the election 
of auditors. In this context, the following 
motions will be put to the meeting: 
 
a. “That the Executive Committee Report 
and Audited Statement of Accounts of 
the Irish Pharmacy Union for the year 
ended 31 December 2016 as submitted to 
this meeting, be and hereby are adopted.”
 
b. “That this meeting agrees to the election 
of JPA Brenson Lawlor as Auditors for  
the IPU and IPU Services Ltd.”
2. IPU Services Limited
Financial Reports and Accounts for  
Year Ended 31 December 2016
At this Annual General Meeting of IPU 
Services Ltd, members are asked to consider 
the Directors’ Report and the Auditor’s 
Report on the Accounts for the Year Ended 
31 December 2016. The full accounts and 
financial reports are available on the  
members’ area of www.ipu.ie. 
If the accounts are approved, members will  
be asked to resolve: 
“That the Directors’ Report and Audited 
Statement of Accounts for the year ended  
31 December 2016 as submitted to this 
meeting, be and are hereby adopted.”
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APPENDIX I
A LIST OF SUBMISSIONS 
MADE SINCE THE  
2016 AGM
The following submissions were made since 
the 2016 AGM, most of which are available 
on www.ipu.ie.
2016
n	Pharmacists: Delivering in the 
Community for the Community – 
Priorities for the New Government – 
Department of Taoiseach, May 2016 
n	Draft Regulations on Videolink – PSI, 
August 2016
n	Draft Standards for Data Collections – 
HIQA, August 2016
n	Pre-Budget Submission – Department 
of Finance & Department of Public 
Expenditure and Reform, August 2016
n	Future of Healthcare – Oireachtas 
Committee on the Future of Healthcare, 
August 2016
n	Draft Standard for eDispensing Dataset 
and CDA – HIQA, September 2016 
n	Statement of Strategy 2016-2019 – 
Department of Health, September 2016
n	Draft Misuse of Drugs Regulations – 
Department of Health, September 2016
n	National Drug Strategy – Department of 
Health, October 2016
n	Draft Standards for Procedure Data Set 
and CDA – HIQA, November 2016 
2017
n	Smoking Cessation HTA – HIQA, January 
2017 (online)
n	PSI Customer Charter – PSI, January 
2017 (online)
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APPENDIX II
KEY CORRESPONDENCE 
SINCE THE 2016 AGM
PSI
n	Brexit and Irish Pharmacy Students  
in the UK
Department of Health 
n	Follow-up to recent meeting
n	Notice of IPHA Price Reductions
n	Notice to Pharmacists re Price Reductions 
on Medicines 
n	Financial Emergency Measures in the 
Public Interest Act
n	Pharmacist Vaccination in Nursing Homes
HSE
n	Notice to Pharmacists re Price  
Reductions on Medicines 
PCRS
n	PCRS Pharmacy Interface Project – 
Owings
n	 Third Party Verification
n	Proposed New Arrangements for Phased 
Dispensing
n	 Incomplete Claims Protocol –  
GP Visit Card Holders
Other Government Departments
n	Regulation on Veterinary Medicinal 
Products
n	Reduction of Price Capitation on 
Prescription Levy
n	Retail Consultation Forum
n	Directive on a Proportionality Test
Manufacturers
n	Neupro® Distribution Policy –  
Impact on Pharmacists 
n	 IPHA/DoH/HSE Framework Agreement 
on the Pricing and Supply of Medicines
n	OFEV® Distribution Policy –  
Impact on Pharmacists
Other Matters
n	Forged Prescriptions
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PSI
Brexit and Irish Pharmacy  
Students in the UK 
Director of Pharmacy Services to Acting 
Registrar and CEO, PSI – 29 June 2016
The recent referendum vote in the UK, in 
which a majority of the population voted 
for the UK to leave the EU, creates some 
significant issues for the future recognition in 
Ireland of pharmacy qualifications gained in 
the UK. While I appreciate that it is early days 
since the vote and no official decisions have 
been taken regarding the process or timing 
for the UK to leave the EU, we have already 
started to receive queries from our members 
about the status of pharmacy students 
currently studying in the UK and those about 
to commence studies. I hope you can provide 
clarity on their situation.
Pharmacy students currently studying in 
the UK commenced their courses with the 
reasonable expectation that qualification and 
registration in the UK would lead to automatic 
recognition as pharmacists in Ireland. What 
will happen to such students who graduate 
after the UK has finally left the EU?
In addition, many students who have just 
completed their Leaving Cert will have 
applied to UK universities to study pharmacy. 
What will happen in their case, given that 
the outcome of the referendum was known 
before they commenced study?
In relation to other Irish pharmacists who are 
currently registered and practising in the UK 
but not yet registered in Ireland, are they 
entitled to automatic recognition now and 
at any time in the future or will a deadline to 
recognition be applied? 
DoH
Follow-up to recent meeting
Secretary General to Minister for Health  
– 18 July 2016 
Thank you for meeting with a delegation from 
the IPU recently. 
As was said at the meeting, we welcome 
the commitment in the Programme for 
Government to expand the role of the 
pharmacist in patient care and wish to work 
constructively with the Department of Health 
and the HSE, as well as other healthcare 
providers and stakeholders, to ensure the best 
possible health service for patients. We were 
glad to note your acknowledgement that the 
last few years have been difficult for everyone 
in healthcare and your statements that the 
Government is now in a position to reinvest 
in healthcare and that the IPU would have 
an important role to play in the development 
of the 10-year vision for healthcare. We look 
forward to engaging with the committee 
which has been convened to progress this 
vision.
FEMPI
We were surprised at the position of the 
Department officials regarding the unwinding 
of FEMPI and the savage cuts to pharmacists’ 
fees and payments which were implemented 
under the Act. Having clarified our position, 
we now anticipate immediate developments 
regarding the monies already due to be 
returned following the review of 2015 and 
await further information on the 2016 review 
which, under the legislation, was due to be 
carried out before the end of June.
DoH / HSE / IPHA Agreement
We note from recent media reports that an 
agreement has been reached between the 
State and the pharmaceutical industry on 
medicine pricing and supply for the next four 
years. We welcome the prospect of savings 
on medicine prices for taxpayers and the 
public and we look forward to full details of the 
specific medicine price reductions being made 
available. 
In the meantime, despite the significant 
implications for pharmacists, we have 
been given no detailed information on 
implementation. As pharmacists cannot 
source medicines at the new lower prices until 
after the final details are known, they face 
significant financial losses on medicines held 
in stock – losses which cannot be mitigated 
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without adequate notice of price changes. 
In the absence of notice, there is a risk of 
disruption in the supply of medicines to 
patients as pharmacists cannot risk holding 
medicines which may be subject to overnight 
devaluation. As advised, we received a 
commitment from the previous Minister 
that a minimum of two weeks’ notice would 
be given to pharmacists in advance of any 
price reductions being implemented. This 
commitment must be honoured. 
We also wish to emphasise, in an environment 
of increasing medicine shortages, the 
importance of following the recommendation 
of the Joint Committee on Health and 
Children that the impact of national drug price 
policy on the drug supply be closely monitored 
in order to balance both cost reductions and 
continuity of supply for Irish patients.
 
Minor Ailment Scheme 
Thank you for launching the Minor Ailment 
Scheme pilot, which is now underway. We 
will continue to cooperate with the HSE 
on gathering the information necessary for 
a robust review at the end of the three-
month period, in order to be in a position 
subsequently to roll out a full Minor Ailment 
Scheme which will allow GMS patients to 
benefit from the same access to pharmacy 
services and appropriate non-prescription 
medicines as private patients currently enjoy.
Vaccination – Pneumococcal and Herpes 
Zoster (Shingles) 
The previous Minister for Health introduced 
new legislation to facilitate pharmacy 
vaccination for pneumococcal and 
herpes zoster in October 2015. Whilst 
we always knew that shingles vaccination 
was not a HSE-remunerated service, we 
had an expectation that reimbursement 
arrangements would be put in place for 
pharmacists to administer the pneumococcal 
vaccine, as is already the case for influenza 
vaccination. It is disappointing, therefore, that 
Department officials did not include this for 
consideration in the estimates for 2016. We 
ask now that you ensure reimbursement of 
pharmacists for provision of pneumococcal 
vaccination is included for 2017.
Emergency Hormonal Contraception (EHC)
We await passage of the Health 
(Miscellaneous Provisions) Bill, which is 
required to facilitate reimbursement of non-
prescription Emergency Contraception for 
medical card holders through community 
pharmacy, and look forward to engaging on 
a service to provide equity of access to EHC 
for medical card holders, in line with the 
recommendations of the HSE’s 2010 Irish 
Contraception and Crisis Pregnancy [ICCP] 
Study. 
IPU Patient Safety Initiative Proposal
We were pleased to briefly outline our 
Patient Safety in Medication Use proposal 
which aims to strengthen the foundations of 
patient safety through the introduction of 
a nationwide cloud-based system to collect 
data relating to errors and/or near-misses in 
the medication prescribing and dispensing 
process, allowing pharmacists, prescribers 
and other health professionals to learn from 
those errors in a structured process of error 
reduction and management. 
Following our recent meeting with the 
Director of Patient Safety & Clinical 
Effectiveness in the Patient Safety and 
Quality Unit, Dr Kathleen MacLellan, to 
discuss and potentially advance the proposal, 
we note that the Department will continue 
to investigate the possibility of achieving 
the same objective through providing an 
interface for community pharmacists to use 
the National Incident Management System. 
We will await further updates from the 
Department.
Again, we greatly appreciate you taking the 
time to meet with us, particularly given the 
numerous competing demands on your 
time. We hope that you will take all of the 
above points on board and we look forward 
to working with you and your Government 
to deliver enhanced access to an improved 
health service to all Irish patients.
Notice of IPHA Price Reductions
Contract Manager to Assistant Secretary 
General, Primary Care Division, Department of 
Health – 22 July 2016
Further to the announcement on Wednesday 
20 July of the agreement reached between 
the State (DoH and HSE) and the 
pharmaceutical industry (IPHA) with regard 
to the reduction in medicine prices, our 
members have still not received all of the 
information in relation to changes of medicine 
prices set for the 1 August; in fact, we only 
received the first notice of price changes 
late yesterday afternoon. There are now 
only five business days remaining until the 
proposed date of implementation of the price 
reductions.
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The IPU has written to the Department 
previously, emphasising the need to ensure 
pharmacists are given adequate notice of 
any changes. We have consistently advised 
the HSE PCRS of the need for maximum 
notice of price changes to be given, so that 
pharmacists are not left nursing significant 
unavoidable losses as a result of an agreement 
to which we are not party. In response to 
requests for information, the HSE PCRS has 
advised us that they are not yet in a position 
to provide details of all the new prices and 
are still awaiting details from some large drug 
companies as late as today.
The announcement on Wednesday gives 
pharmacists just over one week in which to 
prepare for the reductions. This is completely 
unacceptable. The IPU and pharmacists 
should be alerted well in advance of the 
implementation date. A minimum of four 
to six weeks’ notice is necessary to allow 
sufficient time for the IPU to update our IT 
system and to allow pharmacists adequate 
time to dispense stock reimbursed at the 
higher price. 
Pharmacy contractors experienced significant 
loss on the cost of their stock as a direct 
result of the lack of notice provided by the 
Department in previous years. It is important 
that pharmacists are not put in this position 
again. Even in the depths of the financial 
crisis, pharmacists were given a month’s grace 
when price cuts were being implemented, 
whereby the lower prices were applied at 
wholesale level one month before they were 
applied at the point of reimbursement.
I request that the implementation date for the 
reductions is pushed back from 1 August to 
give pharmacists the opportunity to minimise 
any losses that will occur. This is in keeping 
with the notice given to the pharmaceutical 
companies in yesterday’s agreement and in 
the precedent set in the Health (Pricing and 
Supply of Medicinal) Goods Act 2013. 
This matter is of the utmost urgency.
Notice to Pharmacists re Price 
Reductions on Medicines 
Secretary General to Minister for Health  
– 28 July 2016 
cc. Mr Jim Breslin, DoH; Mr Fergal Goodman, 
DoH; Ms Anne Marie Hoey, HSE; Ms Kate 
Mulvenna, HSE; Mr Shaun Flanagan, HSE.
The Irish Pharmacy Union (IPU) recognises 
that the Agreement last week between the 
State (Department of Health and HSE) and 
the pharmaceutical industry (IPHA), which 
will reportedly save €600-€785m over the 
next four years, is a good deal for patients 
and a good deal for the State. The IPU is 
extremely concerned, however, at the lack of 
notice which has been afforded to pharmacists 
in advance of the planned implementation of 
price reductions on 1 August 2016. While it is 
legitimate that the State would seek to ensure 
maximum value for its spend on medicines, it 
is neither fair nor reasonable to impose losses 
on pharmacists, who have already suffered 
severe reductions in their incomes under the 
FEMPI Act, particularly when such a situation 
could be minimised or avoided. 
As of today’s date, pharmacists and the 
IPU still have not received comprehensive 
details of all the proposed price reductions. 
As a result, pharmacists will suffer significant 
losses on the value of medicines held in stock 
to meet the needs of their patients, losses 
which cannot be mitigated. On previous 
occasions when agreements with industry 
led to price reductions, the resulting lower 
prices were applied at wholesale level one 
month before they applied to pharmacy 
reimbursement, in order to allow pharmacists 
to acquire medicines at the lower prices in 
advance of supplying them to patients and 
being reimbursed at the lower price. There 
is no justification for not applying the same 
principle now. It is unfair and unreasonable to 
expect pharmacists to shoulder the immediate 
costs of an agreement to which they are not 
party. 
We have consistently advised the Department 
and the HSE PCRS of the need for adequate 
and reasonable notice of price changes to 
be given to pharmacies. The new Agreement 
between the State and IPHA provides that 
suppliers of individual medicines will receive 
no less than 28 days’ notice of any price 
reductions implemented under its terms 
(sections 7.2.2 & 8.2.2). Pharmacists should 
be entitled to no less consideration. 
We wrote to the Department of Health last 
week (without reply), again outlining our 
concerns and seeking that the implementation 
date be deferred. Following repeated 
representations throughout 2015 seeking 
to have the 28-day notice period which 
applies to the setting of reference prices for 
interchangeable medicines under the 2013 
Act extended to include all price reductions, 
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the IPU received a commitment from 
your predecessor, Minister Varadkar, that 
a minimum of two weeks’ notice, and more 
where possible, would be given to pharmacists 
in advance of any price reductions being 
implemented. This commitment must be 
honoured. 
Although the new, lower, ex-factory 
prices may take effect from 1 August, the 
implementation date for the reimbursement 
price reductions must be deferred until 
1 September, to allow pharmacists the 
opportunity to mitigate what will otherwise be 
significant losses. 
As the situation is now urgent, we ask that you 
give this matter your immediate attention. 
Financial Emergency Measures in 
the Public Interest Act
Secretary General to Minister for Health  
– 19 August 2016 
I write to you in relation to the failure, thus 
far, to implement the long-overdue unwinding 
of the reductions in payments to community 
pharmacy contractors which were introduced 
under the above Act. 
In December of last year, following the 
then Minister’s statutory review in 2015 
of the operation, effectiveness and impact 
of the amounts and rates of payments to 
pharmacists fixed by regulation and his 
consideration of the appropriateness of those 
amounts and rates, the IPU was told that 
a formal process would be initiated under 
the FEMPI Act 2009 in January 2016 to 
commence the gradual unwinding of the 
measures previously implemented under the 
legislation. The amount indicated as being 
made available for return to pharmacists was 
€2.5 million, an extraordinarily low sum in 
the context of the magnitude of the cuts 
suffered by pharmacists. We protested our 
dissatisfaction with the sum at that time. 
In January of this year, we were advised by 
the Department that the Minister proposed 
to make regulations varying the payments 
to community pharmacy contractors and 
that a formal consultation process was being 
commenced in that regard. In February, as 
part of that consultation process, the IPU 
made both written and oral submissions in 
which we welcomed the Minister’s decision 
to commence the unwinding of the FEMPI 
measures but reasserted our view that the 
proposed sum was derisory, given the scale of 
the reductions suffered by pharmacists. 
In a meeting in February this year, which 
took place between the written and oral 
submissions from the IPU, your predecessor, 
Minister Varadkar, acknowledged that the sum 
was less than we had anticipated but indicated 
that it should be interpreted as a token of the 
Government’s genuine intent to commence 
the gradual alleviation of the impact of FEMPI 
on pharmacists, rather than as the totality of 
the unwinding.
In our meeting with you in June, the 
consultation process having long concluded, 
we sought an update on the status of the 
proposed regulations to vary upwards 
the payments to community pharmacy 
contractors and expressed our great surprise 
at the reported position of the Department 
officials regarding the unwinding of FEMPI 
and the savage cuts to pharmacists’ fees and 
payments which were implemented under 
the Act. We were glad of the opportunity 
to clarify our position that, contrary to the 
apparent misunderstanding on the part of 
Department officials, at no time did the IPU 
express a view that the money being made 
available, however little, should not be paid to 
pharmacists. 
Notwithstanding all of the forgoing, and in 
spite of correspondence from the Chief State 
Solicitor dated 8 January 2016, which stated 
that it was the Minister’s intention to consider, 
determine and implement, as soon as possible 
following the consultation process, regulations 
which would have the effect of varying, 
whether by formula or otherwise, the amount 
or rate of payment to contracted community 
pharmacies, no regulations have yet been 
implemented to give effect to that intention. 
In addition, we await further information on 
the 2016 review which, under the legislation, 
was due to have been carried out before 
the end of June. We note the statement 
in paragraph 43 of his Annual Review and 
Report on the FEMPI Acts that the Minister 
for Public Expenditure and Reform is of 
the view that a gradual amelioration of the 
impact of payment reductions for health 
professionals is appropriate.
It is utterly unacceptable that, a full eight 
months since the Department of Health first 
indicated that money cut from community 
pharmacy contractors’ payments was 
budgeted for return to pharmacists, seven 
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months since the Chief State Solicitor gave a 
commitment that it would happen as soon as 
possible and six months since the consultation 
process concluded, no funds have been 
returned to pharmacists. This must now be 
done without further delay.
Secretary General to Minister for Health  
– 29 September 2016 
We have not yet received a reply to our letter 
of 19 August regarding the failure, thus far, to 
implement the long-overdue unwinding of the 
reductions in payments to community 
pharmacy contractors which were introduced 
under the above Act (copy enclosed). 
This is a serious matter which, given the length 
of time that has passed since the statutory 
consultation process, now requires your 
immediate attention. We would be grateful for 
an immediate response.
Secretary General to Minister for Health  
– 01 February 2017 
I am writing to you in connection with the 
unexplained and unjustifiable failure to 
implement the long-overdue and previously 
committed unwinding of the reductions 
in payments to community pharmacy 
contractors which were introduced under the 
above Act. 
In January 2016, in settlement of an 
action before the Supreme Court, the Irish 
Pharmacy Union’s solicitors received a letter 
from the Chief State Solicitor, stating that it 
was the intention of the Minister for Health 
to initiate a formal consultation process under 
Section 9 of the FEMPI Act 2009 before 
the end of January 2016 in relation to the 
regulations made pursuant to Section 9 in 
relation to payments to community pharmacy 
contractors, and that the indicative amount 
available in respect of community pharmacy 
at that time was approximately €2.5m in 
2016. The letter further stated that it was the 
Minister’s intention to consider, determine 
and implement, as soon as possible following 
the conclusion of the consultation process, 
regulations which, with the consent of the 
Minister for Public Expenditure and Reform, 
would have the effect of varying, whether 
by formula or otherwise, the amount or 
rate of payment to contracted community 
pharmacies under the powers conferred on 
him by Section 9(1) of the Act as amended in 
2015. A copy of this letter is attached.
On 27 January 2016, the IPU was notified 
that the Minister for Health, in exercise of 
his powers under the FEMPI Act, proposed 
to make Regulations varying the payments to 
Community Pharmacy Contractors and was 
initiating a period of consultation to which the 
IPU was invited to make a written submission 
and, if we wished, an oral submission. 
Our written submission was sent to the 
Department of Health on 12 February. A copy 
is attached.
In a subsequent meeting on 15 February 2016, 
the then Minister for Health, Leo Varadkar, 
acknowledged receipt of the IPU submission. 
The IPU expressed our dissatisfaction with 
the indicative amount suggested and stated 
our view that no reasonable, fair or thorough 
review which had regard to all the matters 
requiring to be considered by the Minister 
could have arrived at such a figure. The 
Minister acknowledged our position and said 
that this was the only money currently in the 
budget for the unwinding of FEMPI. 
He suggested that, at least, it was a gesture 
to give confidence to pharmacists (as to GPs) 
that the Government was sincere in its intent 
to gradually unwind FEMPI over the coming 
years.
Following this, as part of the consultation 
process, we were invited to make an oral 
submission on 23 February 2016. At this 
meeting, the IPU restated our position 
that we considered the proposed figure of 
€2.5m to be paltry and derisory and that we 
believed that no complete, objective or fair 
review which properly considered the matters 
required to be considered under FEMPI could 
have arrived at such a figure. The officials 
present revealed that there had been no 
comprehensive or in-depth review of the 
contracted professions but that, rather, the 
figure proposed was that which was available 
at that time in their budget.
Following your appointment as Minister, 
we met on 23 June 2016. At that meeting, 
we queried why the regulations had not 
yet been made, despite the commitment 
given by the Chief State Solicitor and your 
predecessor that it would be done as soon 
as possible following the conclusion of the 
consultation process. It then appeared that 
our position, which had been repeatedly been 
made clear to Department officials, had been 
misrepresented to you and that you had been 
told that we declined the monies available. 
We expressed our surprise and clarified that, 
while we regarded the sum of €2.5 million as 
utterly insufficient, at no time had we refused 
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to accept it. You described the situation as 
a misunderstanding and undertook to re-
examine the issue and then revert to us. 
However, following that meeting, there was no 
further communication to us on this issue.
On 18 July 2016, we wrote to you to thank 
you for having met with us and remind you 
of your commitment to re-examine the 
FEMPI misunderstanding. This letter was not 
acknowledged. On 18 August 2016, we once 
again wrote to you, outlining our expectation 
of immediate developments regarding the 
monies already due to be returned following 
the review of 2015 and seeking further 
information on the 2016 review which, under 
the legislation, had been due to be carried out 
before the end of June. This letter was also 
not acknowledged. Finally, on 28 September, 
we wrote again, pointing out that we had not 
yet received a reply to our letter of 18 August 
regarding the failure, thus far, to implement 
the long-overdue unwinding of the reductions 
in payments to community pharmacy 
contractors. This third letter also went 
unacknowledged and unanswered. Copies of 
all three letters are enclosed.
In the meantime, the Minister for Public 
Expenditure and Reform in his June 2016 
Annual Review and Report on the Financial 
Emergency Measures in the Public Interest 
Act stated the following: 
Paragraph 37: “As required under the 
legislation, measures applied to contracted 
Health Professionals and certain other groups 
under section 9 of the Financial Emergency 
Measures in the Public Interest Act 2009 are 
also being considered in the context of the 
overall unwinding of FEMPI legislation.”
Paragraph 43: “I also find that it is 
appropriate, taking account of the 
improvements brought about in the public 
finances, the continuing risks which remain 
and the need to meet our commitments 
to have a prudent fiscal policy under the 
Stability and Growth Pact, and subject to 
the amendments effected in the measures 
through the FEMPI Act 2015… (d) to 
maintain provisions in the legislation which 
provide for the reduction of payments to 
health professionals but allow, subject to the 
considerations of the Minister for Health 
and other Ministers of Government under 
sections 9 and 10 of the FEMPI Act 2009 
and Government’s priorities for the health 
service, for a gradual amelioration of the 
impact of payment reductions.”
In circumstances where your predecessor 
committed to commencing the unwinding 
of the savage reductions in payments to 
community pharmacy contractors which were 
introduced under the FEMPI Act, where this 
commitment was echoed in correspondence 
from the Chief State Solicitor writing on 
behalf of the government, and where the 
IPU participated fully and constructively in 
a statutory consultation process, there is no 
justification for withholding the monies which 
were proposed for return to pharmacists, 
however paltry the sum. Furthermore, it is 
utterly unacceptable that our correspondence 
in relation to this issue has been ignored on an 
ongoing basis.
This is a very serious matter which, given 
the length of time that has passed since the 
statutory consultation process, requires your 
immediate attention. 
We are now seeking an urgent meeting with 
you to resolve this issue.
Pharmacist Vaccination  
in Nursing Homes
Secretary General to Minister for Health  
– 13 January 2017 
Further to our proposal to you on 5 
December 2016 regarding expansion of 
the pharmacy vaccination service, I am 
writing to propose that, given the current flu 
outbreak and its impact on patients and their 
families, pharmacists should be facilitated in 
vaccinating patients in nursing homes or other 
residential care settings, especially against 
seasonal influenza. 
This month, the Health Protection 
Surveillance Centre (HPSC) reported that, 
“influenza is actively circulating in community 
and hospital settings in Ireland. Influenza-
like illness (ILI) rates have risen to 51 per 
100,000 population during the week ended 1 
January 2017 and are above baseline threshold 
levels. Influenza hospitalisations and outbreaks 
in residential care facilities are at high levels 
and are continuing to increase. Influenza A 
(H3) is currently the main influenza virus 
circulating in Ireland, mainly affecting those 
aged 65 years and older. Influenza is expected 
to increase over the coming weeks and to 
continue circulating in the community up to 
mid-February.”
Given the current and predicted future 
shortage of GPs, it is vital to ensure that all 
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patients in residential care facilities have ready 
access to a healthcare professional who can 
provide appropriate and timely vaccinations. 
This could and should be their local 
community pharmacist. Improving access to 
and uptake of vaccination would go some way 
towards assisting in reducing demand on A&E 
and hospital services.
Enabling such a pharmacy service would only 
require a minor amendment to S.I. No. 525 of 
2011, which currently restricts pharmacists to 
supplying and administering vaccinations “at 
the premises of the retail pharmacy business 
in which he or she carries on that professional 
practice”. Given the well-publicised 
difficulties faced by GPs in responding to 
the current outbreak, an immediate removal 
of this unnecessary restriction would allow 
pharmacists to use their existing skills to help 
alleviate the situation by protecting these 
vulnerable patients from further spread of 
illness.
I look forward to hearing from you on this 
matter and would welcome an opportunity to 
discuss it in greater detail.
HSE
Notice to Pharmacists re Price 
Reductions on Medicines 
Secretary General to Director General, HSE  
– 29 July 2016 
cc. Mr Simon Harris T.D., Minister for Health; 
Mr Jim Breslin, DoH; Mr Fergal Goodman, 
DoH; Ms Anne Marie Hoey, HSE; Ms Kate 
Mulvenna, HSE; Mr Shaun Flanagan, HSE.
As you are no doubt aware, an agreement 
was announced on 20 July 2016 between 
the State (the Department of Health and 
the HSE) and the pharmaceutical industry 
(IPHA). This agreement will reportedly save 
€600 - €785m over the next four years. A 
large proportion of these savings will come 
from pharmacists who are not party to the 
agreement. The IPU publicly welcomed the 
agreement and appreciates that it is a good 
deal for patients and for the State. 
As you are also no doubt aware, pharmacists 
around the country are extremely concerned 
and angry at the lack of notice given by the 
HSE of the prices reductions as of 1st August 
2016. Pharmacies will suffer significant losses 
on the value of medicines held in stock to 
meet the needs of patients under the State 
schemes. They now face a considerable 
devaluation in the value of their stocks 
and have been given no time to run down 
their stocks to minimise their losses. Quite 
unbelievably, as of today’s date, pharmacist 
contractors and the IPU have still not even 
received comprehensive details of all the 
proposed reductions. 
We wrote to the Minister yesterday in relation 
to this matter and are copying him on this 
letter. 
We have been advised to make the following 
points to you: 
1. The HSE is a monopsonist buyer of 
medicines under the State schemes 
from pharmacist contractors. 
2. The HSE sets the reimbursement price 
it will pay those pharmacist contractors 
for those medicines. 
3. The HSE can change the 
reimbursement price at any time 
utilising the provisions of the Health 
(Pricing and Supply of Medical Goods) 
Act 2013 (the “2013 Act”). 
4. The effect of a price change can be 
seriously deleterious to the pharmacist 
contractors concerned. 
5. The HSE can change the 
reimbursement price with as much or as 
little notice to pharmacist contractors 
as it chooses. 
6. It is clearly not unreasonable that given 
such potential seriously deleterious 
effects, pharmacists should legitimately 
expect the HSE to cooperate with 
them and give reasonable notice of 
changes to the reimbursement prices. 
7. The HSE has consistently not given 
reasonable notice to pharmacists of 
changes to reimbursement prices. 
8. The IPU has written on numerous 
occasions to both the HSE and the 
Minister for Health noting the failure 
of the HSE to give reasonable notice to 
pharmacist contractors of changes to 
reimbursement prices and requesting 
on behalf of pharmacist contractors 
that such reasonable notice be given 
but the HSE has continued to fail to 
give such reasonable notice. 
9. The latest price changes arise from 
the IPHA Agreement which sets the 
ex-factory price. Under Clause 7.2.2 
and 8.2.2 of the IPHA Agreement, the 
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suppliers will receive a minimum of 28 
days’ notice of price reductions. 
10 If the HSE proposes to alter the 
relevant price of a listed item under 
Section 21 of the 2013 Act, it is 
required to give the supplier at least 28 
days in which to make representations 
to it regarding the proposal.1 This 
means suppliers have at least 28 days’ 
notice of proposed price changes and 
a further 28 days’ notice if there is 
any modification to the initial price 
proposed.2 
11. There has therefore been a consistent 
failure by the HSE to give reasonable 
notice to pharmacist contractors of 
changes to reimbursement prices, the 
effects of which may have seriously 
deleterious effects for those pharmacist 
contractors in the context of the HSE 
being a monopsony; of it setting the 
prices and changing the prices, where a 
period of 28 days is afforded in statute 
and contract to other parties which may 
be affected by the price change; and in 
the face of repeated requests for it to 
give such reasonable notice. 
Pharmacists deal with patients under the State 
Schemes funded by the HSE every day of 
the week. The HSE and IPU are cooperating 
and making good progress on ensuring the 
provision of the best possible care to patients 
under the State schemes including initiatives 
such as the Minor Ailment Scheme and 
the Pharmacy Interface Project. We simply 
cannot therefore understand why pharmacist 
contractors, who provide exemplary service 
on behalf of the State, are being treated with 
apparent contempt and discourtesy, when the 
situation is readily avoidable. 
It is regrettable and potentially very damaging 
to the relationship between the IPU and 
its members on the one hand and the 
Department of Health, the HSE and the 
PCRS on the other, that the HSE has yet 
again decided to implement price changes 
without giving reasonable notice to pharmacist 
contractors. 
Yet again and for the record, we request the 
HSE to extend pharmacists the basic courtesy 
of providing them and the IPU from now on 
with a list of price changes at least 28 days 
before these changes are to take effect. 
With regard to the current proposed 
change in reimbursement prices, although 
the new lower ex-factory prices may take 
effect from 1 August, the HSE should 
defer the implementation date for the 
reimbursement price reductions until 1 
September to allow pharmacist contractors 
the opportunity to mitigate what will 
otherwise be significant losses. 
As the situation is now urgent, we have been 
advised to write to you and apprise you of 
the position as outlined above and request 
that the matter be resolved as set out in the 
penultimate paragraph of this letter, to avoid 
the matter turning contentious. We therefore 
ask that you give this matter your immediate 
attention and we will make ourselves available 
to meet with the HSE at short notice, if 
required, to assist in such resolution. 
1. Schedule 1 Part 3 Paragraph 2(c). 
2. Schedule 1 Part 3 Paragraph 4. 
Director General, HSE, to Secretary General  
– 9 August 2016 
I refer to your correspondence of 29 July 
2016 in the above matter and understand 
that you have likewise corresponded with the 
Minister for Health. 
You will be aware that, in an effort to provide 
as much information as was possible at the 
time, the Primary Care Reimbursement 
Service provided the IPU on 15 July with 
the full portfolio of IPHA products on the 
GMS and High Tech databases whose prices 
could potentially be revised under any new 
agreement. This information would have 
enabled pharmacy contractors to exercise 
caution with stockholding during the second 
half of July.
Following the announcement of the 
IPHA Agreement 2016, the Corporate 
Pharmaceutical Unit within the PCRS 
disseminated files to suppliers for 
verification as agreed during the final stages 
of the negotiations with the Proprietary 
Pharmaceutical Industry. This had the 
inevitable consequence of delaying immediate 
release of the HSE revised databases but was 
a necessary step to ensure all relevant parties 
to the IPHA Agreement 2016 were aligned 
on a common understanding of price points. 
The HSE notes that the Health (Pricing and 
Supply of Medical Goods) Act does not place 
an obligation to provide statutory notice 
period to pharmacy contractors but it will 
continue to provide as much notice as it can 
at an operational level.
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The HSE must deliver an ambitious service 
plan within available resources and, as it 
endeavours to protect the most vulnerable in 
society, cannot afford to defer for a month 
the efficiencies arising from the IPHA 
Agreement 2016.
I assure you that we value the important 
contribution that Pharmacy Contractors 
continue to deliver to their patients and 
clients on behalf of the HSE.
Secretary General to Director General, HSE  
– 10 August 2016 
I refer to your letter dated 9 August 2016 in 
relation to the above matter. The IPU, having 
corresponded with the Minister for Health and 
the Department of Health, has been advised 
that the implementation of price reductions is 
an operational matter for the HSE.
We note your position that you will not accede 
to our request that the HSE should defer the 
implementation date for the reimbursement 
of price reductions until 1 September. This 
refusal, which we strongly protest, will result in 
significant losses for pharmacist contractors 
by virtue of the fact that most of them carry 
approximately four weeks’ stock of medicines 
and will, throughout the month of August, 
be reimbursed at the new, lower, prices for 
supplying medicines which they had already 
purchased at the previous, higher, price.  
We also note that you state ‘the HSE will 
continue to provide as much notice as it 
can at an operational level to pharmacy 
contractors.’ It is, however, our strongly 
held view that the HSE has consistently not 
given reasonable notice to pharmacists of 
changes to reimbursement prices, despite a 
commitment from the previous Minister for 
Health that it would do so. The IPU now seeks 
to engage with the HSE at the most senior 
level to secure for our members an agreed 
minimum period of notice in advance of any 
future price reductions being implemented. 
We view this as a reasonable request in the 
circumstances.  
Given the importance of this matter, we 
would appreciate your proposed dates for an 
early meeting. 
PCRS
PCRS Pharmacy Interface  
Project – Owings 
Secretary General to Assistant National 
Director for Primary Care Reimbursement and 
Eligibility, PCRS – 24 October 2016
Further to our recent discussion regarding 
the PCRS/Pharmacy Interface Project, I 
wish to set out clearly our position in relation 
to item 3.8, “Managing the risk of claims for 
medicine not yet dispensed [“Owings”].” The 
PCRS has previously acknowledged that there 
are legitimate circumstances in which such 
owings can arise. Where there is a genuine 
expectation on the part of the pharmacist at 
the time a claim is submitted that a patient 
will return to collect the balance of a medicine 
owed to them, it has been acknowledged 
by the PCRS that it is legitimate for the 
pharmacist to claim for that medicine.
Currently, and since the 1996 Community 
Pharmacy Contractors Agreement (the 
Contract), the fee paid to a pharmacy where 
an owing arises, regardless of whether it is a full 
or a partial owing, is a standard dispensing fee 
plus the total ingredient cost. The dispensing 
fees payable are set out in Schedule One 
of the Health (Reduction in Payments 
to Community Pharmacy Contractors) 
Regulations 2013 and serve to remunerate 
the pharmacist for the costs involved in the 
dispensing process including the activities 
provided for in Clause Nine of the Contract.
The Memorandum agreed as part of PCRS/
Pharmacy Interface Project (PPIP), 
introduced a mechanism whereby the 
ingredient cost would be reimbursed to 
the pharmacy only if and when the patient 
actually collects the medicine, and the 
amount reimbursed would relate to the exact 
quantity of medicine supplied at the time the 
claim is submitted. 
There is a significant but unquantifiable 
potential saving for the HSE PCRS in that the 
ingredient cost will only ever be reimbursed 
in circumstances where it is collected by the 
patient. There would also be greater clarity 
and transparency in relation to owings as a 
result of the interface developments which 
would prove beneficial to both the HSE and 
pharmacy contractors. It was never envisaged 
in the discussions regarding the PPIP that the 
HSE would seek to use it to alter or reduce 
a fee currently being paid to community 
pharmacy contractors.
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Despite the IPU never having agreed to any 
reduction or alteration of the dispensing 
fee payable where an owing arises, the HSE 
sought to put forward a proposal at recent 
implementation meetings of the PPIP 
that a non-dispensing fee would be paid in 
cases where an owing arises and where a 
zero quantity of the item is supplied on the 
day, with the suggestion that this fee could 
subsequently be adjusted to a Schedule One 
dispensing fee when the item is collected 
and claimed. This proposal, which we fail to 
comprehend as having any rational basis, is 
outside the scope of the PPIP Memorandum 
as agreed between our respective 
organisations.
The non-dispensing fee exists for those 
situations where the pharmacist in the 
exercise of his/her professional judgement 
considers it to be in the patient’s interest that 
they not dispense the medicine concerned. 
It is implied by this that the medicine is never 
going to be supplied in the context of the 
prescription in question and that, therefore, 
it does not require to be considered for the 
purposes of Clause Nine in the same way 
as would an item which is to be supplied or 
treated as an owing for supply in the future. 
An owing is different to a non-dispensing 
in that it constitutes an active dispensing 
and, as such, places further responsibility 
on a pharmacist. Because it is anticipated 
that the patient will collect the medicine in 
the near future, the pharmacist is obliged to 
consider this item in the context of his/her 
responsibilities under Clause Nine, including 
screening for any potential drug therapy 
problems which may arise out of the use of 
the medicine(s) prescribed such as those 
which may be due to therapeutic duplication, 
drug-drug interactions (including serious 
interactions with non-prescription or over-
the-counter medicines or foods), incorrect 
drug dosage or duration of drug treatment, 
drug-allergy interactions and clinical abuse 
and/or misuse. It is for this professional 
activity and this exercise of professional skills 
and judgement that the dispensing fee is 
payable.
In summary, a Schedule One dispensing 
fee, which is currently paid to pharmacists in 
owings situations, should not be confused with 
a non-dispensing fee, which, as outlined above 
is completely different. The Clause Nine 
responsibility of a pharmacist is not diminished 
by virtue of an item being owed to a patient 
rather than collected on the day of dispensing. 
As such, nor should the professional fee 
paid to the pharmacist be diminished. Any 
suggestion to the contrary is and will remain 
unacceptable to the IPU and will serve to 
prevent the advancement of this project.
We are available to explain this position 
further to you if you believe it would 
be helpful. In the meantime, pending 
a satisfactory resolution of this wholly 
unnecessary situation, the PCRS/Pharmacy 
Interface Project must unfortunately remain 
on hold.
Assistant National Director for Primary Care 
Reimbursement and Eligibility, PCRS, to 
Secretary General – 24 November 2016
I refer to your letter of 24 October 2016 in 
relation to the pharmacy interface project.
I wish to advise that PCRS management met 
with the Department of Health in October 
with a proposal for progressing the owings 
issue which includes a payment of a dispensing 
fee within an owings ruleset and I await their 
response. I would like to invite the IPU to re-
engage in the interface project in an effort to 
progress the project overall. The HSE in good 
faith has made a proposal to the Department 
of Health and are awaiting their response, but 
as previously communicated, the interface 
project is wider than owings with benefits to 
be realised for pharmacies and the HSE.
Assistant National Director for Primary Care 
Reimbursement and Eligibility, PCRS, to 
Secretary General – 8 December 2016
I refer to my previous correspondence of 
24 November 2016. The Primary Care 
Reimbursement Service has had further 
engagement with the Department of Health 
on the matter.
Further to those discussions, in the context 
of progressing the visibility and transparency 
provided through the Pharmacy Interface 
Project, I can confirm that the Department 
has agreed in principle to a full dispensing fee 
‘to remunerate the pharmacist involved in 
the dispensing process including the activities 
provided for in Clause Nine of the Contract’ 
with the ingredient cost to be paid when the 
supply element is discharged when the patient 
returns ‘in the near future’ to collect the 
medicine.
The ruleset that will be attached to the 
payment of a dispensing fee in respect of 
owings will reflect:
1. The pharmacy contractor has a genuine 
expectation that the patient will 
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return in the near future to collect the 
remainder of their prescription.
2. In accordance with Clause Nine of 
the Contract, there will be occasions 
that, while the product is listed on 
the prescription by the prescriber, 
the pharmacist in their professional 
judgement believes that there is a risk 
to the patient in supplying the product, 
e.g. where a potential drug therapy 
problem may arise. The pharmacist will 
discuss this with the patient. In such 
circumstances, no supply is occurring 
on that day or will occur in relation to 
that specific prescription form.
3. Items not supplied relating to a 
specific prescription form may only be 
claimed in the following exceptional 
circumstances:
- Split supply of medication where 
the patient has been supplied with 
some of the prescribed drug/item 
and the remainder of the drug/item 
has been specifically ordered by the 
pharmacist, as the total quantity was 
not available in stock.
- Where the prescribed medication 
is not a normal stock item, the item 
was not in stock on presentation of 
the prescription and was specifically 
ordered for the patient. 
- Where the patient paid the 
prescription charge and is returning 
to collect medication as they could 
not physically transport the full 
quantity on the day of the initial 
presentation of the prescription, e.g. 
bulk food products.
4. There is a requirement on behalf of the 
HSE that such owings/non-dispensed 
items charged to the HSE:
- Would be discharged before a further 
claim arises for the same item, i.e. 
in the subsequent month’s supply, 
accommodation of the owing would 
occur in supplying the patient’s 
medication requirement for that 
subsequent month.
- Would be bagged, labelled and 
awaiting collections; or
- Recorded with the date of 
dispensing/supply with the patient 
medication record indicating ‘not 
collected’; or
- Recorded with the date of 
dispensing/supply with the patient 
medication record indicating either 
‘returned to stock’ or ‘destroyed’.
5. For the avoidance of doubt, claims 
for items not supplied or intended for 
supply within a defined timeframe to 
patients could not be submitted to the 
HSE for payment. Owings files should 
therefore be reviewed monthly before 
claims are submitted to the HSE and 
only claims as outlined in 1 to 3 above 
and meeting the requirements of 4 may 
be submitted for payment. 
As part of those discussions, the HSE 
committed to the Department of Health that 
the following rules would apply:
1. The fees per pharmacy would be 
capped at 2.5% of spend for dispensing 
and non-dispensing fees to provide 
a level of assurance that the ‘genuine 
expectation’ element was respected by 
community pharmacies.
2. The HSE will actively monitor claiming 
activity and address any outliers that 
may emerge in communities of practice.
3. The visibility would be used to inform 
the HSE of GPs who are continually 
prescribing items no longer required by 
the patient with a view to (i) enabling 
review of the patient’s requirements 
and (ii) appropriate and cost effective 
prescribing/improving the repeat 
prescribing protocols at GP Practice 
level.
As indicated in previous discussions on this 
matter, the HSE reserves the right to review 
the arrangement within a two-year timeframe 
of it becoming operational and may make 
amendments/adjustments as appropriate.
While the interface project is wider than 
‘owings’ with benefits to be realised for 
pharmacies and the HSE, we believe that 
the Department agreement to the FEMPI 
schedule of fees for the visibility offered in 
relation to ‘O’ line type claims is a significant 
step forward and look forward to your 
engagement with the project as a whole.
We can discuss further at the JCG meeting 
on 12 December.
APPENDIX II 
CONTINUED
62
Secretary General to Assistant National 
Director for Primary Care Reimbursement  
and Eligibility, PCRS – 11 January 2017
Further to your correspondence of 8 
December 2016 and our subsequent Joint 
Consultative Group (JCG) meeting on 12 
December 2016, the IPU welcomes the 
agreement by the Department of Health to 
continue paying the current dispensing fees 
in respect of medicines placed in owings, to 
remunerate the pharmacist involved in the 
dispensing process, in particular the activities 
provided for in Clause Nine of the Contract.
The Memorandum of Understanding 
(MoU) which was agreed as part of the 
PCRS/Pharmacy Interface Project (PPIP) 
introduces a mechanism whereby the 
ingredient cost will be reimbursed to the 
pharmacy only if and when the medicine is 
supplied to the patient. The arrangements set 
out in your most recent correspondence are 
in keeping with the terms of the MoU and 
can form a basis for moving forward with the 
PPIP. However, we do not understand why 
you would now seek, in a technical project, 
to introduce an arbitrary cap for owings of 
2.5% (or any other proportion) of spend for 
dispensing and non-dispensing fees. This 
goes beyond what has been agreed in the 
MoU for the PPIP.  Your stated objective to 
provide a level of assurance for the ‘genuine 
expectation’ element of an owing is redundant 
once there are agreed arrangements in place 
for managing owings. 
It is deeply frustrating, when we have 
consistently endeavoured to make progress 
on the basis of settled agreements, that 
you have again sought to make post hoc 
alterations or insert additional restrictive 
terms or conditions to a project document 
that has already been agreed between 
us. As our concerns in relation to the fee 
element have largely been addressed, the 
IPU proposes that we set aside this notion 
of an arbitrary cap for inclusion in future 
discussions on a new contract and, meanwhile, 
press ahead on the basis of what has already 
been agreed between us. Additionally, we 
should each commit to jointly reviewing the 
project, including the implementation of the 
arrangements for owings, after years one and 
two and then, following these reviews, make 
whatever amendments or adjustments that we 
both agree are necessary or desirable. 
Subject to your agreement that we both 
stick to the existing agreement, the technical 
work of the PPIP can recommence later 
this month and any practical or technical 
matters arising from the implementation of 
the new arrangements, including in relation 
to owings, can be addressed through that 
forum. Proposed changes to our contract or 
remuneration should be dealt with separately.
We are, as always, available to clarify our 
position with you as necessary.
Secretary General to Assistant National 
Director for Primary Care Reimbursement 
and Eligibility, PCRS – 30 January 2017
As set out in our correspondence of 11 
January 2017 regarding the above, the 
IPU remains concerned at the proposed 
imposition of an arbitrary 2.5% cap on 
any legitimately earned fee. However, we 
note your explanation of the intent in your 
letter of 23 January and the subsequent 
assurances given at the IPU PCRS Joint 
Operational Group meeting last week that, 
in circumstances where a pharmacy’s non-
dispensing fees reach 2.5% per pharmacy of 
spend for dispensing and non-dispensing fees, 
while their claims may be reviewed, payments 
to the pharmacy will not be affected. 
We also note and agree with your proposed 
schedule for joint periodic reviews of the 
implementation of the interface project, 
including as it relates to owings. 
We confirm that we will re-engage with the 
PCRS Pharmacy Interface Project (PPIP), 
as our concerns regarding the fee element of 
the owings portion of the project have largely 
been addressed.
We will now liaise with you to schedule 
the next meeting of the PPIP so that the 
technical work of delivering what has been 
agreed in the MoU may proceed.
Third Party Verification
Secretary General to Assistant National 
Director for Primary Care Reimbursement  
and Eligibility, PCRS – 28 October 2016
I refer to your recent correspondence to 
pharmacists advising them of your wish 
that third party verification be introduced 
on the GMS scheme, which the scheme 
has not previously been subject to that 
requirement. As you are aware, it is our 
position that the requirement for third party 
verification of GMS prescriptions will impose 
a disproportionate additional administrative 
burden upon pharmacy teams and will distract 
63
2017 ANNUAL REPORT OF IPU EXECUTIVE COMMITTEE
from patient care. The proposal adds no value 
for the patient, nor does it add value to the 
pharmacy service they receive. Despite this, 
the HSE has indicated a strong imperative to 
implement the measure. 
We have now completed a nationwide round 
of consultations with our members in relation 
to this proposal and a number of issues have 
arisen which will require resolution before 
implementation can be considered, chief 
amongst which is that there will inevitably 
be certain circumstances in which patient 
signatures will not be possible to capture. 
Some examples are set out below, but this list 
is by no means exhaustive:
Emergency Supply
GPs will frequently phone or fax a pharmacy 
to request that medicine be dispensed to a 
patient, with the original prescription being 
forwarded afterwards. In these situations, it 
will not be possible to get the prescription 
signed at the time of dispensing, as the 
document will not be present in the pharmacy 
at that time.
Literacy Challenges
Poor literacy levels are more prevalent among 
lower socio-economic groups, who are also 
more likely to hold a medical card. As such, 
many GMS patients will not be in a position to 
sign the form and pharmacists will not wish to 
risk humiliating them by asking them to. 
Nursing Home GMS Residents
It will not be feasible for residents of 
nursing homes to sign individually for their 
medication; indeed, many would be physically 
incapable of doing so. A protocol needs to be 
put in place whereby the person in charge of 
a nursing home or other staff member can 
acknowledge receipt of medication on behalf 
of a group of residents, whether by way of 
imprinting the nursing home rubber stamp on 
the prescription forms or by signing a single 
statement acknowledging receipt of a multi-
patient medicines delivery.
Relationship of Person Collecting
Why is this necessary? We have a concern 
that this may give rise to a potential breach 
of the Equal Status Act.  Is there a particular 
person who by virtue of their relationship 
to the patient is not eligible to collect a 
prescription on someone’s behalf? It should 
be sufficient for signatories who are not the 
patient to print their names alongside their 
signatures.
Ongoing Monitoring and Review
PCRS must commit to a joint review of the 
implementation of the circular over the next 
six months in order to address jointly any 
unintended consequences or unanticipated 
issues arising from the imposition of this new 
requirement.
Public Awareness
Lastly, for a change as significant as this to be 
introduced, requires that all stakeholders are 
made aware of it sufficiently far in advance 
of implementation. All GMS patients must 
be made aware that they will now be required 
to acknowledge receipt of the medications 
dispensed to them by signing prescriptions. 
The HSE needs to give consideration to how 
it proposes to communicate this change in 
partnership with the pharmacists who are 
expected to implement it.
For the reasons set out and for others as yet 
unforeseen, it must be accepted that, even 
with the best endeavours of pharmacists, 
not all prescriptions will be co-signed by 
patients on every occasion. Despite the 
disproportionate regulatory requirements 
and administrative burden placed on 
pharmacists, patient care must remain their 
priority. Pharmacists who dispense prescribed 
medicines in good faith to eligible patients 
must be paid for doing so in all circumstances, 
including where it has not been possible to 
secure a patient signature. The system has 
to be flexible enough to accommodate the 
existing needs of patients and the obligation 
and desire of pharmacists to meet those 
needs. If pharmacists are to engage with 
this proposal, HSE PCRS must accept their 
bona fides and commit to ensuring that they 
will continue to get reimbursed for all items 
dispensed in good faith. 
Pharmacists have cooperated on an 
extensive range of changes in recent years, 
many of which have come at the expense 
of pharmacists and pharmacy resources 
and were of benefit to the HSE and/or the 
State rather than to pharmacists. The recent 
attempt to force this measure through 
without having given consideration to the 
issues and consequences which will inevitably 
arise is, at best, misguided and will not work. 
Discussions and negotiations are required and, 
if solid assurances are provided of a reasonable 
and proportionate approach that safeguards 
patient access to medicines and ensures the 
continued reimbursement of pharmacists, 
then an implementation in 2017 can be 
considered. In the absence of such discussions 
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and assurances, we consider that the measure 
is not ready to be implemented.
Contract Manager to Assistant National 
Director for Primary Care Reimbursement and 
Eligibility, PCRS – 11 January 2017
Further to the JCG meeting of 12 December 
2015, the IPU wishes to set out practical 
proposals for third party verification of GMS 
prescriptions in the context of Residential 
Settings/Nursing Homes.
Patients on admission to a nursing home are 
normally asked to give consent for the supply 
of their medication from a named pharmacy. 
We understand that the HSE/PCRS will 
accept the signature of the person in charge 
of a nursing home or their nominated staff 
member when receiving medication on a 
patient’s behalf. It is current practice in many 
pharmacies that the person in charge signs 
to acknowledge the receipt of medicines on 
a dedicated form and that this form is then 
retained in the pharmacy. It is not practical 
nor necessary to expect the person in 
charge to sign each prescription individually. 
The person/nurse in charge have onerous 
workloads as it is and, in some cases, they have 
indicated to pharmacies that they are not in 
a position to provide multiple signatures. The 
collection of multiple signatures from the 
same individual on a single occasion will not 
improve the audit trail for HSE/PCRS any 
more than would a single, dated, signature 
on a more comprehensive list of patients and 
medications. 
The relevant PSI guidance states that, when 
delivering/dispensing to Nursing Home/
Residential settings, the delivery method 
used should incorporate an itemised verifiable 
audit trail for the medicine from the point 
at which it leaves the pharmacy to the point 
at which it is handed to the patient or carer. 
This, according to the PSI, entails obtaining 
a signature from the person in charge – 
something which pharmacies therefore 
already do. There is no requirement in the 
PSI guidance for a separate signature per 
prescription.
The PSI also requires that the original 
prescription must be physically present in 
the pharmacy and must be reviewed by a 
pharmacist before the medicine is dispensed 
and/or supplied. They also require that 
the delivery method used must safeguard 
confidential information about the patient and 
their medication. If prescriptions were to be 
removed from the pharmacy in contravention 
of the PSI guidance, there is a small but 
unacceptable risk of prescriptions being 
lost and that confidentiality could not be 
guaranteed.
It is our position that as long as there is a 
verifiable signed audit trail, fully in compliance 
with PSI guidance for medicines dispensed 
and delivered to patients in Nursing Home/
Residential Care settings, this will satisfy the 
probity requirements of the HSE/PCRS and 
therefore negates the need for individual 
signatures on every prescription form.
We remain available to discuss with you as 
necessary.
Assistant National Director for Primary Care 
Reimbursement and Eligibility, PCRS, to 
Contract Manager – 03 February 2017
I refer to your letter of 11 January in relation to 
the above.
The reason for extending third party 
verification to Medical Card Prescriptions 
have been clearly outlined by the HSE.
In addition, the Community Pharmacy 
Contractor Agreement for Provision of 
Services under the Health Acts (January 
2010) Clause 14 states:
1. The pharmacy contractor shall 
make arrangements to supply on an 
appropriate claim form, in relation 
to any medicines dispensed under 
clause 1(1) (b), such information as 
may be deemed relevant by the chief 
executive officer following consultation 
with the Pharmaceutical Contractors 
Committee.
2. The pharmacy contractor shall 
cooperate with the chief executive 
officer and the Primary Care 
Reimbursement Service in the 
discharge of any statutory obligations 
imposed upon them including the 
obligation to establish the accuracy of 
claims.
However, I note your observations in relation 
to the risk of prescriptions being lost and 
that confidentiality could not be guaranteed. 
In maintaining a verifiable signed audit 
trail, pharmacists must ensure they keep 
comprehensive documentation to satisfy 
the HSE as to the supply of the medication 
at patient level to Nursing Homes on a 
particular day, in the event this is requested 
for validation purposes. For nursing home 
65
2017 ANNUAL REPORT OF IPU EXECUTIVE COMMITTEE
patients only, it will be sufficient for a copy 
of the signed delivery records (as required by 
the PSI) to be attached to the prescription 
bundle. 
The HSE will request on occasion further 
supporting documentation from pharmacy 
contractors.
Proposed New Arrangements  
for Phased Dispensing 
Secretary General to Assistant National 
Director for Primary Care Reimbursement and 
Eligibility, PCRS – 11 January 2017
I refer to your correspondence of 8 
December 2016 regarding the HSE 
PCRS proposals to introduce validation 
enhancements for phased dispensing, and to 
our subsequent meeting on 12 December. 
As we have previously made clear, the IPU is 
willing to discuss reasonable and proportionate 
validation enhancements around the existing 
phased dispensing arrangements as set out in 
the 1996 Community Pharmacy Contractor 
Agreement.
The vast majority of pharmacies we represent 
conduct their business in a professional and 
ethical way, putting the needs of their patients 
first and foremost at all times. We understand 
the HSE’s need for greater probity and audit 
at this time but this must be done in a way 
that is practical and fair, and does not impinge 
unduly on the daily work of community 
pharmacists.
The existing phased dispensing arrangements 
are set out in correspondence dated 30 
September 1996 from the then GMS 
board and in the 2006 PCRS Handbook, 
Information and Administrative Arrangements 
for Pharmacists. Appendix A of your letter of 
8 December introduces some terminology 
which does not form part of the existing 
arrangements. For example, neither the 
reference to the ‘totality of the month’s 
medicines’ nor the explicit requirement for 
‘multiple supply occasions’ appear in the 
original agreement or in the PCRS Handbook. 
The latter requirement was first stipulated by 
the HSE in May 2016.
As regards the specific proposals you have put 
forward, we have some observations.
It is our view that the exemption from your 
proposed new validation process for phased 
dispensing should apply to those aged 70 
years and over as was set out in your letter in 
March, rather than 80 years and over, which 
appears to be an arbitrary figure and not in 
keeping with current government practice of 
applying benefits to those aged 70 years and 
over. This must be seen in the context of the 
existing exemption from means testing for GP 
Visit cards for those aged 70 years and over, 
and the reduced prescription charges cap 
which is due to be introduced later this year.
The ‘existing arrangements’ that you propose 
keeping in place should not necessarily be 
limited to patients aged 70 years and over, 
and to those whose medicine is psychotropic 
in nature. There are other categories of 
patients for whom phased dispensing should 
still automatically apply and also other 
medicinal products, such as preparations 
with a short shelf life. We suggest further 
engagement between us to agree what 
criteria would apply to patients who would be 
automatically approved for phased dispensing 
and also which medicines would automatically 
be deemed approved.
For new patients, the application process will 
need to have a fast and efficient turnaround 
time for approval/not approved. If a ‘same 
day’ turnaround time cannot be guaranteed, 
patients ought to be ‘approved’ until such time 
as the pharmacy is notified that an application 
is ‘not approved’. Pharmacists and, more 
importantly, their patients cannot be expected 
to wait a protracted period for approval before 
a necessary service can be commenced.
The initial design of the application as set 
out in ‘Appendix B’ is in keeping with current 
visibility norms and pharmacy awareness of 
the status of an application. It is our view that 
the declaration indicating the acceptance by 
the pharmacist of what is defined as phased 
dispensing by the HSE PCRS does not 
require a subsequent qualifying acceptance 
of what does not constitute phased 
dispensing. Additionally, the reference to 
invalid and fraudulent claims is unnecessary 
and potentially prejudicial, particularly in 
circumstances where there is no evidence of 
any intent to deceive. 
The IPU believes that socio-clinical need is 
unrelated to economic means and that the 
likelihood of a patient requiring any particular 
service is not related to their eligibility under 
the community drugs schemes. Therefore, 
the facility to have medicines phased where 
that is appropriate for the patient in the 
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circumstances should not be limited only to 
those patients who have eligibility under the 
GMS scheme but should apply to all patients 
who have eligibility under the schemes.
Finally, your correspondence sets out 
your position that phased dispensing is 
not the same as providing a Monitored 
Dosage System (MDS).  We welcome your 
acknowledgement that MDS is a quality 
enhancement service. The position you are 
now adopting with regard to payment for 
MDS will result in this service being withdrawn 
from many patients whom it will not suit to 
collect their medicines on a weekly basis, with 
consequential impact on their adherence to 
prescribed therapies and potential adverse 
effect on their health outcomes; therefore, in 
the interests of patient safety, we believe that 
the current requirement for multiple supply 
occasions, which was first stipulated on 5 May 
2016 in your correspondence to pharmacies, 
should be waived where medicine is being 
presented to the patient in MDS. 
We look forward to engaging with you further 
in relation to your proposals in the hope 
that a reasonable way forward can be found 
which meets your objectives and protects 
pharmacists’ ability to provide vital services to 
their patients.
Assistant National Director for Primary Care 
Reimbursement and Eligibility, PCRS, to 
Secretary General – 03 February 2017
I refer to your letter of 11 January in relation to 
the above.
Your letter raises a number of issues which I 
will address hereunder.
n	 In relation to the age limit applied 
to the new approval mechanism 
for ‘phased dispensing’, on further 
analysis, the HSE has found that age 
70 is too young for many individuals to 
require dispensing and that it is more 
reasonable to propose that age 80 is 
more realistic at a juncture at which the 
level of phased dispensing is evidenced 
to increase. However, in response to 
your request, it is reasonable to provide 
for continuous review of the appropriate 
age with the experience and evidence 
from the data following implementation 
of the phased validation. Therefore, 
I propose that we can jointly review 
the experience after six months of 
operation and if this demonstrates 
that a lower age threshold would 
be appropriate, we can discuss the 
possibility of the age threshold reducing 
to 75 years. At a later stage, after we 
have assessed the implications of any 
age reduction from 80 years old, we 
can review further.
n	 I note you are seeking further 
engagement on the categories of 
patients for whom phased dispensing 
should still automatically apply and also 
other medicinal products. It would be 
helpful if this could be discussed jointly 
in an effort to progress the discussion. 
Where products have a short shelf-life, 
there is no intention to change existing 
arrangements. 
n	 In relation to the approval process 
(required in the circumstances already 
specified), PCRS will designate staff 
to deal with applications for approval 
and our commitment will be in so far as 
possible to turn same around in a 24-
hour period during the normal working 
week or on the first working day of the 
week following a weekend. Where a 
GP requests phased dispensing for a 
GMS patient online, approval will be 
contemporaneous. Where a pharmacist 
requests phased dispensing online and 
it aligns with the HSE criteria, approval 
will be contemporaneous. Where it 
does not align with the automatically 
approved criteria, turnaround will be 
24 hours except at weekends. As 
with any new drug or service, awaiting 
approval is not unreasonable. However, 
where a patient is newly prescribed 
a ‘risk’ preparation (the list of which 
can be agreed between the parties), 
consideration could be given to 
applying the Emergency Dispensing 
arrangements.
n	You raise issues in relation to the 
extension of phased dispensing to non 
GMS scheme and also the issue of 
MDS. Phased dispensing applies only 
to the GMS scheme and any extension 
of same is a matter for the Department 
of Health to consider and to fund. 
Similarly, MDS is also an issue which 
the Department of Health did consider 
some years ago and did not approve for 
implementation. Any revisiting of this 
position is a matter for the Department. 
n	 The implementation for phased 
dispensing must be operated in line 
with the PCRS letters of 5 May 2016 
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and that of 30 September 1996. 
The issue of dispensing on multiple 
supply occasions has always been 
clear and was further reinforced in the 
Health Professionals (Reduction of 
Payments to Community Pharmacy 
Contractors) Regulations 2009; the 
Health Professionals (Reduction of 
Payments to Community Pharmacy 
Contractors) Regulations 2011; and by 
a similarly worded provision contained 
in the Health Professionals (Reduction 
of Payments to Community Pharmacy 
Contractors) Regulations 2013, which 
stated, ‘phased dispensing fee – payable 
per drug item for each dispensing phase 
other than the first dispensing phase for 
which the standard dispensing fees is 
payable’.
I trust the above clarifies the issues you 
raise and we look forward to progressing the 
implementation of this proposal with your 
cooperation from March or April 2017. Any 
further issues can be raised or clarified with 
myself or Ms Kate Mulvenna should you 
require. 
Secretary General to Assistant National 
Director for Primary Care Reimbursement and 
Eligibility, PCRS – 15 March 2017
I am writing in response to our discussions at 
the recent Joint Consultative Group (JCG) 
meeting regarding your proposed validation 
enhancements to the existing phased 
dispensing arrangements and to set out our 
concerns.
The rules regarding phased dispensing, as 
set out in the PCRS Handbook, Information 
and Administrative Arrangements for 
Pharmacists, 2006 are: 
(i) At the request of a patient’s physician;
(ii) Due to the inherent nature of a 
medicinal product, i.e. product 
stability and shelf life;
(iii) Where a patient is commencing 
new drug therapy with a view to 
establishing patient tolerance and 
acceptability before continuing on a 
full treatment regime; and
(iv) In exceptional circumstances where 
the patient is incapable of safely 
managing the medication regimen.
There have been no changes to these rules 
since their introduction in 1996, save for the 
stipulation in May 2016 that patients who 
avail of phased dispensing must present in the 
pharmacy on multiple occasions in order to 
collect the next instalment of their medicines.
We note that no changes to criteria (i) to (iii) 
are proposed but that patients’ entitlement 
to have a phased dispensing service provided 
at the discretion of the pharmacist under 
criterion (iv) above will in the future be subject 
to prior approval by the HSE PCRS. 
It is our understanding that automatic 
approval for phased dispensing fees will apply 
if any one of the following criteria is satisfied:
n	Where the patient meets standard 
phased dispensing criteria (to be 
agreed);
n	Where there is an existing phased 
dispensing history;
n	Following an application for approval by 
the GP; and
n	Following pharmacy application and 
PCRS approval.
The proposal put forward at the JCG was 
more restrictive than was set out originally 
in your correspondence of 8 December 
2016. The latest iteration of the proposal, 
i.e. the requirement that the patient be aged 
80 years or over and be using psychotropic 
drugs and be receiving five or more items 
concurrently to be eligible for automatic 
approval, seems excessively restrictive. It 
remains our view that the age eligibility for 
phased dispensing should be 70 years, not 
80, as indeed you first proposed in March 
and again in December of last year; and we 
welcome your agreement to keep this matter 
under review.
In light of the proposal to apply an age limit 
of 80, a more reasonable approach to the 
proposed eligibility rules would be that a 
patient should only need to satisfy any two of 
the three criteria in order to be automatically 
eligible for phased dispensing at the discretion 
of the pharmacist acting in the patient’s 
interests. 
You advised that, under the proposed new 
arrangements, it would be possible for GPs 
to apply directly to the HSE PCRS for a 
patient to have their medicines dispensed on 
a phased basis. It is essential that pharmacists 
are given real-time visibility of GPs requests 
and subsequent authorisations for phased 
dispensing on the pharmacy application suite, 
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to avoid unnecessary delays in providing this 
service to patients who have been adjudged to 
require it.
In relation to the approval process itself, 
we have concerns that non-pharmacist 
staff in PCRS, such as technicians, will be 
adjudicating on the professional judgement 
of pharmacists who, knowing the patient and 
his/her circumstances and capabilities, apply 
for approval to provide a phased dispensing 
service to that patient. We cannot agree to 
any arrangement under which a pharmacist’s 
professional judgement is questioned and 
potentially over-ruled by non-qualified 
personnel. 
Regardless of the finer detail of the 
arrangements that are eventually agreed and 
put in place, it is imperative that requests 
for approval in respect of new patients will 
at all times be prioritised over reviews of 
existing patient approvals. You have assured 
us that all approval decisions will be taken and 
communicated to the pharmacist within a 
24-hour time frame. However, we are seeking 
an absolute commitment from HSE PCRS to 
keeping to this timeline.
Lastly, the proposed implementation date of 
1 April is not reasonable or achievable and, 
in the interest of achieving a practical and 
workable solution, must be deferred to the 
1 June 2017 or later to ensure a seamless 
transition to the new process for all parties 
concerned. Pharmacy contractors will need 
to be given adequate notice of the proposed 
changes, due to the workload implications and 
the impact on future patients. The ultimate 
commencement date for the enhanced 
validation process can be confirmed once we 
have agreed on the business rules and the 
system has been tested.  You will understand 
that pharmacists cannot be expected to 
tolerate another hastily imposed last-minute 
change, such as was seen with the reduction 
in the GMS prescription levy this month.
We remain available to meet with you to 
explain our position further if needed.
Assistant National Director for Primary Care 
Reimbursement and Eligibility, PCRS, to 
Secretary General – 24 March 2017
I refer to your letter of 15 March 2017.
You will be aware from previous discussions 
that there has been a significant rise in claims 
for phased dispensing in recent years. As the 
HSE addresses the anomalies presenting in 
our review of historical phased dispensing 
claims, it is clear that further validation is 
required.
Phased dispensing was introduced in 1996. 
For the avoidance of any doubt, I reiterate 
that where a phased dispensing claim is 
submitted, the requirement that an item be 
dispensed across multiple supply occasions 
has always been present through:
a. The 1996 Agreement 
Paragraph 12(ii) of the April 1996 
Agreement between the HSE and the 
IPU states as follows:
“Fee for phased dispensing – The 
Group recommends that the GMS 
dispensing fee should be paid in 
respect of each part of the necessary 
phased dispensing. An example of a 
prescription which requires phased 
dispensing would be a prescription 
for a month’s supply of a paediatric 
antibiotic (which is unstable) which 
would be dispensed more frequently.”
It is clear from the language of the 
Agreement that a prescription that is 
“phased” is intended to be “dispensed 
more frequently” than a prescription 
that is not phased. 
b. The Regulations
 The Health Professionals (Reduction 
of Payments to Community Pharmacy 
Contractors) Regulations 2009, 
2011 and 2013 all support that a 
phased dispensing fee is only payable 
in circumstances where a drug item 
is dispensed across multiple supply 
occasions. The 2013 Regulations 
currently in place state that:
Phased dispensing fee – payable per 
drug item for each dispensing phase 
other than the first dispensing phase 
(for which the standard dispensing fee 
specified in Schedule 1 is payable).
The language obviously indicates that 
phased dispensing fees are payable only 
in circumstances where there is more 
than one dispensing occasion. 
c. PCRS Handbook
 The PCRS Handbook (Information 
and Administrative Arrangements for 
Pharmacists) also communicates the 
rule set out in the 30 September 1996 
letter, and provides claiming directions 
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for electronic claims submissions, as 
follows:
Electronic claimants should select the 
relevant category, change the Script 
Type to Phased Script, then select the 
appropriate phased reason plus the 
total phased dispensings being claimed, 
excluding the initial dispensing. Finally, 
enter the quantity to be dispensed on 
the day. 
The language above requires that 
the pharmacy inputs the number of 
total Phased Dispensings “excluding 
the initial dispensing”. The use of the 
phrase “initial dispensing” indicates that 
there will be more than one dispensing 
occasion. 
Furthermore, the Handbook references 
“the quantity to be dispensed on the 
day”, again indicating that the full 
quantity would not be dispensed on one 
occasion. 
In responding to your communication of 15 
March 2017, I must also clarify that automatic 
approval will apply:
1. Where the doctor writes Phased 
Dispensing on the face of the 
prescription;
2. Following an application for approval 
by the GP on the GP application suite 
(removing the need to write phased 
dispensing on the face of future 
prescriptions); or
3. Following pharmacy application and 
subsequent PCRS approval where 
the pharmacist believes the criteria 
– in exceptional circumstances where 
the patient is incapable of safely and 
effectively managing their medication 
regimen’ pertains
I can confirm that, where a GP makes an 
application for phased dispensing online, 
it is contemporaneously available on the 
Pharmacy Applications Suite.
Patients for whom phased dispensing claims 
have been historically submitted will be called 
into the review cycle at a time in the future. 
There is evidence that some pharmacies are 
endeavouring to enrol patients in their service 
developments to circumvent the intention 
of the HSE to be more equipped to monitor 
phased dispensing claims prospectively. 
The review, as agreed, will include age criterion. 
We are not satisfied that it is appropriate to 
reduce the criteria further to that outlines 
in our letter of 3 February 2017 until after 
the first review period. In that review, we can 
discuss further building on experience with the 
enhanced validation system.
In inspecting and reviewing phased dispensing 
fee claims, we have encountered at 
pharmacy level, an unsatisfactory disconnect 
between submitted phased claims and 
the documentation held in the pharmacy 
to substantiate the patient assessment 
one would have expected to occur when 
determining ‘exceptional circumstances where 
the patient is incapable of safely and effectively 
managing their medication regimen’.
You have raised concerns that non-pharmacist 
staff in PCRS will be assessing applications 
received. Your concern is surprising in that 
in many pharmacies, non-pharmacist staff 
(technicians) play a key role in dispensaries, 
operating under the supervision of a 
pharmacist. I can confirm that the non-
pharmacist (Pharmaceutical Assistant & 
Technician) staff will be discharging their 
duties under the supervision of a pharmacist 
as the HSE deals with applications received 
from pharmacies and queries arising. They will 
be operating under internal protocols and a 
negative decision will not be communicated 
back to the pharmacy without pharmacist 
signoff. The HSE expects that the online 
application system would enable sufficient 
particulars to be provided by the pharmacy for 
an assessment to be made in conjunction with 
reimbursement histories that PCRS already 
hold. Furthermore, for negative decisions by 
the PCRS, we have previously outlined that 
an appeal mechanism through the local HSE 
pharmacist will be available to the pharmacy 
to present further information. 
In relation to your request to defer to 1 june 
2017, we indicated at the JCG neeting an 
earlier start date. The HSE has confirmed 
to the Department of Health our plans 
doeo enhancing phased validations and the 
Separtment is anxious that we progress these 
on schedule. However, we will defer for a 
further couple of weeks and propse a demo of 
the system at the meeting scheduled for the 
JOG on 30 March 2017.
As outline above, it remains open for the 
GP to write phased dispensing on the 
face of the prescription where they are 
concerned for patient safety. The HSE has 
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not encountered any instance where the 
GP wrote a ‘Phased Dispensing’ request 
on the face of the prescription that the GP 
request was not discharged correctly by the 
dispensing pharmacy. It is the maximising 
of claims by the pharmacy, where no other 
healthcare professional is involved in the 
patient assessment, that is the risk for the 
HSE, a concern unfortunately substantiated 
by claiming behaviour in recent years. 
Incomplete Claims Protocol  
– GP Visit Card Holders 
Secretary General to Assistant National 
Director for Primary Care Reimbursement and 
Eligibility, PCRS – 27 January 2017
I am writing in relation to an issue which has 
arisen in the case of GMS prescription forms 
erroneously issued by contracted General 
Practitioners to their GP Visit Card patients 
which has resulted in an apparent break with 
the Incomplete Claims Protocol by the HSE 
PCRS.
At the inception of the GP Visit Card 
scheme, the IPU recommended to the HSE 
PCRS that the new type card numbers should 
be in a different format to GMS numbers 
to differentiate them from medical card 
numbers and thereby avoid unnecessary 
confusion between the schemes at the points 
of prescribing and dispensing. However, GP 
Visit Cards were instead issued with numbers 
whose format is identical to GMS numbers.  
You will be aware that, on occasion, some GPs 
issue GMS prescription forms to patients 
whose correct eligibility is under the GP Visit 
Card scheme and not the GMS Scheme. As a 
result, when a pharmacist is presented with a 
properly completed GMS prescription form, 
complete with a patient number in the correct 
format, the prescription may inadvertently be 
dispensed as a GMS prescription, through no 
fault of the pharmacist who is simply providing 
patient care under with the terms of their 
contract with the HSE. This is acknowledged 
by the HSE PCRS as an issue and has, for six 
years, been dealt with under the Incomplete 
Claims Protocol which was agreed between 
the IPU and the HSE PCRS and circulated 
to pharmacies in September 2010 (copy 
enclosed) and has operated successfully ever 
since.
It now appears that the HSE PCRS has, 
without notice, instituted a new practice, in 
breach of the Incomplete Claims Protocol, 
resulting in our members being refused 
reimbursement having dispensed medicines 
in good faith on foot of properly completed 
prescription forms in cases where GPs have 
issued GMS prescriptions for patients with 
GP Visit Card eligibility only. The agreed 
protocol and practice in place (until now) is 
that an invalid claim will be paid and reported 
on the pharmacy’s detailed payment listing 
so that the pharmacist is alerted to the fact 
that the eligibility is not clear and has an 
opportunity to rectify this with the patient 
concerned. 
In the absence of agreement with the IPU 
to make changes to the terms of the existing 
protocol or notice of your intention to 
break with the protocol, our members had 
a legitimate expectation that they would 
continue to be reimbursed as before.
At the March 2016 meeting of the Joint 
Consultative Group (JCG), a draft document, 
entitled Incomplete Claims Protocol – 
Discussion Document (copy enclosed), was 
circulated by the HSE PCRS. The IPU 
proposed at the following meeting in May, 
that Point 2 of the draft document, which 
states, “In cases where the card number 
does not exist, i.e. no record of previous 
eligibility over the last xx years the HSE will 
not honour such claims” be removed and that 
Point 1 be applied to all categories of claims. 
The IPU also proposed that the HSE PCRS 
writes to GPs to remind them not to write 
prescriptions for GP Visit Card patients on 
GMS prescriptions, which was subsequently 
done. The HSE PCRS did not raise the draft 
discussion document at any further meetings 
of the JCG.
It is redolent of bad faith for the HSE PCRS 
to have unilaterally imposed new practices 
without notification or discussion. The 
Relationship Values Charter agreed between 
PCRS and IPU sets out at Article 14 that “all 
existing agreements /arrangements will be 
respected and honoured in full”. Therefore, 
we expect that the HSE PCRS will honour 
the existing Incomplete Claims Protocol and 
immediately reimburse our members for 
claims which were dispensed in good faith and 
wrongfully rejected.
A continuing failure by HSE PCRS to adhere 
to arrangements previously agreed will 
inevitably lead to difficult questions regarding 
the purpose of collaboration and the value or 
otherwise of agreements between us. Please 
give this matter your urgent attention. 
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Secretary General to Assistant National 
Director for Primary Care Reimbursement and 
Eligibility, PCRS – 20 March 2017
The IPU in our correspondence of 27 
January 2017 and again at the recent Joint 
Consultative Group (JCG) meeting expressed 
our disappointment that the agreed protocol 
and practice in place for managing GMS 
claims involving invalid medical card numbers 
(i.e. the Incomplete Claims Protocol) was 
breached without notice by HSE PCRS in the 
case of numbers which are valid for the GP 
Visit Card Scheme. The agreement in place 
is that all such incomplete claims are paid and 
reported on the pharmacy’s detailed payment 
listing, so that the pharmacist is alerted to the 
fact that the eligibility could not be confirmed, 
and they and the patient concerned have an 
opportunity to rectify this. 
The IPU therefore welcomes your 
commitment, given at the JCG, that the 
HSE PCRS will in future provide two 
months’ notice on the itemised claims listing 
before ceasing reimbursement of affected 
claims. This will allow the pharmacist to alert 
the patient of the need to regularise their 
situation and/or eligibility prior to next visiting 
the pharmacy in order to continue to access 
their medicines. Can you please confirm this 
process is now in place? 
As pharmacists were not notified of any 
changes to protocol and continued to abide by 
it, they therefore had a legitimate expectation 
that they would be reimbursed as before. Can 
you please confirm as a matter of priority 
that the HSE PCRS will honour the agreed 
protocol in place and immediately reimburse 
our members for claims which were dispensed 
in good faith and wrongfully rejected?
Finally, we anticipate that in future, the HSE 
PCRS will at all times consult with us in line 
with the Relationship Values Charter prior to 
any proposed changes to current agreements/
arrangements.
Other Government 
Departments
Regulation on Veterinary  
Medicinal Products
Secretary General to Minister for Agriculture, 
Food & the Marine – 12 May 2016 
I am writing to you on behalf of the Irish 
Pharmacy Union (IPU), the representative 
body for community pharmacists, in 
connection with the reform of European 
legislation on veterinary medicinal products 
proposed by the European Commission. 
We are aware of your role in the future 
Council discussion on the proposal on 
veterinary medicinal products and we would 
like to take the opportunity to draw your 
attention to some issues of crucial importance 
for us. 
1. Distribution of veterinary medicinal 
products through the internet
The Commission proposal aims at 
harmonising and removing existing 
restrictions on the internet sale of 
prescription medication [Article 108 and 
recital 56]. We believe Member States 
should be able to decide whether the 
internet selling of prescription veterinary 
medicines is allowed in their territory. 
The harmonisation of the conditions of 
supply of veterinary medicines must not 
jeopardise Member States’ competences 
on health.
We request that you include in the 
proposal a right for Member States 
to prohibit the sale at a distance of 
prescription veterinary medicinal products. 
Moreover, we strongly support the 
approach taken by the Institutions when 
regulating the sale at a distance of human 
medicinal products and we ask you to 
consider the solutions proposed in that 
legislation [DIRECTIVE 2011/62/EU 
TITLE VIIA].
2. Special licences and distribution channels
The Commission proposal requires 
special licences in order to retail anabolic, 
anti-infectious, anti-parasitic, anti-
inflammatory, hormonal or psychotropic 
veterinary medicinal products [ Article 
109 § 1]. The right of pharmacists to 
dispense medicines of this nature without 
a particular licence is recognised in all 
European countries. Moreover, it would be 
absurd if pharmacists were able to dispense 
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these kinds of medicines for humans under 
the normal pharmacy licence, but need a 
specific licence for veterinary medicinal 
products.
We call for the removal of the need 
for special licences for pharmacies 
when supplying and purchasing certain 
medicines.
In addition, we are concerned by the 
amendment proposed by the European 
Parliament (EP) regarding the distribution 
of non-prescription veterinary medicinal 
products [Amendment 232]. According to 
the EP, all retailers, including pharmacies 
and supermarkets, may sell non-
prescription veterinary medicinal products 
without the need to be specifically 
authorised to do so. Thus, the EP is 
harmonising and deciding on the channel 
of distribution of certain categories of 
non-prescription veterinary medicinal 
products. If this proposal is carried, 
Member States will lose competences on 
deciding how to organise the distribution of 
non-prescription medicines. 
We ask you to disregard the amendment 
proposed by the EP on the distribution 
of certain categories of non-prescription 
veterinary medicinal products.
3. Record keeping
The Commission proposal [Amendment 
229] establishes record keeping obligations 
when supplying non-prescription and 
prescription veterinary medicinal products. 
The obligation to record non-prescription 
veterinary medicinal products may impose 
an unnecessary burden on community 
pharmacies and the proportionality of 
the measure will need to be assessed at 
national level.
We call for the right of Member States to 
decide whether to require the keeping of 
records for the supply of non-prescription 
veterinary medicines.
4. Recognition of prescriptions
In relation to [Amendment 235], the 
recognition of prescriptions issued 
for human medicines prescribed for 
veterinarian purposes needs to be 
limited to avoid cross border veterinary 
prescription abuse.
We call for a derogation to the recognition 
of veterinary prescriptions issued to cover 
human medicinal products in the cross 
border context.
5. Right to refuse
Pharmacists’ right to refuse recognition of 
prescriptions must be clearly stated in the 
core text of the Regulation [Amendment 
236]. 
We call for a provision in the core text 
establishing the right of pharmacists to 
refuse to dispense a prescription when 
this is justified on professional or ethical 
grounds.
We thought it would be helpful to set out our 
proposed amendments against the current 
text of the Regulation. 
We would welcome an opportunity to meet to 
discuss these matters further.
Reduction of Price Capitation  
on Prescription Levy 
Secretary General to Minister for Public 
Expenditure and Reform – 18 October 2016 
I write to you on behalf of our members 
concerns in relation to the decision to reduce 
the cap on the prescription levy from €25 
to €20 to those aged over 70. The IPU has 
consistently called for an alleviation of the 
burden of prescription charges from those 
least able to afford them and welcomes any 
reduction in fees which will allow easier access 
to healthcare for GMS patients. Indeed, in our 
pre-budget submission, we sought that the 
prescription levy be phased out in its entirety.
The decision to reduce the fee to those over 
70, however well-intentioned it may be, is 
not practical or feasible for pharmacy staff to 
implement.  Pharmacy staff should not be put 
in a position where they have to establish the 
age of their older patients at every encounter. 
The current medical card scheme is standard 
across all patients and does not discriminate 
against any card-holder on the basis of age. 
Problems will arise where families who are 
entitled to a medical card may have members 
who fall either side of the age divide. By way 
of example, the 69-year-old spouse of a 
70-year-old will appear as being ineligible 
for the €5 cap reduction on the current IT 
system; although they are in fact eligible.
The administrative costs for the HSE to 
further develop the current IT system, with 
proper accountable standards, to identify and 
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flag those over 70, and their family members, 
would be wasteful. Equally there would be 
additional administrative and financial burdens 
for individual pharmacies to implement this 
measure. Pharmacy staff will have to check 
the prescription charge status on their IT 
system of any medical card holder who 
appears to be over 70 years of age; this is 
simply not practical. 
The only practical way for the scheme to 
work is to apply the reduction of €5 to all 
medical card holders. A cost benefit analysis 
should be conducted before the introduction 
of the reduced fee on 1 March 2017 and, 
to the extent that resources are available to 
alleviate the burden of this levy, they should 
be allocated towards exempting the most 
vulnerable, not simply those who have reached 
an arbitrary age.
Please contact us if you require any 
clarification or further information. We are 
available to meet with you as necessary.
Retail Consultation Forum
Director of Communications & Strategy to 
Minister for Jobs, Enterprise and Innovation  
– 7 December 2016
In response to your recent letter requesting 
members of the Forum to submit material 
to explain price differentials for customers 
between prices quoted in Euro and Sterling, I 
would like to confirm that in retail pharmacy 
this is not an issue for customers, as all pricing 
is generally shown in Euro. 
However, while on the subject, there is 
serious concern from IPU members at the 
impact of a weaker Sterling, particularly for 
members who trade near the border. While 
the pharmacies impacted are attempting 
to compete as best they can, many have 
indicated to us that it is becoming increasingly 
difficult, particularly due to the high costs of 
running a community pharmacy in comparison 
to our Northern counterparts. 
While wages, rents, insurance, energy 
and local charges are generally in excess 
of those across the border for all retail 
businesses, pharmacists have an additional 
cost in the form of regulatory fees, which 
places us at a further distinct disadvantage 
to pharmacies in Northern Ireland. The 
annual registration fee each pharmacy 
must pay to the Pharmaceutical Society 
of Ireland (PSI) is €2,135 (€3,325 on first 
registration). However, in Northern Ireland 
the annual registration fee for a pharmacy 
business is €185 (€135 on first registration), 
which is only a small fraction of the cost of 
registration in the Republic of Ireland. Given 
the demographic and regulatory similarities 
between the two jurisdictions, there is no 
satisfactory explanation for this extraordinary 
disparity.
I have raised this matter a number of times at 
previous meetings of the Forum. 
I am happy to discuss this in greater detail with 
you at the next meeting of the Forum, if you 
think it would be helpful.
Directive on a Proportionality Test 
Secretary General to Minister for Jobs, 
Enterprise and Innovation  
– 4 April 2017
I write on behalf of the Irish Pharmacy Union 
(IPU), the representative and professional 
body for community pharmacy, with concerns 
on the proposed Directive on a proportionality 
test. We are aware of your role in the future 
EU Parliament discussion on the proposal 
for a Directive on a proportionality test and 
we would like to take the opportunity to 
draw your attention to some issues of crucial 
importance to us:
1. Special nature of healthcare professions
The Commission’s proposal for the 
Directive on a proportionality test 
establishes an EU-wide legally binding 
framework for Member States’ 
competent authorities to assess the 
proportionality of the regulation of more 
than 700 professions including healthcare 
professions. This is highly surprising given 
the fact that the European legislator has 
recognised the special nature of healthcare 
professions on many occasions in the past, 
including in the Professional Qualifications 
Directive and the Falsified Medicines 
Directive1. This was equally recognised 
by the European legislator during the 
preparation of the Services Directive which 
excludes health professions from its scope, 
by explicitly stating that such a horizontal 
instrument is not appropriate for health 
services2.
It is also contrary to the European Court 
of Justice’s well established case-law, 
which acknowledges that it is the right 
of Member States to determine the 
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level of protection which they wish to 
afford to public health and the way in 
which that level is to be achieved3. The 
need to respect Member States’ margin 
of discretion when assessing whether 
the principle of proportionality has been 
observed in the field of public health 
has been confirmed by such case-law. 
In particular, the Court of Justice has 
acknowledged that “the fact that one 
Member State imposes less strict rules than 
another Member State does not mean that 
the latter’s rules are disproportionate”4.
2. Importance of regulation in  
European health systems 
European health systems are consistently 
ranked among the top performing in the 
world and are recognised for providing high 
quality and accessible healthcare services 
to citizens. Article 168 of the Treaty of 
Functioning of the EU (TFEU) establishes 
the need for a high level of human health 
protection to be ensured in the definition 
and implementation of all Union policies 
and activities. In addition, this provision 
states that the organisation and delivery of 
health services to citizens is a responsibility 
of Member States. In general, and unless 
explicitly defined otherwise, Union action 
is therefore restricted to a complementary 
and coordinating function where added 
value can be achieved.
European health systems, as well as the 
access to and the practice of healthcare 
professions, are highly regulated at 
national level. These provisions are 
characterised by a high number of 
obligations and restrictions on the 
healthcare professionals. The main goal 
of such provisions is to ensure the highest 
quality of healthcare and the protection of 
patients and public health in general.
 
For instance, in the pharmacy profession, 
the opening of pharmacies in Ireland 
is subject to registration requirements 
and inspection. In addition, all EU 
countries have reserved certain activities 
for pharmacists (such as providing 
advice on use of medicines, dispensing, 
compounding, etc.). Pharmacists are 
subject to continuous professional 
development requirements and 
professional ethics and supervision, among 
other obligations. The application of 
such criteria has proven to be key in the 
organisation of national healthcare systems 
and guarantees high quality, safe and 
accessible pharmacy services throughout 
the national territory.
Furthermore, cost-containment for public 
health expenditure (either by the State 
budget or by Statutory Health Insurance) 
is an important goal of national regulation 
in the health sector. These economically 
specific circumstances of the health sector 
constitute an outstanding distinction from 
other economic sectors and call for a 
different approach.
We believe that Member States should 
remain fully responsible to define the 
conditions for access to and practice 
of healthcare professions, such as 
pharmacists, as well as to choose the 
most appropriate method to assess the 
proportionality and necessity of such 
requirements. When implementing new 
regulation for healthcare professions, 
Member States are best placed to consider 
the country-specific issues and take into 
account the interests of patient safety and 
quality of healthcare. In addition, given that 
health and life of humans rank foremost 
among the assets and interests protected 
by the TFEU, we would like to stress that 
the objectives of healthcare systems 
and the regulation of health professions 
(namely ensuring accessibility and quality) 
should always take priority. 
3. Administrative burden versus  
evolution of health systems 
Member States currently take into 
account the principle of proportionality in 
their respective health policies, including 
regulation of healthcare professions. 
Accordingly, professional regulation 
evolves along with the evolution of health 
systems and scientific developments. 
This proposal introduces an additional 
burdensome and time-consuming process 
which is not adapted to each country’s 
realities and resources and has very limited 
added value. In addition, it generates a 
significant degree of legal uncertainty 
about the adoption of new requirements 
for the access to and exercise of 
healthcare professions. We are concerned 
that the proposal might demotivate 
Member States from introducing new, or 
amending existing requirements, which 
may be necessary and justified on the 
grounds of public health and in line with 
scientific and practice developments. 
Ultimately, this may be detrimental to both 
patients and public health.
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In conclusion, we believe that it is not 
appropriate to address the regulation 
of healthcare professions, including 
pharmacists, in a general manner, together 
with other professions which perform 
professional activities of varying natures 
and which are subject to different legislative 
rules and have completely different safety 
implications. Healthcare policy decisions 
relating to the regulation of professions 
must serve the objective of attaining the 
best possible quality of care for every 
patient. Under no circumstances may 
quality of care, access to care or patient 
safety be put at risk by decisions driven 
by other agendas, in particular economic 
concerns. We therefore ask you to support 
the exclusion of health professions from 
the scope of this proposal.
In order to facilitate the reading, please find 
attached the set of amendments suggested by 
the IPU.
We would welcome an opportunity to meet 
with you to discuss the implications of this 
legislation for pharmacists. I look forward to 
hearing from you.
1. See Recital 26 of Directive 2005/36/EC “This Directive 
does not coordinate all the conditions for access to activities 
in the field of pharmacy and the pursuit of these activities. 
In particular, the geographical distribution of pharmacies 
and the monopoly for dispensing medicines should remain 
a matter for the Member States (…)”, and Recital 22 of 
Directive 2011/62/EU “When examining the compatibility 
with Union law of the conditions for the retail supply of 
medicinal products, the Court of Justice of the European 
Union (‘the Court of Justice’) has recognised the very 
particular nature of medicinal products, whose therapeutic 
effects distinguish them substantially from other goods. The 
Court of Justice has also held that health and life of humans 
rank foremost among the assets and interests protected by 
the TFEU and that it is for Member States to determine the 
level of protection which they wish to afford to public health 
and the way in which that level has to be achieved (…)”.
2. See Recital 22 of Directive 2006/123/EC “The exclusion 
of healthcare from the scope of this Directive should cover 
healthcare and pharmaceutical services provided by health 
professionals to patients to assess, maintain or restore 
their state of health where those activities are reserved to a 
regulated health profession in the Member State in which 
the services are provided” and Article 2.2 (f) of the same 
Directive.
3. See, inter alia, judgement of the Court of 19 May 2009 
in joint cases C-171/07 and C- 172/07 Apothekerkammer 
des Saarlandes and Others v Saarland, judgement of the 
Court of 19 May 2009 in Case C-531/06 Commission v 
Italian Republic and judgement of the Court of 11 September 
2008 in Case C-141/07 Commission v Federal Republic of 
Germany.
4. Judgement of the Court of 11 September 2008 in Case 
C-141/07 Commission v Federal Republic of Germany 
(paragraph 51).
Manufacturers
Neupro® Distribution Policy – 
Impact on Pharmacists 
Secretary General to Managing Director for 
the British and Irish Isles, UCB Pharma Ltd  
– 27 June 2016 
The Irish Pharmacy Union is the 
representative and leadership body for 
community pharmacists, with a membership 
comprising approximately 2,200 pharmacists 
and more than 1,700 pharmacies. We have 
been informed by members that they have 
encountered a problem with the distribution 
arrangement for your product Neupro®.
The Health Service Executive (HSE) sets the 
price which they will pay to pharmacies for 
medicines dispensed on behalf of the State, 
based on a fixed margin above a notional ex-
factory price. Manufacturers then typically 
provide their products to wholesalers at a 
price which allows the wholesalers to supply 
them to pharmacies at a net cost which takes 
account of the HSE reimbursement price. It 
appears, however, that under your distribution 
arrangement this is not the case. 
There are only two full-line pharmaceutical 
wholesalers in Ireland, United Drug and 
Uniphar. Your company has chosen to 
distribute Neupro® through only one of those 
wholesalers, United Drug, which does not 
offer discounts to pharmacies which do not 
use it as their primary wholesaler. As a result, 
many pharmacies are paying a net price for 
Neupro® which exceeds the reimbursement 
price paid by the HSE. The details are below.
This places some of our members at a 
considerable disadvantage when dispensing 
these items on the State’s community drug 
schemes. Because the price charged to them 
by the wholesalers for this product exceeds 
the HSE reimbursement price, the pharmacy 
suffers a loss on each occasion they dispense 
Neupro®. Given the tight margins that 
already exist in community pharmacies, these 
kinds of losses are not sustainable.
We would welcome your proposals to address 
this issue.
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IPHA/DoH/HSE Framework 
Agreement on the Pricing and 
Supply of Medicines 
Secretary General to Manufacturers  
– 23 August 2016 
I wish to refer to the recent agreement 
which your company, as a member of the 
Irish Pharmaceutical Healthcare Association 
(IPHA), has entered into with the Department 
of Health and the Health Service Executive.
This agreement has brought about reductions 
in the prices of medicines supplied by your 
company. Our members are concerned about 
the impact of these reductions on the value 
of their stocks of medicines which had been 
purchased prior to the implementation of the 
agreement at the prevailing price and which, 
as a consequence of this agreement to which 
they were not party, will now be reimbursed at 
the new, lower, price. At this point, they are 
anxious to establish what steps your company 
intends to take to compensate them for the 
significant losses which they incurred as a 
result of the overnight devaluation in their 
stocks of the affected medicines.
I would welcome an early response from you 
which we will convey to our members in due 
course. 
I look forward to hearing from you.
OFEV® Distribution Policy – 
Impact on Pharmacists 
Secretary General to General Manager, 
Boehringer Ingelheim Limited –  
18 January 2017 
The Irish Pharmacy Union is the representative 
and leadership body for community 
pharmacists in Ireland, with a membership 
comprising approximately 2,200 pharmacists 
and more than 1,700 pharmacies. We have 
recently been informed by our members of 
an issue with the distribution arrangement for 
your product OFEV® (nintedanib).
It is reported to us that patients have been 
advised by their consultant to go to their chosen 
pharmacy where they can collect the medicine 
“free of charge”. It is noteworthy that you have 
not consulted with the pharmacy profession, 
the benefit of whose premises and professional 
services you presume to secure free gratis. 
Given the tight margins that already exist in 
community pharmacies and the significant 
professional and regulatory obligations which 
pharmacists must comply with, this kind of free 
service is simply not sustainable.
Pharmacists are healthcare professionals 
whose primary concern is the health and 
wellbeing of their patients. However, their 
time has a value and their professional services 
come at a cost. As such, it is presumptuous 
of you to assume that pharmacists would 
be prepared to provide their services free 
of charge in order to facilitate the particular 
reimbursement arrangements which your 
company wished to secure with the HSE. 
It is a matter for each pharmacist to decide 
whether or not to charge for their services 
and, if so, to set the amount themselves. If 
it is your position that you do not wish to 
compensate the pharmacists for providing a 
dispensing service on your behalf then, in the 
interests of providing accurate information to 
patients, please make it clear in your written 
information to prescribers and patients that a 
charge may apply at the pharmacy. 
 
If you believe it would be helpful, we would be 
pleased to discuss these issues with you further.
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Forged Prescriptions 
Secretary General to Chief Executive,  
Medical Council – 3 October 2016 
The Irish Pharmacy Union is the professional 
representative organisation for community 
pharmacists in Ireland, with a membership 
of 2,200 pharmacists working in over 1,700 
pharmacies nationwide. 
The IPU regularly receives notifications from 
community pharmacists, GPs and hospitals 
of forged or alleged forged prescriptions 
and of thefts of prescription notepaper. We 
disseminate this information to all of our 
members through our weekly eNewsletter 
and monthly General Memorandum in order 
to alert them to the specific incidences and 
reduce the risk of medicines being supplied on 
foot of a non-genuine prescription. 
Over the past few months, there has been a 
significant increase in the number of forged 
or alleged forged prescriptions reported to 
us. I am bringing this matter to your attention 
as I thought it may be of interest to you. For 
your information, I attach a copy of all reports 
received during September and October 2016.
Please don’t hesitate to contact me if you 
believe further discussion on this matter 
would be helpful.
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A LIST OF PRESS 
RELEASES ISSUED  
TO THE MEDIA  
SINCE THE 2016 AGM
2016
May 
9 IPU calls on new government to 
commit to expansion of role of 
pharmacists in Programme for 
Government
11 Pharmacists issue warning on  
Hay Fever and offer tips to help 
minimise symptoms
15 Statement in response to Sunday 
Business Post re ‘GPs to slash drug 
prices by cutting out pharmacies’
June 
1 Exam stress impacting students’ health
9 Pharmacists warn that buying 
prescribed medicines online or from 
an unauthorised source can have 
potentially lethal consequences
14 Pharmacists Urge Men to Tackle  
Health Concerns
29 Nominate your Pharmacist for 
Pharmacist of the Year
30 Statement in response to Owings
July
1 New pharmacy-based Minor Ailment 
Scheme for medical card patients
18 Pharmacists welcome proposed cut in 
medicine prices
19 Pharmacists issue Safety Guidelines to 
Stay Safe in the Sun
20 IPHA AGREEMENT:  
Pharmacists Welcome Deal to  
Lower Medicine Prices
29 Brexit Vote in UK has Hit  
Business Confidence in the Irish 
Pharmacy Sector
August 
24 Back to School – Pharmacists’  
Advice on Treating Head Lice
September 
1 Pharmacists Offer Healthcare Tips  
to Electric Picnic Fans
6 Actavis Academy Training &  
Mentoring Bursary
29 Avoid the flu and get the vaccine - 
Pharmacists urge patients in at-risk 
category to get the flu vaccine
October
6 Pharmacists call for €2.50 Prescription 
Levy on Medical Card Holders to be 
Phased Out (Budget 2017)
11 Budget 2017: Pharmacists Welcome 
Small Movement on Prescription 
Levy, but Criticise Minimal Progress 
on Programme for Government 
Commitment 
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November 
4 Business Confidence among 
pharmacists continues to decline with 
many stating business environment is 
worsening 
13 Pharmacists warn that antibiotic 
resistance is one of the most significant 
threats to patient safety in Ireland
18 Pharmacists warn drivers to be aware of 
possible dangers when taking prescribed 
medications
23 IPU Welcomes Call by the Pharmacy 
Regulator to Expand the Role of 
Pharmacists in Healthcare Delivery
December 
9 Pharmacists reporting spike in 
respiratory and flu-like symptoms in last 
two weeks
15 Pharmacists Warn of the Dangers of 
Mixing Alcohol with Medicines
30 Thinking about New Year Resolutions?
2017
January 
3 Pharmacists Advise Patients to get  
Flu Vaccination in Response to 
Significant Increase in Flu Rates
19 Crime against Pharmacies Reaching 
Crisis Levels
26 IPU joins with Operation 
Transformation to offer FREE blood 
pressure measurements in pharmacies 
27 IPU urges Motorists to talk to 
their Pharmacist before Driving on 
Prescription Medication
February
28 National No Smoking Day:  
Pharmacists offer help to those  
wanting to stop smoking
28 IPU welcomes reduction in prescription 
levy for those aged 70 and over as ‘only 
a first step’ in necessary reforms
March
22 Pharmacists warn parents of health 
risks when giving medicines to children
27 Pharmacists Team Up with HSE 
to Promote Dementia Understand 
Together Campaign
30 IPU and eHealth Ireland launch 
Healthmail service for community 
pharmacy
April
12 IPU urges Motorists to talk to  
their Pharmacist before Driving  
on Prescription Medication
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